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Click hydrogels for controlled local
antibody delivery
The important thing is not to stop
questioning. Curiosity has its own
reason for existing.
(Albert Einstein)
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Introduction
The Diels–Alder reaction:
A powerful tool for the design of
drug delivery systems and
biomaterials
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Abstract
Click reactions have the potential to greatly facilitate the development of drug
delivery systems and biomaterials. These reactions proceed under mild conditions,
give high yields, and form only inoffensive by-products. The Diels–Alder cycloaddi-
tion is one of the click reactions that do not require any metal catalyst; it is one
of the most useful reactions in synthetic organic chemistry and material design.
Herein, possible applications of the Diels–Alder reaction in pharmaceutics and
biomedical engineering are highlighted. Particular focus is placed on the synthesis
of polymers and dendrimers for drug delivery, the preparation of functionalized
surfaces, bioconjugation techniques, and applications of the Diels–Alder reaction
in nanotechnology. Moreover, applications of the reaction for the preparation
of hydrogels for drug delivery and tissue engineering are reviewed. A general
introduction to the Diels–Alder reaction is presented, along with a discussion of
potential pitfalls and challenges. At the end of the chapter, a set of tools is provided
that may facilitate the application of the Diels–Alder reaction to solve important
pharmaceutical or biomedical problems.
4
1.1 Introduction
1.1 Introduction
The formation of new chemical bonds between molecules is one of the key challenges
in the development of drug delivery systems and biomaterials. For example,
the synthesis of polymer-drug conjugates, the assembly of nanomaterials, the
attachment of targeting moieties onto delivery systems, or the preparation of
hydrogels require fast, efficient, and selective coupling reactions. These reactions
are typically performed in aqueous solution; moreover, mild reaction conditions are
preferred to preserve the activity of biopharmaceuticals such as proteins, nucleic
acids, or living cells. Click chemistry has the potential to greatly facilitate the
development of drug delivery systems and biomaterials [1–5]. The term “click
chemistry” was first introduced by Sharpless and coworkers in 2001 to define a
group of “spring-loaded” reactions that proceed under mild conditions, give high
chemical yields, and generate only inoffensive by-products [6, 7]. Furthermore, click
reactions are stereospecific and modular, i.e., the reactions are applicable to various
materials and environments. During the last decade and a half, click chemistry has
opened up new possibilities in polymer chemistry, materials science, nanotechnology,
and drug discovery [8–12]. In the biomedical field, click chemistry has become
a powerful tool for the synthesis of polymers and dendrimers for drug delivery,
the functionalization of surfaces, and for the preparation and functionalization
of nanoscale drug delivery systems. Moreover, click chemistry has emerged as
an efficient cross-linking method for the preparation of hydrogels [1–5]. Several
chemical reactions have been identified that meet the criteria of click chemistry
[6, 7]. One of the most popular click reactions is the copper(I)-catalyzed azide-
alkyne Huisgen cycloaddition (CuAAC). The reaction reaches almost quantitative
conversion in both aqueous and organic media and offers “an unprecedented level
of selectivity” [13, 14]; it is often referred to as “the cream of the crop” of click
chemistry [6, 7]. However, the potential toxicity of the copper(I) catalyst is a major
concern in the design of drug delivery systems and biomaterials; furthermore, the
presence of copper(I) can be detrimental to biomolecules such as lipids, nucleic
acids, polysaccharides, or proteins [2–4]. Consequently, there has been considerable
interest in identifying alternative, metal-free click reactions. While the azide-alkyne
Huisgen cycloaddition can also be achieved in the absence of metal catalysts, the
extremely low reaction rate at room temperature limits its practical usefulness.
To increase the rate of the coupling reaction, Bertozzi and coworkers developed a
copper-free, strain-promoted azide-alkyne cycloaddition (SPAAC) [15]. Compared
5
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to terminal alkynes, the reactivity of cyclooctyne derivatives toward azides is
greatly enhanced [16], in particular when difluorinated cyclooctynes are used [17].
However, these cyclooctyne derivatives are difficult to synthesize, which may limit
the widespread use of SPAAC. The Diels–Alder (DA) cycloaddition is another
click reaction that does not require any metal catalyst [18–21]. Although being
accelerated by Lewis acids [22–25], the DA reaction remains efficient in the absence
of catalysts, even though the reaction rate can then be slow at room temperature.
The reaction was first described by Otto Diels and his student, Kurt Alder, in
1928 [26, 27]. In appreciation of their discovery, Diels and Alder were awarded
the Nobel prize in chemistry in 1950. The DA reaction is stereoselective, atom
economical, and highly efficient; it is one of the most powerful methods to synthesize
unsaturated six-membered rings [28]. For example, the DA reaction was utilized in
the total synthesis of steroids by Woodward et al. [29], or in the first total synthesis
of morphine by Gates and Tschudi [30, 31]. The DA cycloaddition is undoubtedly
one of the most useful reactions in synthetic organic chemistry and its importance
for biomedical applications, such as the development of drug delivery systems or
biomaterials, is steadily increasing.
In this chapter possible applications of the DA reaction in pharmaceutics and
biomedical engineering will be highlighted. Particular focus will be placed on the
synthesis of polymers and dendrimers for drug delivery, the preparation of func-
tionalized surfaces, bioconjugation techniques, and applications of the DA reaction
in nanotechnology. Moreover, applications of the reaction for the preparation of
hydrogels for drug delivery and tissue engineering will be reviewed. The chapter is
complemented by a general introduction to the DA reaction, along with a discussion
of potential pitfalls and challenges. A major goal of this chapter is to provide a set
of tools that may facilitate pharmaceutical or biomedical applications of the DA
reaction.
1.2 Diels–Alder chemistry
The DA reaction is a [4 + 2] cycloaddition of a conjugated diene and a substi-
tuted alkene (also termed dienophile) during which six pi-electrons rearrange to
form a cyclic, six-membered product (Scheme 1.1A). If both the diene and the
dienophile are part of the same molecule, the DA reaction is usually referred to
as intramolecular DA cycloaddition (Scheme 1.1B). Moreover, DA reactions are
known in which at least one heteroatom is involved; these are collectively called
6
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hetero-DA reactions (Scheme 1.1C). Since the discovery of the DA reaction, the
precise reaction mechanism has been subject of controversial discussion. It has
been debated whether the DA reaction occurs by a two-step mechanism involving a
diradical, or by a one-step mechanism. Today, the “prevailing opinion” is that the
DA cycloaddition is a concerted, synchronous reaction involving a cyclic transition
state [32–36]. The mechanism of the DA reaction is frequently explained by using
ethylene and 1,3-butadiene as reaction partners. However, this particular reaction
should be understood as a theoretical example as it proceeds exceptionally slowly.
potential toxicity of the copper(I) catalyst is a major concern in the
design of drug delivery systems and biomaterials; furthermore, the
presence of copper(I) can be detrimental to biomolecules such as
lipids, nucleic acids, polysaccharides, or proteins [2–4].
Consequently, there has been considerable interest in identifying
alternative, metal-free click reactions. While the azide–alkyne
Huisgen cycloaddition can also be achieved in the absence of metal
catalysts, the extremely low reaction rate at room temperature
limits its practical usefulness. To increase the rate of the coupling
reaction, Bertozzi and coworkers developed a copper-free,
strain-promoted azide–alkyne cycloaddition (SPAAC) [15].
Compared to terminal alkynes, the reactivity of cyclooctyne deriva-
tives toward azides is greatly enhanced [16], in particular when
difluorinated cyclooctynes are used [17]. However, these cyclooc-
tyne derivatives are difficult to synthesize, which may limit the
widespread use of SPAAC. The Diels–Alder (DA) cycloaddition is
another click reaction that does not require any metal catalyst
[18–21]. Although being accelerated by Lewis acids [22–25], the
DA reaction remains efficient in the absence of catalysts, even
though the reaction rate can then be slow at room temperature.
The reaction was first described by Otto Diels and his student,
Kurt Alder, in 1928 [26,27]. In appreciation of their discovery,
Diels and Alder were awarded the Nobel prize in chemistry in
1950. The DA reaction is stereoselective, atom economical, and
highly efficient; it is one of the most powerful methods to synthe-
size unsaturated six-membered rings [28]. For example, the DA
reaction was utilized in the total synthesis of steroids by
Woodward et al. [29], or in the first total synthesis of morphine
by Gates and Tschudi [30,31]. The DA cycloaddition is undoubtedly
one of the most useful reactions in synthetic organic chemistry and
its importance for biomedical applications, such as the develop-
ment of drug delivery systems or biomaterials, is steadily
increasing.
In this review article we will highlight possible applications of
the DA reaction in pharmaceutics and biomedical engineering.
Particular focus will be placed on the synthesis of polymers and
dendrimers for drug delivery, the preparation of functionalized
surfaces, bioconjugation techniques, and applications of the DA
reaction in nanotechnology. Moreover, applications of the reaction
for the preparation of hydrogels for drug delivery and tissue engi-
neering will be reviewed. The article is complemented by a general
introduction to the DA reaction, along with a discussion of poten-
tial pitfalls and challenges. It is our goal to provide a set of tools
that may facilitate pharmaceutical or biomedical applications of
the DA reaction.
2. Diels–Alder chemistry
The DA reaction is a [4 + 2] cycloaddition of a conjugated diene
and a substituted alkene (also termed dienophile) during which six
p-electrons rearrange to form a cyclic, six-membered product
(Fig. 1A). If both the diene and the dienophile are part of the same
molecule, the DA reaction is usually referred to as intramolecular
DA cycloaddition (Fig. 1B). Moreover, DA reactions are known in
which at least one heteroatom is involved; these are collectively
called hetero-DA reactions (Fig. 1C). Since the discovery of the
DA reaction, the precise reaction mechanism has been subject of
controversial discussion. It has been debated whether the DA reac-
tion occurs by a two-step mechanism involving a diradical, or by a
one-step mechanism. Today, the ‘‘prevailing opinion’’ is that the
DA cycloaddition is a concerted, synchronous reaction involving a
cyclic transition state [32–36]. The mechanism of the DA reaction
is frequently explained by using ethylene and 1,3-butadiene as
reaction partners. However, this particular reaction should be
understood as a theoretical example as it proceeds exceptionally
slowly. The reason for the slow reaction kinetics is the unfavorable
electron distribution within the reaction partners. The cycloaddi-
tion proceeds dramatically faster if electron-poor dienophiles are
reacted with electron-rich dienes (normal electron-demand DA
reaction). Therefore, typical DA reactants are substituted accord-
ingly: reactive dienophiles are substituted with electron with-
drawing groups, such as carbonyls, ketones, carboxyls, nitriles or
halogens, whereas ‘‘good’’ dienes are substituted with electron
donating groups, such as alkyl chains. In accordance with
Sharpless’ demands for click reactions, a major advantage of the
DA cycloaddition is its predictable stereochemistry. The configura-
tion of the substituents in both the diene and the dienophile is pre-
served in the cycloaddition adduct (‘‘cis-principle’’) [37]. If cyclic
dienes or dienophiles are involved, a bridged product is formed
that can be either endo- or exo-oriented. In most cases, the
endo-product is favored due to secondary orbital interactions
(‘‘endo-rule’’). However, the ratio of endo to exo isomers can vary
depending on whether the reaction is kinetically or thermodynam-
ically controlled [37,38]. At this point it should be noted that the
DA reaction and its counterpart, the retro-Diels–Alder (rDA) reac-
tion, are reversible under certain conditions. Increasing the tem-
perature favors the rDA reaction and shifts the equilibrium
position, which offers exciting possibilities in polymer chemistry
and material design [39–42]. In addition to the normal
electron-demand DA reaction, which typically involves
electron-rich dienes and electron-poor dienophiles, an alternative
reaction, in which the electron distribution between the two reac-
tants is reversed, has been described. During this reaction, which is
termed inverse electron-demand DA (IEDDA) reaction, a
six-membered ring is formed between an electron-poor diene
and an electron-rich dienophile (Fig. 1D) [34,43].
3. Advantages of the Diels–Alder reaction
The DA reaction plays an essential role in synthetic organic
chemistry [28], and its importance for pharmaceutical or biomed-
ical applications is steadily increasing. Suitable diene–dienophile
Fig. 1. Normal electron-demand Diels–Alder (DA) reaction (A), intramolecular DA
reaction (B), hetero-DA reaction (C), and inverse electron-demand DA reaction (D).
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Scheme 1.1: Normal electron-dema d Diels–Alder (DA) reactio (A), intramolecular
DA reaction (B), hetero-DA reaction (C), and inverse electron-demand DA reaction
(D).
The reason for the slow reaction kinetics is the unfavorable electron distribution
within the reaction partners. The cycloaddi ion proce ds dramatically faster if
electron-poor dienophiles are reacted with electron-rich dienes (normal electron-
demand DA reaction). Therefore, typical DA reactants are substituted accordingly:
reactive dienophiles are substituted with l ctron wit drawing groups, such as
carbonyls, ketones, carboxyls, nitriles or halogens, whereas “good” dienes are
substituted with electron donating groups, such as alkyl chains. In accordance with
Sharpless’ demands fo click re ctions, a maj r dvant ge of the DA cycloaddition
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is its predictable stereochemistry. The configuration of the substituents in both the
diene and the dienophile is preserved in the cycloaddition adduct (“cis-principle”)
[37]. If cyclic dienes or dienophiles are involved, a bridged product is formed
that can be either endo- or exo-oriented. In most cases, the endo-product is
favored due to secondary orbital interactions (“endo-rule”). However, the ratio
of endo to exo isomers can vary depending on whether the reaction is kinetically
or thermodynamically controlled [37, 38]. At this point it should be noted that
the DA reaction and its counterpart, the retro-Diels–Alder (rDA) reaction, are
reversible under certain conditions. Increasing the temperature favors the rDA
reaction and shifts the equilibrium position, which offers exciting possibilities in
polymer chemistry and material design [39–42]. In addition to the normal electron-
demand DA reaction, which typically involves electron-rich dienes and electron-poor
dienophiles, an alternative reaction, in which the electron distribution between the
two reactants is reversed, has been described. During this reaction, which is termed
inverse electron-demand DA (IEDDA) reaction, a six-membered ring is formed
between an electron-poor diene and an electron-rich dienophile (Scheme 1.1D)
[34, 43].
1.3 Advantages of the Diels–Alder reaction
The DA reaction plays an essential role in synthetic organic chemistry [28], and
its importance for pharmaceutical or biomedical applications is steadily increasing.
Suitable diene-dienophile pairs (e.g., furan and maleimide) are readily available,
and the molecules of interest can be easily functionalized with the reactive moieties.
For example, to introduce furan moieties, carboxylic acids can be reacted with
furfuryl alcohol or furfurylamine. In the same manner, amines can be reacted with
3-furoic acid or 3-(2-furyl)propionic acid. Alcohols can be directly reacted with
2-furoyl chloride, or converted to amines for further derivatization. To introduce
maleimide moieties, amines can be reacted with N-methoxycarbonylmaleimide
or 3-(maleimido)propionic acid. Furthermore, the DA reaction has a number of
favorable characteristics that make its application particularly appealing. In the
case of medicinal products and devices, purity and safety of the employed materials
are important prerequisites. Consequently, it is advantageous that the DA reaction
readily proceeds in water; expensive and potentially toxic solvents are not required.
Interestingly, the reaction is greatly accelerated in water due to both enhanced
hydrogen bonding to the activated complex and enforced hydrophobic interactions
8
1.4 Pharmaceutical and biomedical applications of the Diels–Alder reaction
between the reactants [44–47]. But most importantly, the DA reaction can go
to completion at room temperature, even though the reaction kinetics is slow
under these mild conditions [48–50]. For example, when peptides equipped with
hexadienyl and maleimide groups were exposed to each other at 25 ◦C in water,
the cycloaddition proceeded smoothly with a conversion of 92% after 47 h [48].
For that reason, the DA reaction is a useful bioconjugation reaction with many
potential applications, e.g., in the preparation of polymer-drug conjugates or in the
development of targeted nanoparticles. However, it should be noted that both the
equilibrium conversion and the reaction rate depend on the substitution pattern
of the involved diene-dienophile pair [51]. Moreover, in many cases, purification
of the product is hardly necessary, as no catalyst or initiator is required and no
by-product is formed. This is particularly important if macromolecules, such as
polymers, dendrimers, proteins or nucleic acids, are involved in the reaction. Due to
these favorable characteristics (i.e., reaction in water, reaction at room temperature
without the use of catalysts, absence of by-products, etc.), the DA reaction is also an
effective cross-linking method to prepare in situ forming materials, such as hydrogels
for drug delivery and tissue engineering. In contrast to the above-mentioned features,
the reversibility of the reaction, which has already been discussed in the previous
section, can be considered both advantageous and disadvantageous. For example,
the DA cycloaddition/cycloreversion reaction can be used to protect or deprotect
functional groups; furthermore, the DA/rDA equilibrium can be exploited in the
preparation of degradable or self-healing materials, or in the design of controlled
drug delivery systems. On the other hand, the reversibility of the DA reaction
may prove problematic if stable adducts should be formed, e.g., in bioconjugation
reactions. Interestingly, the reversibility of the DA reaction can be controlled
by selecting the proper diene-dienophile pair, or by changing the solvent system
[51, 52].
1.4 Pharmaceutical and biomedical applications of
the Diels–Alder reaction
The following section provides examples of pharmaceutical and biomedical applica-
tions of the DA reaction. The section is divided into six subsections that highlight
applications of the DA reaction in the synthesis of copolymers, the synthesis of
branched polymers and dendrimers, the functionalization of surfaces, the synthesis
9
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of bioconjugates, the assembly or disassembly of nanomaterials, and in the prepa-
ration of hydrogels for drug delivery and tissue engineering. The advantages and
disadvantages of the DA reaction are briefly discussed throughout the text; a more
detailed discussion of potential pitfalls and challenges can be found at the end of
the chapter.
1.4.1 Synthesis of copolymers
Copolymers are polymers that are composed of two or more different monomers
(e.g., monomers A and B). Depending on how the monomers are organized along
the backbone, different types of copolymers can be distinguished. In statistical
copolymers, the sequence of monomer units follows statistical rules (e.g., A-A-B-
A-B-A-B-B-B-A), whereas block copolymers comprise two or more homopolymer
subunits (e.g., A-A-A-A-A-B-B-B-B-B). Graft copolymers are a special type of
branched polymer in which the side chains are constitutionally different from the
main chain; the individual chains can be distinct homopolymers or copolymers.
Since the individual segments of block copolymers or graft copolymers can have
different physicochemical properties, such as hydrophobicity or crystallinity, copoly-
mers have many potential applications in drug formulation, biomaterial design and
nanotechnology. For example, copolymers consisting of hydrophobic and hydrophilic
segments are able to self-assemble in water to form micellar structures, which have
numerous applications in drug delivery [53–56] and gene therapy [57, 58]; they are
also used to prepare nanomaterials [59–61], surface coatings [62–64] or hydrogels
[65–67]. Block copolymers can be synthesized by living polymerization, such as
atom transfer free radical polymerization (ATRP), reversible addition fragmen-
tation chain transfer (RAFT), ring-opening metathesis polymerization (ROMP),
and living anionic or cationic polymerizations. Another strategy to prepare block
copolymers is the stepwise coupling of homopolymer precursors made of different
monomers. To avoid tedious purification procedures, the coupling reaction should
be both efficient and chemoselective, i.e., the coupling reaction must not interfere
with other functional groups present in the same molecule. The DA reaction meets
these criteria and offers the possibility to create thermoreversible bonds, which is a
key difference to other click reactions.
Among all possible reaction partners, the DA reaction of furan and maleimide
has received particular attention [19, 21]. The rDA reaction of the furan-maleimide
adduct occurs at relatively low temperature (i.e., around 100 ◦C), which opens the
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way to many interesting applications, such as self-healing or recyclable materials. In
the following section, those approaches with potential pharmaceutical or biomedical
applications will be highlighted. For example, Inoue et al. [68] described the
synthesis and characterization of recyclable shape-memory polymers. For this
purpose, star-shaped poly(lactic acid) (PLA) macromonomers were functionalized
with furyl groups and cross-linked with bismaleimides via DA reaction. In a
similar manner, recyclable shape-memory polymers were prepared by melt-blending
star-shaped poly(ε-caprolactone)s end-functionalized with furan and maleimide
moieties [69, 70]. In a further approach for the synthesis of biodegradable shape-
memory elastomers, Ninh and Bettinger [71] coupled hyperbranched furan-modified
poly(glycerol-co-sebacate) precursors with bifunctional maleimide cross-linking
agents (Fig. 1.1). These kinds of biodegradable shape-memory polymers may be
useful in the biomedical field [72, 73]. For example, stents used in endovascular
aneurysm repair must be designed to allow administration by minimally invasive
techniques. Implants made of shape-memory polymers have a compact shape at
room temperature; they can be inserted through keyhole incisions and unfold to
their functional shape inside the body.
In addition to the reversible coupling of polymers, the DA reaction of furan
and maleimide can be used to protect the maleimide group during polymerization.
For example, Onbulak et al. [74] prepared biodegradable poly(carbonate)s with
pendant, furan-protected maleimide groups. Deprotection via rDA reaction yielded
maleimide groups that could react with thiol-containing molecules in a Michael-
type addition reaction. This thermal deprotection is interesting, especially for
biodegradable polymers, because acid or basic catalysts, which are prone to degrade
the polymer in the presence of water, are not required. The only requirement is
that the polymer has to be thermally stable at the temperature at which the rDA
reaction takes place. Another interesting application of the DA reaction is the
preparation of organic-inorganic hybrid materials. The synthesis of these polymer
hybrids was accomplished by reacting a styrene copolymer bearing pendant furan
moieties with a maleimide-containing silane coupling agent in the presence of
tetraethoxysilane [75]. Such hybrid materials, which combine the advantages of
both organic and inorganic materials, could be used as biomaterials in certain
applications requiring high mechanical strength. For example, the stiffness and
compressive strength of polymeric biomaterials are often insufficient to be used as
scaffolds for bone tissue engineering. Organic-inorganic nanocomposites usually
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show improved mechanical characteristics compared to their individual components
and are, therefore, regarded as promising alternative to polymeric scaffolds [76].
Besides the furan-maleimide pair, the DA reaction between anthracene and
maleimide has been used for the preparation of block copolymers [77], graft
copolymers [78], and star-shaped copolymers [79]. Since the rDA reaction of
the anthracene-maleimide adduct occurs at temperatures above 200 ◦C, the cy-
cloaddition of anthracene and maleimide yields stable conjugates [19]. For example,
poly(methyl methacrylate)-b-polystyrene (PMMA-b-PS), poly(ethylene glycol)-b-
polystyrene (PEG-b-PS), and PMMA-b-PEG copolymers were obtained in almost
quantitative yields, demonstrating the high efficiency of the coupling reaction
[77]. Biodegradable Y-shaped block copolymers were synthesized in a similar
way using hydrophobic poly(ε-caprolactone) and hydrophilic PEG; the polymers
formed micelles in aqueous media, which could be used as a carrier for the anti-
cancer drug vinorelbine [80]. Similarly, poly(ethylene terephthalate) copolymers
containing 2,6-anthracenedicarboxylate units were cross-linked by DA reaction with
bismaleimides [81]. Furthermore, the combination of DA reaction and CuAAC
allowed the one-pot synthesis of triblock copolymers consisting of polystyrene,
PMMA, and PEG or poly(ε-caprolactone) [82]. Besides these examples, the hetero-
DA reaction [83, 84] and the IEDDA reaction [85–88] have been successfully applied
to the synthesis of copolymers. While the DA cycloaddition between anthracene
and maleimide requires temperatures in excess of 110 ◦C and long reaction times
(48–120 h) [77], Inglis et al. [83] demonstrated that the hetero-DA cycloaddi-
tion between cyclopentadienyl-terminated PEG and polymers bearing pyridinyl
dithioester groups can be completed within 10 min. The efficiency of this reaction
is comparable to other click reactions, such as CuAAC or thiol-ene reactions, which
typically require reaction times ranging from 5 min to 3 h to achieve completion
[89–92].
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Figure 1.1: Cross-linking of hyperbranched furan-modified poly(glycerol-co-sebacate)
precursors with 1,10-(methylenedi-4,1-phenylene) bismaleimide (A). Fabrication of
elastomers via DA/rDA reaction. The process reprograms the polymer network into a
complex permanent geometry (B). The material can be fixed into a temporary planar
geometry below the glass transition temperature; when heated above the glass transi-
tion temperature, the material returns to its permanent helical shape. Adapted with
permission from Ref. [71].
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1.4.2 Synthesis of branched polymers and dendrimers
Dendrimers are highly branched molecules; the name is derived from the Greek
word dendron, which translates into “tree”. Unlike star-shaped polymers, den-
drimers are monodisperse; they are typically symmetric, spherical compounds with
nanoscale dimensions. The large number of functional groups on their surface
enables the conjugation of targeting ligands, dye molecules or pharmaceutically
active compounds. Due to these favorable properties, dendrimers have strong
potential as diagnostic agents, drug carriers or vehicles for gene delivery [93–95].
Monodisperse dendrimers can be synthesized by divergent or convergent methods.
Divergent methods start from a multifunctional core, which is extended outward
by repeated branching reactions. Each reaction step must be driven to completion
to avoid imperfections and impurities, which are extremely difficult to separate.
Alternatively, dendrimers can be built starting from the periphery; in these conver-
gent methods, small molecules are assembled to larger dendrons and eventually
attached to a central core. The removal of impurities is less problematic; however,
the resulting dendrimers are usually not as large as those synthesized by divergent
methods. The molecular weight of dendrimers is increasing with the number of
branching cycles that are performed during synthesis. As a consequence thereof,
the number of functional groups on the surface is increasing with each successive
generation.
The DA reaction has been successfully applied to the synthesis of dendrimers;
the synthetic strategies are quite similar to those used in the preparation of block
copolymers. In most approaches, the coupling between furan and maleimide was
utilized to assemble symmetrical, thermally responsive dendrimers. For instance,
benzyl aryl ether based dendrons with furan moieties at their focal point were
cross-linked with a bismaleimide linker [96, 97]. Since the DA reaction does not
require metal catalysts, the formed dendrimers are free of metal impurities, which is
an advantage if their biological use is intended. Furthermore, approaches combining
the CuAAC and the furan-maleimide DA reaction have been described [98, 99].
These approaches yield thermally reversible dendrimers that disassemble at 90-
120 ◦C via rDA reaction and reassemble at 50 ◦C. A similar strategy has been
used to prepare dendrimers carrying multiple drug molecules, which are released
under physiological conditions by rDA reaction [100]. A dendrimer core was
synthesized via a sequence of CuAAC reactions; lipoic acid was then conjugated
to the periphery using DA chemistry (Fig. 1.2). Lipoic acid, which was used as a
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model drug, is an important cofactor and antioxidant; the synthesized dendrimers
could protect microglial cells from oxidative stress. However, it should be noted that
the combination with CuAAC eliminates the advantage of the DA cycloaddition
of being a metal-free click reaction. In a different approach, furan-functionalized
poly(aryl ether) dendrons were reacted with maleimide-functionalized polyester
dendrons to obtain segment block dendrimers [101]. In contrast to other approaches,
in which the DA reaction was utilized to assemble symmetrical dendrimers, this
is an example for the synthesis of unsymmetrical dendrimers. Moreover, the DA
reaction was exploited in the synthesis of carbosilane dendrimers [102, 103] and
spherical polyphenylene dendrimers [104].
As already discussed in the previous section, the DA reaction between furan and
maleimide can be used to protect the maleimide group during incompatible reaction
steps, such as radical polymerizations or Michael-type additions. For example,
polyester dendrons containing furan-protected maleimide groups at their focal point
were synthesized. In situ thermal deprotection exposed the maleimide groups; these
were then reacted with an anthracene-appended polystyrene to afford dendronized
polymers [105]. The same group described the synthesis of diblock and triblock
dendron-polymer conjugates containing biodegradable polyester blocks and PEG
[106]. It might be possible to cast such dendronized polymers as hydrophilic films;
the multiple hydroxyl groups on these films could be converted to more reactive
groups and functionalized with molecules of interest. In a different approach,
multiarm star polymers were synthesized by ATRP using an initiator containing a
furan-protected maleimide group. Thermal deprotection provided a thiol-reactive
maleimide group; the polymer core was then successfully functionalized with
glutathione [107]. The combination of DA chemistry and Michael-type addition
reaction is, therefore, a promising strategy to decorate dendrimers with peptides or
proteins.
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Figure 1.2: Lipoic acid (MaLA) is conjugated to the periphery of thermosensitive
dendrimers via DA reaction (A). The rDA-mediated release of MaLA is temperature-
dependent, as evaluated by 1H-NMR spectroscopy (B). Adapted from Ref. [100] with
permission of The Royal Society of Chemistry.
1.4.3 Surface functionalization
The fabrication of surfaces that interact with cells in a specific way is an enormous
challenge in the development of biomaterials. For example, hydrophobic surfaces
are frequently coated with hydrophilic polymers, such as PEG or poly(vinyl alcohol),
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to create “stealth” materials, which effectively prevent the non-specific adsorption
of plasma proteins and cells. On the other hand, synthetic materials that do
not inherently interact with cells, such as hydrophilic polymer matrices, can
be modified with proteins of the extracellular matrix (ECM), such as collagen,
fibronectin, laminin or vitronectin, to provide “cues” that regulate cell attachment,
proliferation and differentiation [108, 109]. Alternatively, biomaterials can be
functionalized with short peptides such as Arg–Gly–Asp (RGD), Tyr–Ile–Gly–Ser–
Arg (YIGSR) or Ile–Lys–Val–Ala–Val (IKVAV). The RGD sequence is derived
from the integrin-binding site of fibronectin; surfaces modified with this tripeptide
were shown to promote cell adhesion and spreading [110, 111]. The combination
of both design principles (i.e., immobilization of PEG and functionalization with
cell-binding peptides) enables the fabrication of biomimetic materials that interact
with specific cell types in a certain way. The DA reaction is without doubt a useful
tool for surface functionalization. The modification process basically comprises
two major steps: first, either a diene or a dienophile is chemically bound to the
surface; in a second step, a biomolecule is added that has been modified with the
appropriate counterpart. Since the DA reaction proceeds in water without metal
catalysts, the process can be carried out under physiological conditions and in the
presence of cells.
For example, the DA cycloaddition has been successfully used for the immobi-
lization of streptavidin-diene conjugates on maleimide-functionalized glass surfaces
[48, 112]. Sun et al. [113] described a similar method for the chemoselective immo-
bilization of biomolecules through DA chemistry. To this end, heterobifunctional
PEG linkers containing cyclopentadiene in the α-position and a biomolecule in
the ω-position were synthesized. The linkers were then coupled to maleimide-
functionalized glass slides; in this way, biotin, lactose and protein A could be
immobilized on solid substrates. The same group demonstrated the applicability
of sequential DA reaction and CuAAC for the immobilization of biomolecules
[114]. PEG linkers carrying cyclopentadiene and alkyne groups were immobilized
on maleimide-functionalized glass slides via DA reaction; the alkyne groups on
the surface enabled the conjugation of azide-containing biomolecules via CuAAC.
Similar strategies could be applied to immobilize ECM proteins or antibodies on
solid substrates; however, it should be kept in mind that the presence of copper(I)
can induce severe damage to biomolecules [2–4]. Another way of functionalizing
surfaces with cell adhesion peptides is the DA reaction between benzoquinone
and cyclopentadiene. In this example, cyclopentadiene-tagged RGD peptides were
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immobilized on a benzoquinone-functionalized substrate [115]. Interestingly, benzo-
quinone could be electrically reduced to hydroquinone; these hydroquinone groups
were unable to react with cyclopentadiene-tagged RGD peptides, which allowed
the generation of patterned surfaces.
Figure 1.3: Generation of complex 3D structures by photolithography. Multifunctional
furan and maleimide monomers (A) form a cross-linked polymer network (B) by DA
reaction. In the irradiated areas (C), oxy-norbornene groups are converted to irre-
versible cross-links by radical reaction with thiol-containing molecules. Heating in-
duces the rDA reaction and removes the material from the non-irradiated areas (D).
Adapted with permission from Ref. [116].
Photolithography is another method for surface modification; thereby, patterned
surfaces and complex 3D structures can be created with high precision. For this
purpose, multifunctional furan and maleimide monomers were first cross-linked
by DA reaction to form oxy-norbornene groups [116]. Irradiation and radical
reaction with thiol-containing molecules converted these oxy-norbornene groups
to irreversible cross-links. Heating the sample caused the material in the non-
irradiated areas to depolymerize by rDA reaction, while leaving the irradiated
regions unaffected (Fig. 1.3). In conjunction with thiol-functionalized molecules,
such as cysteine-containing peptides, this process would enable the fabrication of
patterned surfaces or complex 3D structures with defined chemical functionaliza-
tion. A related method involved the modification of silicon oxide surfaces with
photoreactive 3-(hydroxymethyl)naphthalene-2-ol moieties [117]. Irradiation with
UV light generated reactive moieties, which rapidly underwent DA reaction with
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suitable dienophiles. In this way, various molecules, such as fluorescent dyes or
vinyl ether-biotin conjugates, could be selectively immobilized in the light-exposed
areas.
1.4.4 Bioconjugation
As described in the previous section, the DA reaction can be utilized to immo-
bilize biomolecules on solid substrates. Similar strategies can be applied to the
functionalization of nanoparticles with DNA [118] or antibodies [119–123]. For
example, Shi and Shoichet [119] synthesized furan-functionalized, amphiphilic block
copolymers. Using a membrane dialysis method, these polymers self-assembled into
nanoparticles with a hydrophobic inner core and a hydrophilic outer shell carrying
furyl groups. Anti-HER2 antibodies (trastuzumab) were modified with maleimide
functional groups in their Fc region and covalently bound to the nanoparticles via
DA coupling (Fig. 1.4) [120]. These anti-HER2 immuno-nanoparticles specifically
bound with HER2-overexpressing SKBR-3 breast cancer cells, demonstrating their
capacity for targeted drug delivery. As a further proof of concept, the chemothera-
peutic doxorubicin was bound to anti-HER2 immuno-nanoparticles via DA coupling
[121]. While free doxorubicin showed similar cytotoxicity against both SKBR-3
cells and healthy HMEC-1 cells, doxorubicin-conjugated immuno-nanoparticles
were significantly more cytotoxic against SKBR-3 cells. A similar strategy was used
for the targeted delivery of small interfering RNAs and antisense oligonucleotides
[123]. A potential disadvantage of this bioconjugation method is the electrophilicity
of maleimide, which can result in side reactions with nucleophilic groups (e.g.,
sulfhydryl or amino groups) of other molecules (e.g., polymers, peptides or proteins),
cells or tissues.
Furthermore, the DA/rDA reaction of furan and maleimide can facilitate the
synthesis of maleimide-terminated polymers, which react with cysteine residues of
proteins in a Michael-type addition reaction. For example, heterotelechelic polymers
with a biotin group at one end and a furan-protected maleimide group at the other
end were synthesized by RAFT polymerization [124]. After thermal deprotection,
the polymer was conjugated to model proteins and anchored to streptavidin-
functionalized surfaces. A similar approach was pursued by Mantovani et al. [125];
they used an initiator containing a furan-protected maleimide for the synthesis
of hydrophilic polymers via ATRP. After the polymerization step, the maleimide
group was reintroduced by rDA reaction; these maleimide-terminated polymers
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were successfully employed in conjugation reactions with reduced glutathione and
bovine serum albumin. Besides the preparation of protein-polymer conjugates,
the hetero-DA reaction has been successfully used for the covalent modification
of the interior surface of viral capsids [126]. Moreover, the DA reaction has
been used for the preparation of peptide-oligonucleotide conjugates and synthetic
neoglycoproteins; for this purpose, the reaction partners were equipped with a
suitable diene-dienophile pair [127, 128].
Besides the normal electron-demand DA reaction, the IEDDA reaction is a
valuable tool for bioconjugation. Both reactions share common characteristics;
for example, they proceed in water at room temperature and do not require any
catalyst. However, the IEDDA reaction has the additional advantage of being
bioorthogonal, i.e., the reaction is inert to the myriad of functionalities found in
proteins or cells. This opens up further possibilities for bioconjugation. In this
context, especially the cycloaddition of s-tetrazine and trans-cyclooctene derivatives
has proven to be useful. The reaction proceeds in high yield in organic solvents,
water, cell media, or cell lysate [129, 130]. It has been utilized for site-specific
fluorescence labeling of proteins on the cell surface and inside living mammalian cells
[131]. Another important application of the IEDDA reaction is tumor pretargeting.
In this approach, an antibody-conjugated trans-cyclooctene was injected into tumor
bearing BALB/C mice [132]. After binding of the antibody to the tumor tissue, a
tetrazine-functionalized clearing agent was injected. This clearing agent was bound
to the circulating antibody via IEDDA coupling and enabled its rapid removal
from blood. Afterward, a radiolabeled tetrazine was injected and coupled to the
tumor-bound antibody via IEDDA reaction. This approach could boost the tumor
radiation dose compared to non-pretargeted radioimmunotherapy. Using a similar
principle, Zeglis et al. [133] developed a pretargeted PET imaging technology. A
human A33 antibody was modified with trans-cyclooctene and injected into mice
bearing SW1222 xenografts; afterward, the mice were injected with a radiolabeled
tetrazine for PET imaging.
Using the IEDDA ligation, a temozolomide (TMZ) BioShuttle has been developed
for the treatment of prostate cancer and brain tumors [134, 135]. In brief, a cell
penetrating peptide (CPP) was linked via a redox-sensitive disulfide bridge to a
nuclear localization sequence (NLS) carrying a cyclooctatetraene as the dienophile.
In a second step, a TMZ-tetrazine conjugate was linked to the peptide via IEDDA
ligation. The CPP module can facilitate cellular uptake of the cargo, while
the NLS module mediates its transport into the nucleus. Compared to TMZ
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Figure 1.4: Functionalization of nanoparticles with antibodies. Furan-functionalized,
amphiphilic block copolymers self-assemble into nanoparticles with a hydrophobic
core and a hydrophilic outer shell carrying furyl groups. Maleimide-labeled anti-HER2
antibodies are covalently bound to the nanoparticles via DA coupling. Reprinted with
permission from Ref. [120].
alone, the TMZ-BioShuttle was more cytotoxic against prostate cancer and human
glioblastoma cell lines. Moreover, the IEDDA reaction has been employed to enable
the instantaneous release of drug substances. To this end, Versteegen et al. [136]
developed a novel bioorthogonal elimination reaction. First, a (E)-cyclooct-2-en-
1-yl doxorubicin carbamate was prepared; IEDDA reaction with tetrazine and
subsequent cleavage of the carbamate released the drug from the conjugate in a
second step. Using this strategy, it would be possible to prepare antibody-drug-
conjugates; the drug would be released from the tumor-bound antibody through
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reaction with subsequently administered tetrazine. At this point it should be
mentioned that other ligation reactions, such as the tandem [3 + 2] cycloaddition-
retro-DA reaction, are promising bioconjugation methods as well. In this reaction,
trifluoromethyl-substituted oxanorbornadiene derivatives react with various azides
to form stable 1,2,3-triazole-linked products [137, 138].
1.4.5 Nanotechnology
Nanomaterials, such as dendrimers, polymeric micelles, polyplexes, nanoparticles,
nanocapsules or liposomes, afford new opportunities in drug development and drug
delivery. For example, many nanomaterials improve the solubility of hydrophobic
drugs, prolong the circulating half-life, and reduce potential immunogenicity. Fur-
thermore, nanomaterials can provide sustained or triggered release of drugs, and
thus reduce the administration frequency. Nanoscale drug delivery systems often
accumulate in specific tissues (e.g., tumors) through the enhanced permeability
and retention effect (passive drug targeting). In addition, the presence of targeting
ligands, such as antibodies or aptamers, can enhance the retention and cellular
uptake of nanomaterials (active drug targeting). Both principles can enhance
the therapeutic efficacy of drugs and reduce undesired side effects. Besides drug
development and drug delivery, nanotechnology is also benefitting the development
of diagnostics and biomaterials. In the field of tissue engineering, nanotechnology
can enable the fabrication of scaffolds that closely resemble the native ECM [139].
The DA/rDA reaction has been successfully used for the assembly or disassembly
of nanostructures. For example, Bapat et al. [140] synthesized block copolymers of
maleic anhydride and styrene; subsequent ring opening of the anhydride groups
with furfurylamine resulted in pendant furyl groups. These block copolymers were
allowed to pre-assemble into polymeric micelles. The addition of a bismaleimide
gave thermoreversible, core-crosslinked micelles; heating caused the micelles to
dissociate back to the individual polymers. In an approach to control the dispersion
and migration of nanomaterials, Costanzo et al. [141, 142] coated gold nanoparticles
with thiol-terminated PS-b-PEG copolymers, where the PS and PEG blocks were
joined via thermoreversible DA linkages. These PEG-functionalized nanoparticles
were dispersed in a PS-b-PMMA copolymer matrix. Since PEG and PMMA are
miscible, the nanoparticles were preferentially located within the PMMA domains
of the matrix. Thermal treatment caused the PS-b-PEG copolymers to dissociate
and exposed the PS ligands on the surface of the nanoparticles. Since PS and
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PMMA are immiscible, migration of the nanoparticles to the PS domains of the
matrix could be observed. Moreover, the rDA reaction has been exploited to
fabricate reactive nanostructures via thermal nanoimprint lithography [143]. To
this end, a polymer film with furan-masked maleimide groups was spin-coated onto
a silicon substrate. Nanoimprinting was performed with a patterned silicon mold
at 175 ◦C and a pressure of 400 psi; thereby, the mold pattern was transferred into
the polymer. The high temperature simultaneously triggered the rDA reaction to
yield a maleimide-patterned surface. These surfaces could be post-functionalized
with iron oxide nanoparticles or RGD peptides. The reactive patterns may provide
versatile scaffolds, e.g., for cellular patterning.
The rDA reaction can also be exploited to control drug release from nanopar-
ticulate carriers. Bakhtiari et al. [144] developed an interesting approach for the
release of molecules based on the photothermal effect of gold nanoparticles. A
fluorescein dye was anchored on the surface of silica-gold core-shell nanoparticles via
a thermoreversible DA linker. The fluorescence emission was efficiently quenched
by the gold layer of the nanoparticles. When the system was illuminated at the
surface plasmon resonance (SPR) wavelength of gold nanoparticles (typically 400 -
1100 nm), the absorbed light energy was converted into heat. This induced the
rDA reaction; the dye was released from the nanoparticles, as indicated by the
increasing fluorescence intensity (Fig. 1.5). The developed technology provides
both temporal and spatial control of release and would, therefore, be useful for drug
delivery and other biomedical applications. In a similar approach, gold nanorods
were modified with PEG chains through DA cycloadducts [145]. Gold nanorods
have an SPR band in the near-infrared (NIR) region, where light has its maximum
tissue penetration depth. When the modified gold nanorods were irradiated with
NIR light, the rDA reaction was induced by the photothermal effect and the PEG
chains were released from the gold nanorods. This technology would enable the
preparation of controlled release systems that respond to external stimuli.
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Figure 1.5: A fluorescein dye is anchored on the surface of silica-gold core-shell nanopar-
ticles via a thermoreversible DA linker (A). The fluorescence intensity increases when
aqueous dispersions of nanoparticles are heated or irradiated with NIR light (B). The
technology enables the development of drug delivery systems that respond to external
stimuli. Adapted with permission from Ref. [144].
1.4.6 Hydrogels
Hydrogels are polymer networks that are expanded throughout their whole volume
by water; they can be fabricated from a wide range of natural (e.g., alginate, dextran
or hyaluronic acid) and synthetic polymers (e.g., PEG or polymers based on acrylate
monomers). Depending on how the polymer networks are formed, hydrogels can be
classified into physical and chemical gels. In physical hydrogels, the networks are
formed by reversible aggregation of polymer chains (e.g., hydrophobic interactions
or ionic bonding), whereas chemical hydrogels contain covalently cross-linked
networks [109, 146]. Covalently cross-linked hydrogels are versatile materials with
many favorable properties (e.g., high water content, biocompatibility, mechanical
flexibility, etc.). It is therefore not surprising that many pharmaceutical and
biomedical applications of hydrogels have been proposed and investigated.
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Hydrogels for drug delivery
The use of hydrogels as release systems for biopharmaceuticals, such as therapeutic
proteins, seems highly attractive: many hydrogels can be administered by injection,
they protect incorporated proteins against degradation, and they provide sustained
or triggered drug release [146]. Drug loading and cross-linking are often performed
simultaneously; the release rate can be adjusted by controlling the cross-linking
density and, hence, the mechanical properties and permeability of the hydrogel. This
requires efficient cross-linking reactions that do not adversely affect the stability of
incorporated proteins. The DA reaction meets these criteria: the reaction proceeds
in water at room temperature; furthermore, no purification step is required to
remove potentially toxic catalysts or initiators. The DA reaction is, therefore, a
suitable cross-linking method to prepare hydrogels.
For example, a self-healing dextran-based hydrogel was formed by cross-linking
of a fulvene-modified dextran with a dichloromaleic acid-modified PEG [147].
Although the DA reaction between fulvene and dichloromaleic acid proved to
be straightforward, the furan-maleimide pair is predominantly used for hydrogel
formation. In most approaches, linear polymer chains with pendant furan moieties
were cross-linked with bismaleimides. For example, hydrogels were prepared from
N-vinyl-2-pyrrolidine, poly(N-isopropylacrylamine) or poly(furfuryl amine maleic
acid monoamide-co-N-isopropyl-acrylamide) [148–150]. In this context, it has been
shown that the gelation time, cross-linking density and swelling capacity depend
on both the furan intake and the maleimide concentration. In contrast to that, the
depolymerization temperature was only marginally influenced by the furan and
maleimide concentrations [151]. At this point it should be mentioned that molecules
bearing two furan moieties can act as cross-linking agent as well. For example,
amphiphilic gels were prepared by DA reaction of acetylene dicarboxylate-containing
PEG with furan-functionalized oligomers [152]. Alternatively, hydrogels can be
formed by multiple DA reactions between two linear polymer chains with pendant
furan and maleimide groups, respectively [153, 154]. For example, furan- and
maleimide-functionalized HA derivatives formed biodegradable hydrogels in aqueous
environment at 37 ◦C. Two model proteins, insulin and lysozyme, were successfully
encapsulated and released over 21 days. However, possible side reactions between
maleimide-functionalized HA and encapsulated proteins were not investigated in
this study. Furthermore, the hydrogels preserved the viability of human adipose-
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derived stem cells [154]. Therefore, these polysaccharide hydrogels may serve as a
platform for both drug delivery and tissue engineering.
Despite the reversibility of the DA/rDA reaction, most hydrogels cross-linked
by DA reaction do not readily degrade at 37 ◦C. It has been shown that the
equilibrium conversion of the furan-maleimide pair varies from 74% at 85 ◦C to 24%
at 155 ◦C; at sufficiently high temperature, significant depolymerization occurs via
rDA reaction [49]. In order to cause degradation, multiple rDA reactions must occur
simultaneously at significant rate, which is unlikely in densely cross-linked networks
at 37 ◦C. However, Kirchhof et al. [155, 156] recently reported the preparation
of PEG-based hydrogels that degraded under physiological conditions via rDA
reaction. Star-shaped PEG was end-functionalized with furan and maleimide
groups, respectively; hydrogels were formed by step-growth polymerization of the
obtained macromonomers. Interestingly, the cross-linked gels degraded at pH 7.4
and 37 ◦C by rDA reaction and subsequent ring-opening hydrolysis of the generated
maleimide groups (Fig. 1.6). Removal of the maleimide groups from the DA/rDA
equilibrium by hydrolysis caused the DA adducts to revert to the starting materials.
In this way, the rate of the rDA reaction was increased according to Le Chaˆtelier’s
principle without the need for elevated temperatures. The gel properties (e.g., gel
time, complex shear modulus and degradation time) were found to depend on the
concentration, branching factor and molecular weight of the macromonomers. The
determined values of the average network mesh size indicated that the prepared
hydrogels could provide controlled release of therapeutic antibodies.
In the above-mentioned examples, the polymer networks were formed by DA
reaction of suitable diene-dienophile pairs. However, it is also possible to combine
two different gelation mechanisms (e.g., thermal gelation and covalent cross-linking).
For example, Hsu et al. [157] synthesized furan-terminated poly(ethylene glycol)-b-
poly(L-lactide) and poly(ethylene glycol)-b-poly(D-lactide) copolymers. Micellar
solutions of the two polymers showed a temperature-dependent sol-gel phase
transition at concentrations above 25%; the addition of a bismaleimide cross-linker
could reinforce the gel structure, as indicated by the increased storage modulus.
The combination of two different gelation mechanisms is an effective strategy to
overcome the long gelation time of hydrogels cross-linked by DA reaction. This
is particularly important when drug-loaded hydrogels are formed in situ (e.g.,
after subcutaneous or intravitreal injection) and rapid diffusion of the active
ingredient from the injection site must be avoided. Besides serving as cross-
linking reaction, the DA reaction between furan and maleimide can be used to
26
1.4 Pharmaceutical and biomedical applications of the Diels–Alder reaction
Figure 1.6: Preparation of degradable DA hydrogels. Eight-armed PEG is function-
alized with furan and maleimide groups, respectively; hydrogels are formed by DA
reaction of the obtained macromonomers. The cross-linked gels degrade under phys-
iological conditions by rDA reaction and subsequent ring-opening hydrolysis of the
generated maleimide groups. Reprinted from Ref. [156] with permission from The
Royal Society of Chemistry.
protect the maleimide group during cross-linking. For example, hydrogels could
be synthesized by radical polymerization of PEG monomethyl ether methacrylate
and a furan-protected maleimide monomer [158]. Thermal deprotection by rDA
reaction afforded maleimide-containing hydrogels. In a second step, these gels
could be functionalized with a thiol-containing fluorescent dye or a thiol-containing
biotin derivative via thiol-ene addition.
Hydrogels for tissue engineering
In the field of tissue engineering, hydrogels can be used as space filling agents,
as vehicles for the delivery of bioactive molecules, or as scaffolds for cell delivery.
Hydrogels designed to encapsulate cells must meet specific requirements. For
example, the gelation process and the cross-linked material must be compatible
with cells and the surrounding tissue, the hydrogel must allow the diffusion of
nutrients and metabolites, and the scaffold must have sufficient mechanical integrity
to withstand the occurring mechanical loads [109]. Furthermore, the hydrogel
must present chemical and physical stimuli to direct the formation of a desired
tissue [159]. Since the DA cycloaddition proceeds under physiological conditions
without any catalyst or initiator, the reaction is suitable for the preparation of
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cell-laden hydrogels. In general, two strategies involving the DA reaction can
be distinguished: first, the DA reaction can be used as a cross-linking method;
second, the DA/rDA equilibrium can be exploited for the conjugation and/or
release of bioactive molecules that regulate cell growth, spreading or differentiation.
Therefore, most hydrogels are hybrid materials consisting of both synthetic and
natural compounds.
For example, furan-modified hyaluronic acid (HA) derivatives were cross-linked
with maleimide-functionalized PEG [160]. The mechanical and degradation proper-
ties of the resulting hydrogels could be tuned by varying the furan to maleimide
molar ratio. Since neither additional cross-linking agents nor catalysts were re-
quired, HA-PEG hydrogels showed a high level of cell survival, suggesting that these
hydrogels would be suitable for applications in tissue engineering. Furthermore,
epidermal growth factor gradients could be generated by photopatterning [161].
These chemical gradients are important in guiding cell migration, development and
growth. In a related approach, an injectable HA-PEG hydrogel was prepared by
integrating two cross-linking processes [162]. HA was modified with tyramine and
furylamine functional groups; the hydrogel was formed by enzymatic cross-linking
between the tyramine groups, followed by a second cross-linking step between furan
groups and maleimide-functionalized PEG. As already discussed in the previous
section, the combination of two different cross-linking methods ensures the fast
gelation of in situ forming hydrogels. Encapsulated ATDC-5 cells showed high
viability and proliferation, indicating the great potential of HA-PEG hydrogels
in cartilage tissue engineering. To refine the system, interpenetrating networks
were synthesized from HA, gelatin and chondroitin sulfate. Cross-linking by DA
chemistry gave biodegradable hydrogels that are expected to mimic the natural
ECM of cartilage [163].
To enhance cell adhesion and better mimic the ECM, Silva et al. [164] synthesized
a novel peptide-modified gellan gum hydrogel. To this end, a maleimide-containing
GRGDS peptide was linked to furan-modified gellan gum via DA chemistry. These
GRGDS-modified hydrogels have been shown to promote adhesion and proliferation
of neural stem/progenitor cells (NSPCs). Co-culture with olfactory ensheathing
glia could further improve survival and outgrowth of NSPCs. Therefore, the
developed system may be beneficial in regenerative medicine, e.g., to promote
repair after spinal cord injury. Besides the normal electron-demand DA reaction,
the tetrazine-norbornene IEDDA reaction has been used for the formation of
cell-laden hydrogels [165]. A multifunctional PEG-tetrazine macromonomer was
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reacted with an enzymatically degradable dinorbornene peptide; a norbornene-
containing RGDS peptide was added to promote cell adhesion. Encapsulated human
mesenchymal stem cells (hMSCs) showed high viability after 72 h, demonstrating
the cytocompatibility of the cross-linking reaction.
Figure 1.7: rDA-mediated release of RGDS peptides from PEG hydrogels. Furan-
labeled RGDS peptides are covalently linked to tetrafunctional PEG-maleimide
macromonomers via DA reaction. Hydrogels are formed by Michael addition reac-
tion between PEG-maleimide and tetrafunctional PEG-thiol macromonomers. The
release of furan-labeled RGDS is mediated by rDA reaction; increasing the tempera-
ture results in higher release rates. Reprinted with permission from Ref. [166].
As already mentioned before, the DA/rDA equilibrium can be exploited to control
and sustain the release of drugs from hydrogels. As a proof of concept, furan-
labeled RGDS peptides were covalently linked to multifunctional PEG-maleimide
macromonomers via DA reaction; a Michael-type addition reaction between the
remaining maleimide groups and multifunctional PEG-thiol macromonomers was
then performed to create a covalently cross-linked hydrogel [166]. In vitro release
experiments at three distinct temperatures demonstrated rDA-mediated release of
the furan-labeled RGDS peptide from the hydrogel (Fig. 1.7). To demonstrate the
practical utility of this approach, a furan-containing dexamethasone peptide was
covalently linked to a PEG hydrogel via DA reaction as described above [167]. In
a 2D culture model, rDA-mediated release of dexamethasone stimulated hMSCs
to undergo osteogenic differentiation. More distinct differences were observed in
3D culture, when a dexamethasone releasing hydrogel was encapsulated within an
hMSC-laden hydrogel, as indicated by increased alkaline phosphatase activity and
mineral deposition.
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1.5 Pitfalls and challenges of the Diels–Alder
reaction
As outlined in the previous section, the DA reaction has been successfully applied
to various problems in drug delivery and biomaterial design. However, to exploit
the full potential of the DA reaction, it is necessary to talk about possible pitfalls
and challenges as well. Although the DA reaction is extremely efficient, the
comparatively slow reaction rate at room temperature may be a potential drawback.
While the reaction rate may be less of an issue in applications such as the synthesis
of polymers or dendrimers, it is certainly critical in the preparation of in situ
forming hydrogels. Such hydrogels must completely encapsulate the drug after
injection and rapidly form a drug depot at the application site, e.g., under the skin
or inside the eye. Cross-linking via DA reaction can result in dose dumping; this
may cause adverse effects or drug-induced toxicity. In theory, the gel time could
be decreased by increasing the temperature [49] or pressure [168]; furthermore,
Lewis acids, such as AlCl3, Cu(NO3)2 or Ni(NO3)2, can dramatically accelerate the
DA reaction [22–25]. However, these reaction conditions are not compatible with
biological systems or proteins. Instead, the gel time can be decreased by combining
two separate cross-linking processes. For example, fast-gelling thermoresponsive
hydrogels were obtained by stereocomplex formation of enantiomeric PLA and
concomitant DA reaction [157]. Similarly, the integration of enzymatic cross-linking
and DA chemistry proved to be successful in the preparation of injectable hydrogels
[162]. Furthermore, it has been reported that the addition of β-cyclodextrin
catalyzes the DA reaction of some dienes and dienophiles [44, 169]. Therefore,
β-cyclodextrin might serve as innocuous alternative to Lewis acids and accelerate
the formation of hydrogels.
Besides the reaction rate, the reversibility of the normal electron-demand DA
reaction represents another potential pitfall that needs to be considered. Although
the reversibility of the reaction opens up many possibilities, such as the fabrication
of degradable materials or the development of controlled release systems, the
formation of stable adducts may be required in applications such as the synthesis of
non-degradable polymers or dendrimers. Similarly, the functionalization of surfaces
or nanoparticles with biomolecules often requires the formation of stable conjugates.
While the furan-maleimide pair undergoes rDA reaction at around 100 ◦C, the
cycloreversion of the anthracene-maleimide adduct occurs at temperatures above
200 ◦C [19]. It is therefore possible to prepare stable conjugates by using anthracene
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as diene and maleimide as dienophile. Furthermore, the reversibility of the reaction
can be controlled by changing the substitution pattern of the involved DA pair,
or by changing the solvent system [51, 52]. To circumvent the above-mentioned
drawbacks, the IEDDA reaction has been proposed as an alternative ligation method
[129, 130]. The primary adduct of the IEDDA reaction stabilizes by eliminating
nitrogen so that the reverse reaction is excluded (Scheme 1.1D). Furthermore,
systems can be designed in such a way that the DA reaction can be “locked” and
“unlocked” using light [170]. In the first step, a photoresponsive dithienylfuran
was reacted with N-ethylmaleimide. Irradiation with UV light led to ring closure
of the DA product; this ring-closed photoisomer lacked the cyclohexene ring
necessary for the rDA reaction to proceed. However, irradiation with visible light
regenerated the ring-open photoisomer and the ability to undergo rDA reaction.
This concept could be used, e.g., to control drug release. It would be possible to
bind drug molecules to a polymeric carrier and turn “off” the rDA reaction by UV
irradiation. This would effectively prevent premature drug release, e.g., during
storage. Irradiation with visible light would then “unlock” the DA reaction and
enable drug release. In the context of bioconjugation, the necessity to insert reactive
moieties, such as maleimide or trans-cyclooctene groups, into the biomolecule
represents another disadvantage of the DA reaction [120, 127, 131, 133]. The
relevant groups can be incorporated by reacting the biomolecule, e.g., with N-
succinimidyl 4-maleimidobutyrate or (E)-cyclooct-4-en-1-yl succinimidyl carbonate;
however, these labeling reactions are not site-specific and the product needs to
be purified by dialysis, ultrafiltration or size-exclusion chromatography. The
site-specific incorporation of norbornene, trans-cyclooctene or furan moieties into
proteins can be realized using the pyrrolysyl-tRNA synthetase/tRNACUA pair from
Methanosarcina species [171–174]. These genetically encoded groups enable the
selective modification of proteins via DA or IEDDA chemistry. In approaches where
the DA/rDA equilibrium is exploited to control the release of drugs, it should
be furthermore considered that incorporated furan or maleimide moieties remain
attached to the molecule after release. These remaining “tags” may affect the
stability, bioactivity, receptor affinity or immunogenicity of peptides and proteins
[175–181].
However, the most serious drawback is that the normal electron-demand DA
reaction is not inert to nucleophiles of proteins or cells. For example, maleimide is
a strong electrophile; it can undergo Michael-type addition with cysteine, lysine,
arginine, histidine and tryptophan residues of proteins [182]. This side reaction can
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on the one hand inhibit the DA cycloaddition; on the other hand, it can result in
the formation of unwanted side products, e.g., during the synthesis of bioconjugates
(Fig. 1.8A). When the DA reaction is used to prepare hydrogels, the Michael-type
addition of nucleophilic amino acid residues to maleimide groups can affect both the
availability and biological activity of entrapped biomolecules [182–184]. To prevent
this side reaction, the bioconjugation or cross-linking reaction should be carried
out in acidic buffer (e.g., MES buffer pH 4.5-5.5). Amino groups are protonated at
this pH; this lowers the nucleophilicity of basic amino acid residues and inhibits
their Michael-type addition to maleimide [182]. Another advantage is the increased
stability of maleimide at acidic pH. As a result, bioconjugation or cross-linking
processes become more efficient, as less maleimide groups are consumed by ring-
opening hydrolysis [156]. However, it should be noted that lowering the pH may
induce protein denaturation and aggregation [185, 186]. To develop a nucleophile-
tolerant DA ligation reaction, Tang et al. [187] calculated the Gibb’s free energies
of activation (∆G6=) of DA and Michael-type addition reactions. They found that
the Michael-type addition of methanethiol to N-methylmaleimide has a much lower
energy barrier (∆G 6= = +3.4 kcal mol-1) than the DA reaction of 1,3-butadiene and
N-methylmaleimide (∆G 6= = +20.9 kcal mol-1). Compared with this, the energy
barrier for the thiol addition to 1,2-bis(hydroxymethyl)-3-carboxycyclopropene is
much higher (∆G 6= = +26.2 kcal mol-1); however, the energy barrier for the DA
reaction (∆G6= = +24.2 kcal mol-1) is still relatively low due to the ring strain
of cyclopropene. Therefore, 1,2-bis(hydroxymethyl)-3-carboxycyclopropene may
act as a nucleophile-tolerant dienophile in DA ligation reactions (Fig. 1.8B). As a
last point, I would like to remind the reader that the IEDDA reaction is, unlike
the normal electron-demand DA reaction, a bioorthogonal ligation reaction that
tolerates a broad range of biological functionality [129, 130].
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Figure 1.8: Michael-type addition reaction of the thiol group to maleimide (A).
1,2-Bis(hydroxymethyl)cyclopropene derivatives may act as nucleophile-tolerant
dienophiles in DA ligation reactions (B).
1.6 Summary and perspectives
Although the DA reaction has certain limitations, it is without doubt one of the most
useful reactions for the development of drug delivery systems and biomaterials.
Fig. 1.9 illustrates possible applications of the DA reaction in pharmaceutics
and biomedical engineering. For reasons of clarity, the furan-maleimide pair is
exemplarily used in the illustration; in practice, other diene-dienophile pairs, such
as anthracene and maleimide, can be employed as well. The DA cycloaddition is
an efficient and selective coupling reaction that can be employed for the synthesis
of copolymers and dendrimers (Fig. 1.9A). In this context, the cycloaddition of
furan and maleimide can protect the maleimide functionality during incompatible
reaction steps, e.g., during radical polymerizations (Fig. 1.9B). In the biomedical
field, the DA reaction (and in particular the IEDDA reaction) can be applied
to bioconjugation. For example, the DA cycloaddition can be employed for the
functionalization of drug delivery systems with targeting ligands such as peptides,
antibodies or aptamers (Fig. 1.9C). In the context of drug delivery systems, the
DA/rDA equilibrium can also be exploited to control and sustain the release of
active ingredients from nanoparticulate carriers or hydrogels (Fig. 1.9D). Similar
strategies can be applied to the functionalization of surfaces with biomolecules,
such as cell adhesion peptides or ECM proteins (Fig. 1.9E). And last but not least,
the DA reaction can be used as a cross-linking method for hydrogel preparation
(Fig. 1.9F). These kinds of hydrogels may serve as controlled release systems for
biopharmaceuticals or as three-dimensional scaffolds for cell transplantation. At
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the end, I hope that the herein provided set of tools may facilitate the application
of the DA reaction to solve important pharmaceutical or biomedical problems.
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Figure 1.9: Possible applications of the DA reaction in pharmaceutics and biomedical
engineering.
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Since the approval of the first monoclonal antibody Muromonab-CD3 by the
US Food and Drug Administration in 1986, antibodies have revolutionized the
treatment of cancer, autoimmune disorders, and other severe diseases [188, 189].
However, despite their high specificity, systemic administration of antibodies can be
associated with adverse effects, such as immune reactions, autoimmune conditions,
platelet disorders, and infections [190]. Therefore, localized antibody therapy can
be superior to systemic administration when diseases are confined to a specific
area or tissue. In local therapy, antibodies are directly administered to the site
of disease. During this treatment, comparably low antibody doses can be utilized
to achieve therapeutic goals while avoiding systemic effects and reducing therapy
costs [191].
Local antibody delivery has already been demonstrated to be beneficial for a
variety of diseases. Prominent examples include intra- or peritumoral injections
[192–194], intraarticular injections for the treatment of arthritic joint diseases
[195], and intrathecal injections to alleviate disorders of the central nervous system
[196]. A particularly interesting example is intravitreal antibody administration
for the treatment of vitreoretinal diseases, such as neovascular age-related macular
degeneration (AMD) or proliferative diabetic retinopathy (PDR) [197, 198]. During
the treatment, VEGF-neutralizing antibodies or antibody fragments are injected
directly into the vitreous humor to mitigate retinal and choroidal neovascularization
[199]. As the ocular half-life of commonly used antibodies is limited, e.g., 9.8 days
for bevacizumab [200] and 7.2 days for ranibizumab [201], injections must be
repeated on a regular basis to maintain therapeutic levels. However, intravitreal
injections are associated with patient discomfort and may be accompanied by rare
but serious complications [202]. Antibody reservoirs that enable controlled long-
term release would help to reduce the dosing frequency, improve patient compliance,
and reduce treatment costs. Therefore, the development of delivery systems that
provide controlled local antibody release is a core aspect for improving antibody
therapy in general and for the treatment of vitreoretinal diseases in particular.
Hydrogels can be considered nearly ideal carriers for antibody delivery as they can
be administered using minimally invasive techniques, are biocompatible, provide a
protective environment against degradation, and can be loaded with high amounts
of antibody [146, 184]. There is a myriad of materials and a great variety of
gelation mechanisms that can be utilized to prepare hydrogels. As introduced in
Chapter 1, the Diels-Alder (DA) reaction, especially the one between maleimide
and furan, is a highly promising click reaction for the design of hydrogels and
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biomaterials. DA click hydrogels can be formed via covalent cross-linking at mild
conditions without the need for a catalyst. Moreover, no toxic by-products are
formed and the resulting hydrogels are degradable. Therefore, DA hydrogels can be
cross-linked directly at the site of injection which makes them highly attractive for
pharmaceutical applications. However, it has also been highlighted in the previous
chapter that the use of DA reactions is limited by two major drawbacks. First,
gel formation proceeds slowly which prevents rapid depot formation at the site of
injection. Consequently, antibodies may not be reliably entrapped inside the gel
matrix which could result in dose dumping and adverse effects. Second, maleimide
cannot only undergo DA reactions as a dienophile but is also a strong electrophile.
Therefore, Michael-type addition reactions with nucleophilic residues on proteins
are a serious concern that should be prevented because these reactions could alter
antibody structure, lead to activity loss, or adversely affect release. The goal of
this thesis was to utilize click chemistry for the development of antibody delivery
systems. A particularly important aim was to identify new ways to circumvent
the drawbacks of the DA click reaction while maintaining its advantages. In this
way, the full potential of DA click hydrogels as a delivery system for local antibody
therapy could be utilized.
For the preparation of conventional DA hydrogels, multi-armed poly(ethylene
glycol) (PEG) functionalized with maleimide or furyl groups are combined in
aqueous solution and gelation is achieved via chemical cross-linking [155]. However,
as mentioned above the gel formation proceeds too slowly for many applications.
In a first approach to accelerate gelation, hydrophobic alkyl spacers were inserted
between the PEG backbone and the functional end-groups. The goal of this
approach was to induce hydrophobic association of the terminal ends and to
facilitate the interaction of the functional groups. Consequently, a more efficient
cross-linking process should be achieved which would be accompanied by shorter
gel times, fewer network defects, improved mechanical properties, and the ability
to delay antibody release (Chapter 3).
In an alternative approach, macromonomers were synthesized employing poloxam-
ine instead of PEG as a polymer backbone. Poloxamine solutions are biocompatible
and well-known for exhibiting temperature induced gelation. Ideally, functionaliza-
tion of four-armed poloxamines with maleimide and furyl groups would lead to dual
gelling hydrogels that immediately gel at body temperature and concomitantly
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cross-link via the DA reaction. Such hybrid hydrogels combine the immediate
physical sol-gel transition with the stability of chemically cross-linked hydrogels
and, therefore, the best properties of both mechanisms. Moreover, eight-armed
macromonomers were synthesized to study the effect of branching and to tailor
mechanical properties and antibody release profiles (Chapter 4).
As introduced above, Michael-type reactions of maleimide with nucleophilic amino
acid side chains are a serious concern. In order to overcome this issue, antibodies
could be loaded into micro-sized gel particles to safeguard them from detrimental
side-reactions. Moreover, such antibody-loaded microgels could be utilized as a
delivery platform for local antibody delivery. However, the fabrication of antibody-
loaded microgels with narrow size-distribution and without negatively affecting
antibody stability is highly challenging. To achieve this goal, the combination
of microfluidics and thiol-ene photoclick chemistry was evaluated as a protein
compatible fabrication process for antibody-loaded microgels (Chapter 5).
Finally, it would be ideal if undesired side-reactions could be suppressed by
simply adding a protective excipient before cross-linking. In this way, hydrogel
properties, macromonomer structure, and cross-linking conditions could remain
unchanged while protein-conjugation and activity loss is circumvented. Various
pharmaceutically relevant polyanions were evaluated as protective excipients. In this
approach it was hypothesized that electrostatic interactions cause reversible binding
of polyanions to the protein surface and thereby act as a “shield” to protect the
proteins against detrimental reactions. The effect of polyanions on protein-polymer
conjugation, protein activity, and release was investigated (Chapter 6).
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Abstract
Biodegradable hydrogels were prepared from furan- and maleimide-functionalized
eight-armed poly(ethylene glycol) with an average molecular mass of 40,000 Da
(8armPEG40k-furan and 8armPEG40k-maleimide) using the Diels–Alder (DA)
reaction as a cross-linking mechanism. Hydrophobic 6-aminohexanoic acid (C6)
and 12-aminododecanoic acid (C12) spacers were introduced between the polymer
backbone and the functional end-groups; the influence on the gel properties was
studied. Modification with C6 and C12 spacers induced hydrophobic interactions
between the macromonomers leading to association and increased viscosity of
the polymer solutions; both effects were influenced by the spacer length. In
combination with DA cross-linking, hydrophobic derivatives of 8armPEG40k-furan
and 8armPEG40k-maleimide led to hydrogels with improved properties. Upon
introduction of C12 spacers, gelation of 8armPEG40k hydrogels occurred twice as
fast. Interestingly, no effect was observed when only one of the two components had
been modified. Our experiments suggest that the association of macromonomers
by hydrophobic interactions facilitates chemical cross-linking via DA chemistry.
This hypothesis is supported by calculations of the network mesh size and the
Young’s modulus of compression, which showed an increased cross-linking density of
hydrophobically modified hydrogels. As a consequence of the increased cross-linking
density, the degradation stability of C12-modified hydrogels increased by a factor
of 4. Moreover, hydrophobic modification improved the hydrolytic resistance of
maleimides; this also contributes to gel stability. The in vitro release of bevacizumab,
which served as a model antibody, could be delayed for almost 60 days using
modification with C12. Similar trends were observed for C6-modified 8armPEG40k
hydrogels; however, the effects were considerably weaker. In summary, utilizing
hydrophobic association and chemical cross-linking in tandem is a promising
approach to create biodegradable hydrogels for delayed antibody release.
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3.1 Introduction
Since the introduction of recombinant insulin [203] more than three decades ago,
the steady progress in pharmaceutical biotechnology has resulted in the launch of
numerous biologics. In 2014 alone, 12 new biologics, such as recombinant proteins
and monoclonal antibodies, were approved by the US Food and Drug Administration
[204]. Among these, monoclonal antibodies are exceptionally promising therapeutics
as they provide great specificity and affinity toward their clinical targets [205–207].
Indeed, therapeutic antibodies have significantly advanced the treatment of severe
diseases, such as cancer [208], rheumatoid arthritis [209], or age-related macular
degeneration [197]. However, despite their therapeutic value, antibodies have two
major shortcomings that limit potential applications [210]. Firstly, antibodies are
fragile molecules and, therefore, prone to aggregation [211] and degradation [212].
Secondly, most antibodies have to be administered by injection or infusion, as
their oral bioavailability is generally low [213]. To improve the compliance and
reduce the administration frequency, innovative drug delivery systems that provide
sustained, delayed or intermittent antibody release are needed.
Among these drug delivery systems, hydrogels are particularly suitable for
controlled antibody release [146]. Firstly, hydrogels can act as a drug depot
that protects the incorporated protein from degradation. Secondly, the release
rate can be tailored to the specific therapeutic needs; for example, hydrogels can
prolong the dosing intervals by providing sustained or delayed antibody release.
Hydrogels can be prepared from a wide range of natural and synthetic polymers via
physical or chemical cross-linking [183, 214]. Physical cross-linking (e.g., via ionic or
hydrophobic interactions) enables the preparation of in situ forming hydrogels that
respond to external stimuli, such as ionic strength or temperature [67, 215–217].
These systems can be administered in liquid form and rapidly turn into a solid gel
after injection. However, the resulting hydrogels are often considered not stable
enough for sustained drug release [218–220]. Chemically cross-linked hydrogels,
on the other hand, provide superior mechanical properties and stability against
dissolution. However, only few chemical reactions are suitable for in situ cross-
linking [184]; furthermore, controlling the cross-linking rate can be challenging.
Gelation must be fast enough to completely encapsulate the drug after injection;
on the other hand, rapidly gelling formulations can clog the needle and prevent the
application of the gel. As a consequence, the combination of physical interactions
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and chemical cross-linking may open up new possibilities to design rapidly forming
hydrogels with improved stability.
Recently, the Diels–Alder (DA) reaction has been introduced as a promising cross-
linking mechanism for the preparation of degradable, poly(ethylene glycol) (PEG)
based hydrogels [155, 156, 221]. Since the DA reaction proceeds at body temperature
in the absence of potentially toxic catalysts, it is in principle suitable for in situ cross-
linking. However, the slow cross-linking rate can prove problematic and prevent the
formation of a drug depot after injection [222]. In conventional DA hydrogels, star-
shaped PEG is end-functionalized with furyl and maleimide groups; gelation occurs
by step-growth polymerization of complementary macromonomers. In this study,
hydrophobic alkyl spacers were introduced between the PEG chains of eight-armed
PEG and the reactive end-groups. In this way, amphiphilic macromonomers were
created. The hydrophilic PEG core ensures water solubility, while the hydrophobic
end-groups are expected to stick together and facilitate cross-linking via DA reaction.
In the first part of this study, the association of amphiphilic macromonomers in
aqueous solution was investigated by means of fluorescence spectroscopy and
viscosity measurements. In the second part, hydrogels were prepared and the
impact of physical interactions on gel formation, average network mesh size, and
mechanical properties was studied. In the last part, the hydrogels were characterized
regarding their swelling and degradation behavior. Finally, the gels were loaded
with bevacizumab and the in vitro release was determined.
3.2 Materials and methods
3.2.1 Materials
Anhydrous 1,4-dioxane, dichloromethane, sodium bicarbonate (NaHCO3), sodium
sulfate (Na2SO4), and triphenylphosphine were purchased from Acros Organics
(Geel, Belgium). Boc-6-aminohexanoic acid was purchased from Bachem (Weil am
Rhein, Germany). Diethyl ether was obtained from CSC Ja¨cklechemie (Nurem-
berg, Germany). Eight-armed poly(ethylene glycol) with a molecular mass of
40,000 Da (8armPEG40k-OH) was purchased from JenKem Technology (Allen,
TX, USA). Ceteareth-20 was obtained from Kolb Distribution Ltd (Hedingen,
Switzerland). Acetyl chloride, 12-aminododecanoic acid, anhydrous dimethyl-
formamide, anhydrous tetrahydrofuran, deuterated chloroform (CDCl3), N,N’-
dicyclohexylcarbodiimide (DCC), diisopropyl azodicarboxylate, N,N’-diisopropyl-
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ethylamine, di-tert-butyl dicarbonate, fluorescamine, 3-(2-furyl)propanoic acid, N-
hydroxysuccinimide (NHS), N-methoxycarbonylmaleimide, piperidine, and pyrene
were received from Sigma-Aldrich (Taufkirchen, Germany). All other chemicals
were obtained from Merck KGaA (Darmstadt, Germany). Bevacizumab (Avastin
r©
,
25 mg mL-1, Roche Ltd, Basel, Switzerland) was kindly provided by the hospi-
tal pharmacy of the University of Regensburg (Germany). Purified water was
freshly prepared using a Milli-Q water purification system (Millipore, Schwalbach,
Germany).
3.2.2 1H-NMR spectroscopy
1H-NMR spectra were recorded in CDCl3 at 295 K using a Bruker Avance 300
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany).
3.2.3 Synthesis of Boc-12-aminododecanoic acid
Boc-12-aminododecanoic acid was synthesized as described by Dorn et al. [223]
with the following modifications. 12-Aminododecanoic acid (9.3 mmol, 2.0 g) was
suspended in 30 mL of absolute methanol containing triethylamine (11.2 mmol,
1.5 mL). Di-tert-butyl dicarbonate (9.3 mmol, 2.0 g) was dissolved in 10 mL of
absolute methanol and added to the suspension. The mixture was heated to 60 ◦C
and refluxed under stirring for 12 hours, leading to a clear solution. The solvent
was removed under reduced pressure and the residue was dissolved in ethyl acetate.
The solution was extracted four times with 0.25 M HCl. The organic phase was
dried over anhydrous Na2SO4 and filtered. The solvent was evaporated to give a
white solid (94% yield). The complete Boc-protection of the primary amino groups
was confirmed using a fluorescamine assay [224].
3.2.4 Synthesis of unmodified macromonomers (Scheme 3.1)
Eight-armed PEG-amine with a molecular mass of 40,000 Da (8armPEG40k-
NH2) was synthesized as previously described [225]. The resulting PEG-amine
was then functionalized with furyl (8armPEG40k-furan) or maleimide groups
(8armPEG40k-maleimide) as described for 8armPEG20k-NH2 [155]. However,
higher reagent concentrations were required due to the lower concentrations of
amino groups. For the synthesis of 8armPEG40k-furan, 16 equivalents of 3-(2-
furyl)propanoic acid, NHS, DCC, and NaHCO3 were used; for the preparation of
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8armPEG40k-maleimide, 40 equivalents of N-methoxycarbonylmaleimide were used.
The degree of end-group functionalization was 75-80% for 8armPEG40k-furan and
65-70% for 8armPEG40k-maleimide, as determined by 1H-NMR. The degree of
functionalization was reproducible and sufficient to enable cross-linking.
3400 | J. Mater. Chem. B, 2016, 4, 3398--3408 This journal is©The Royal Society of Chemistry 2016
by a fluorescamine assay. Following this procedure, the obtained
8armPEG40k-C6-NH-Boc was deprotected (8armPEG40k-C6-NH2)
and subsequently functionalized with furyl (8armPEG40k-C6-furan)
or maleimide groups (8armPEG40k-C6-maleimide) as described
above. 8armPEG40k-C12-NH-Boc, 8armPEG40k-C12-furan and
8armPEG40k-C12-maleimide were synthesized in the same
way using Boc-12-aminododecanoic acid instead of Boc-6-amino-
hexanoic acid. The degree of end-group functionalization was
65–70% for 8armPEG40k-C6-furan and 8armPEG40k-C12-furan,
and 60–65% for 8armPEG40k-C6-maleimide and 8armPEG40k-
C12-maleimide, as determined by
1H-NMR. The degree of
functionalization was reproducible and sufficient to enable
cross-linking.
Determination of the critical micelle concentration
To check for the presence of micellar structures, emission
spectra of pyrene in pure water, a micellar solution of
ceteareth-20, and a 20% (w/V) solution of 8armPEG40k-C12-
NH-Boc were recorded at an excitation wavelength of 339 nm,
using a Perkin Elmer LS-55 fluorescence plate reader (Perkin
Elmer, Wiesbaden, Germany). The emission spectra were
normalized to the peak at 383 nm (I3); the results of five
independent measurements were averaged. To determine the
critical micelle concentration (CMC), aqueous solutions of
8armPEG40k-OH, 8armPEG40k-C6-NH-Boc, and 8armPEG40k-
C12-NH-Boc were prepared; concentrations of 0.1%, 0.25%,
0.5%, 1.0%, 2.5%, 5.0%, 7.5%, 10%, 15%, and 20% were used.
First, 30 mg of pyrene was dissolved in 750 mL of acetone.
Equivalents of this solution corresponding to 1.0 mg of pyrene
were transferred to amber glass vials and the acetone was
allowed to evaporate. Then, 200 mL of the polymer solutions
were added and the samples were incubated on an orbital
shaker for 24 hours. Following this, 100 mL of each sample were
transferred into a 96-well plate (Greiner Bio-One, Frickenhausen,
Germany) and the fluorescence intensity of pyrene was determined
at an excitation wavelength of 339 nm and an emission wavelength
of 390 nm. A linear regression was performed for both the non-
ascending and the ascending part of the graph; the CMC was
determined from the intersection of the two lines.
Viscosity measurements
Aqueous solutions of 8armPEG40k-OH, 8armPEG40k-C6-NH-Boc,
and 8armPEG40k-C12-NH-Boc were prepared; the polymer con-
centrations were 2% (w/V) and 20% (w/V). Viscosity measure-
ments were performed on a TA Instruments Discovery HR-2
rheometer (TA Instruments, Eschborn, Germany) at a constant
temperature of 25 1C. The instrument was equipped with a
20 mm parallel steel plate; the sample volume was 350 mL. The
shear rate was increased from 0.1 to 10.0 s!1. The TA Instru-
ments Trios software was used to calculate the viscosity from
Scheme 1 Functional end-groups of 8armPEG40k-maleimide and
8armPEG40k-furan. Both macromonomers were synthesized from
8armPEG40k-OH (molecular mass 40000 Da, hexaglycerol core) as
previously described.
Scheme 2 End-groups of hydrophobically modified macromonomers.
Hydrophobic 6-aminohexanoic acid (C6) or 12-aminododecanoic acid
(C12) spacers were introduced between the PEG backbone and the func-
tional end-groups.
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Scheme 3.1: Functional end-groups of 8armPEG40k-maleimide and 8armPEG40k-
furan. Both macromonomers were synthesized from 8armPEG40k-OH (molecular
mas 40,000 Da, hexaglycerol core) as previously described.
3.2.5 Synthesis of hydrophobically modified macromonomers
(Scheme 3.2)
8armPEG40k-NH2 was first reacted with Boc-6-aminohexanoic acid as previously
described for 8armPEG20k-NH2 [221]. The complete functionalization with Boc-
6-aminohexanoic acid was confirmed by a fluorescamine assay. Following this
procedure, the obtained armPEG40k C6-NH-Boc was deprotected (8armPEG40k-
C6-NH2) and subsequently functionalized with furyl (8armPEG40k-C6-furan) or
maleimide groups (8armPEG40k-C6-maleimide) as described above. 8armPEG40k-
C12-NH-Boc, 8armPEG40k-C12-furan and 8armPEG40k-C12-maleimide were syn-
thesized in the same way using Boc-12-aminododecanoic acid instead of Boc-6-
aminohexanoic acid. The degree of end-group functionalization was 65-70% for
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8armPEG40k-C6-furan and 8armPEG40k-C12-furan, and 60-65% for 8armPEG40k-
C6-maleimide and 8armPEG40k-C12-maleimide, as determined by
1H-NMR. The
degree of functionalization was reproducible and sufficient to enable cross-linking.
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by a fluorescamine assay. Following this procedure, the obtained
8armPEG40k-C6-NH-Boc was deprotected (8armPEG40k-C6-NH2)
and subsequently functionalized with furyl (8armPEG40k-C6-furan)
or maleimide groups (8armPEG40k-C6-maleimide) as described
above. 8armPEG40k-C12-NH-Boc, 8armPEG40k-C12-furan and
8armPEG40k-C12-maleimide were synthesized in the same
way using Boc-12-aminododecanoic acid instead of Boc-6-amino-
hexanoic acid. The degree of end-group functionalization was
65–70% for 8armPEG40k-C6-furan and 8armPEG40k-C12-furan,
and 60–65% for 8armPEG40k-C6-maleimide and 8armPEG40k-
C12-maleimide, as determined by
1H-NMR. The degree of
functionalization was reproducible and sufficient to enable
cross-linking.
Determination of the critical micelle concentration
To check for the presence of micellar structures, emission
spectra of pyrene in pure water, a micellar solution of
ceteareth-20, and a 20% (w/V) solution of 8armPEG40k-C12-
NH-Boc were recorded at an excitation wavelength of 339 nm,
using a Perkin Elmer LS-55 fluorescence plate reader (Perkin
Elmer, Wiesbaden, Germany). The emission spectra were
normalized to the peak at 383 nm (I3); the results of five
independent measurements were averaged. To determine the
critical micelle concentration (CMC), aqueous solutions of
8armPEG40k-OH, 8armPEG40k-C6-NH-Boc, and 8armPEG40k-
C12-NH-Boc were prepared; concentrations of 0.1%, 0.25%,
0.5%, 1.0%, 2.5%, 5.0%, 7.5%, 10%, 15%, and 20% were used.
First, 30 mg of pyrene was dissolved in 750 mL of acetone.
Equivalents of this solution corresponding to 1.0 mg of pyrene
were transferred to amber glass vials and the acetone was
allowed to evaporate. Then, 200 mL of the polymer solutions
were added and the samples were incubated on an orbital
shaker for 24 hours. Following this, 100 mL of each sample were
transferred into a 96-well plate (Greiner Bio-One, Frickenhausen,
Germany) and the fluorescence intensity of pyrene was determined
at an excitation wavelength of 339 nm and an emission wavelength
of 390 nm. A linear regression was performed for both the non-
ascending and the ascending part of the graph; the CMC was
determined from the intersection of the two lines.
Viscosity measurements
Aqueous solutions of 8armPEG40k-OH, 8armPEG40k-C6-NH-Boc,
and 8armPEG40k-C12-NH-Boc were prepared; the polymer con-
centrations were 2% (w/V) and 20% (w/V). Viscosity measure-
ments were performed on a TA Instruments Discovery HR-2
rheometer (TA Instruments, Eschborn, Germany) at a constant
temperature of 25 1C. The instrument was equipped with a
20 mm parallel steel plate; the sample volume was 350 mL. The
shear rate was increased from 0.1 to 10.0 s!1. The TA Instru-
ments Trios software was used to calculate the viscosity from
Scheme 1 Functional end-groups of 8armPEG40k-maleimide and
8armPEG40k-furan. Both macromonomers were synthesized from
8armPEG40k-OH (molecular mass 40000 Da, hexaglycerol core) as
previously described.
Scheme 2 End-groups of hydrophobically modified macromonomers.
Hydrophobic 6-aminohexanoic acid (C6) or 12-aminododecanoic acid
(C12) spacers were introduced between the PEG backbone and the func-
tional end-groups.
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Scheme 3.2: End-groups of hydrophobically modified macromonomers. Hydrophobic
6-aminohexanoic a id (C6) or 12-aminododecanoic acid (C12) spacers were introduced
between the PEG backbone and the functional end-groups.
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3.2.6 Determination of the critical micelle concentration
To check for the presence of micellar structures, emission spectra of pyrene in
pure water, a micellar solution of ceteareth-20, and a 20% (w/V) solution of
8armPEG40k-C12-NH-Boc were recorded at an excitation wavelength of 339 nm,
using a Perkin Elmer LS-55 fluorescence plate reader (Perkin Elmer, Wiesbaden,
Germany). The emission spectra were normalized to the peak at 383 nm (I3); the
results of five independent measurements were averaged. To determine the critical
micelle concentration (CMC), aqueous solutions of 8armPEG40k-OH, 8armPEG40k-
C6-NH-Boc, and 8armPEG40k-C12-NH-Boc were prepared; concentrations of 0.1%,
0.25%, 0.5%, 1.0%, 2.5%, 5.0%, 7.5%, 10%, 15%, and 20% were used. First,
30 mg of pyrene was dissolved in 750 µL of acetone. Equivalents of this solution
corresponding to 1.0 mg of pyrene were transferred to amber glass vials and the
acetone was allowed to evaporate. Then, 200 µL of the polymer solutions were
added and the samples were incubated on an orbital shaker for 24 hours. Following
this, 100 µL of each sample were transferred into a 96-well plate (Greiner Bio-One,
Frickenhausen, Germany) and the fluorescence intensity of pyrene was determined
at an excitation wavelength of 339 nm and an emission wavelength of 390 nm. A
linear regression was performed for both the non-ascending and the ascending part
of the graph; the CMC was determined from the intersection of the two lines.
3.2.7 Viscosity measurements
Aqueous solutions of 8armPEG40k-OH, 8armPEG40k-C6-NH-Boc, and 8arm-
PEG40k-C12-NH-Boc were prepared; the polymer concentrations were 2% (w/V)
and 20% (w/V). Viscosity measurements were performed on a TA Instruments
Discovery HR-2 rheometer (TA Instruments, Eschborn, Germany) at a constant
temperature of 25 ◦C. The instrument was equipped with a 20 mm parallel steel
plate; the sample volume was 350 µL. The shear rate was increased from 0.1 to
10.0 s-1. The TA Instruments Trios software was used to calculate the viscosity
from the relation between shear rate and stress assuming Newtonian flow behavior.
3.2.8 Hydrogel preparation and characterization
For hydrogel preparation, equal molar amounts of 8armPEG40k-furan and 8arm-
PEG40k-maleimide, 8armPEG40k-C6-furan and 8armPEG40k-C6-maleimide, or
8armPEG40k-C12-furan and 8armPEG40k-C12-maleimide were separately dissolved
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in water. Gel formation was initiated by mixing complementary macromonomer
solutions; the overall polymer concentrations were 5% (w/V), 10% (w/V) and 15%
(w/V). Rheological characterization was performed using a TA Instruments AR
2000 rheometer (TA Instruments, Eschborn, Germany) as previously described
[155]. Storage (G′) and loss modulus (G′′) were recorded over time; the crossover of
G′ and G′′ was regarded as the gel point. The average mesh size (ξ) was determined
as previously described [221].
3.2.9 Young’s modulus of compression
To characterize the mechanical properties of hydrogels, the Young’s modulus of
compression (E) was determined. For this purpose, gel cylinders with a volume
of 250 µL were prepared as described above. The gel samples were cross-linked
for 6 hours at 37 ◦C. The polymer concentrations were 5% (w/V), 10% (w/V)
and 15% (w/V). Diameter and height of the gel cylinders were determined using
a caliper. The samples were then subjected to a compression test on an Instron
5542 materials testing machine (Norwood, MA, USA). For this purpose, the gel
cylinders were placed upright on the lower steel plate of the instrument. The upper
steel plate was set to compress the samples at a velocity of 1 mm min-1. The
compressive force (N) and the compressive strain (%) were recorded over time. The
Young’s modulus of compression was determined from the linear part of the curve
between 10% and 50% compression using the Instron Bluehill Software (Norwood,
MA, USA). Data is presented as mean ± standard deviation, based on the results
of three independent samples.
3.2.10 Swelling, degradation and antibody release
Swelling and degradation of 8armPEG40k, 8armPEG40k-C6 and 8armPEG40k-C12
hydrogels was studied in phosphate buffer, pH 7.4 at 37 ◦C as previously described
[221]. The polymer concentrations were 5% (w/V), 10% (w/V) and 15% (w/V).
For the release experiments, 8armPEG40k, 8armPEG40k-C6 and 8armPEG40k-C12
hydrogels were loaded with bevacizumab (Avastin
r©
); cross-linking was carried out
in 5 mM acetate buffer, pH 5.0. The polymer concentration was 10% (w/V); the
bevacizumab loading was 5 mg mL-1. The in vitro release of bevacizumab was
determined in phosphate buffer, pH 7.4 at 37 ◦C as previously described [221].
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3.2.11 Hydrolytic stability of maleimides
In order to investigate the hydrolytic stability of maleimides, 20.0 mg of 8arm-
PEG40k-maleimide, 8armPEG40k-C6-maleimide or 8armPEG40k-C12-maleimide
were dissolved in 2.0 mL of 50 mM phosphate buffer, pH 7.4. The polymer
solutions were transferred into 10 mm quartz cuvettes. The absorbance at 299 nm
was recorded for 900 min using a Kotron UVIKON
r©
941 spectrophotometer (Kotron
Instruments S.p.A., Milan, Italy). The cuvette holder was equipped with a heating
jacket; the temperature was set to 37 ◦C.
3.2.12 Statistical analysis
All results are presented as mean ± standard deviation, based on the data obtained
from at least n = 3 samples. Statistical significance was determined by means
of one-way ANOVA, followed by Tukey’s post hoc test using GraphPad Prism
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Differences were considered
statistically significant at p < 0.05.
3.3 Results and discussion
3.3.1 Association of macromonomers in aqueous solution
The major goal of this study was to prepare in situ forming hydrogels for drug de-
livery by combining physical interactions with DA chemistry. In order to induce hy-
drophobic interactions between the macromonomers, hydrophilic 8armPEG40k-NH2
was first reacted with Boc-6-aminohexanoic acid (C6) or Boc-12-aminododecanoic
acid (C12). After deprotection, the hydrophobically modified PEG was functional-
ized with furyl and maleimide groups, respectively. While it has already been shown
in a previous publication that introducing hydrophobic C6 spacers gives hydrogels
with increased stability to degradation [221], the present study aimed at providing
a deeper mechanistic understanding of the molecular processes responsible for the
improved gel properties. Furthermore, another goal of this study was to investigate
whether the gel properties, such as gel time and stability to degradation, depend
on the spacer length. In the first experiment, the hydrophobic interactions between
the synthesized macromonomers were investigated. To this end, the association
of 8armPEG40k-C6-NH-Boc or 8armPEG40k-C12-NH-Boc in water was studied
using pyrene as a probe molecule. The Boc-protected polymers were chosen since
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they were uncharged. Furthermore, their association is solely due to hydrophobic
interactions; covalent cross-linking via DA reaction cannot take place.
Figure 3.1: Emission spectra of pyrene in pure water (negative control), a micellar
solution of ceteareth-20 (positive control), and a 20% (w/V) solution of 8armPEG40k-
C12-NH-Boc (A). The spectra are normalized to the fluorescence intensity at 383 nm
(I3); a decrease of the peak at 372 nm (I1) is an indicator for micelle formation. Pyrene
fluorescence in aqueous solutions of 8armPEG40k-OH (B), 8armPEG40k-C6-NH-Boc
(C) and 8armPEG40k-C12-NH-Boc (D) at concentrations ranging from 0.1% (w/V)
to 20% (w/V). A sharp increase in the fluorescence intensity (C and D) indicates the
beginning of polymer association.
To check for the existence of polymeric micelles, the emission spectra of pyrene
in pure water (negative control), a micellar solution of the detergent ceteareth-20
(positive control), and a 20% (w/V) solution of 8armPEG40k-C12-NH-Boc were
compared. Pyrene is commonly used to probe the formation of micelles as its
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fluorescence intensity is greatly influenced by the hydrophobicity of the environment.
The emission spectra were normalized to the peak at 383 nm (I3). Fig. 3.1A shows
that, in comparison to water, the relative intensity at 372 nm (I1) strongly decreased
for both ceteareth-20 and 8armPEG40k-C12-NH-Boc. A decrease in I1 has been
reported as an indicator for micelle formation [226–228]. In addition, the ratio
between I1 and I3 was determined. In hydrophobic environments, the ratio is
relatively low (e.g., 0.53 in hexane), whereas in hydrophilic environments, the ratio
is significantly higher (e.g., 1.88 in water). In ceteareth-20 and 8armPEG40k-
C12-NH-Boc, values of 1.12 and 1.26 have been determined. I1/I3 values of about
1.2 have been reported to be typical for associative polymers and surfactant
micelles in aqueous solutions [229]. This suggests that pyrene is located within
hydrophobic domains of ceteareth-20 and 8armPEG40k-C12-NH-Boc, respectively.
To follow the formation of micelles, pyrene fluorescence was measured in aqueous
solutions of 8armPEG40k-OH, 8armPEG40k-C6-NH-Boc and 8armPEG40k-C12-
NH-Boc at concentrations ranging from 0.1% (w/V) to 20% (w/V). As expected,
in solutions of 8armPEG40k-OH, no micelle formation was detected (Fig. 3.1B).
However, in solutions of 8armPEG40k-C6-NH-Boc and 8armPEG40k-C12-NH-
Boc, a sharp increase in the fluorescence intensity was detected above a certain
concentration (Fig. 3.1C and D). This indicates the beginning of polymer association
and the formation of micelles. The critical micelle concentrations (CMCs) were
determined as 10.4% (2.3 mM) and 3.3% (0.73 mM) for 8armPEG40k-C6-NH-Boc
and 8armPEG40k-C12-NH-Boc, respectively. In comparison, for poloxamer 407, an
amphiphilic poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)
copolymer, CMC values of 0.26–0.8% (w/V) have been determined [230]; for linear
PEGs end-capped with n-hexadecyl groups, CMC values of 2–5 mM have been
reported [231]. These values compare with the results reported in the present study.
Fig. 3.1 clearly shows that modification of 8armPEG40k-NH2 with hydrophobic
residues leads to hydrophobic interactions between the macromonomers. Moreover,
the interactions become stronger as the length of the hydrophobic alkyl chain
increases, as indicated by the lower CMC. It, therefore, seems reasonable to employ
even longer alkyl spacers, such as 18-aminooctadecanoic acid, to amplify the effect.
However, it should be kept in mind that increasing the spacer length can affect
the water solubility of the polymer. In fact, another hydrophobically modified
PEG was synthesized by reacting 8armPEG40k-C12-NH2 with further molecules of
12-aminododecanoic acid. However, the obtained macromonomer (8armPEG40k-
C12-C12-NH2) was almost insoluble in water (data not shown). As water solubility of
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the macromonomers is a prerequisite for the formation of hydrogels, this derivative
was not included in the present study.
3.3.2 Viscosity of macromonomer solutions
The presence of polymeric micelles above a certain macromonomer concentration
is an interesting finding. To understand possible effects on hydrogel formation, the
mechanism of polymer association should be discussed in more detail. It is well
established that water-soluble polymers with hydrophobic end-modification form
flower- or star-like micelles [232, 233], i.e., associates with a dense hydrophobic core
surrounded by a corona of hydrophilic polymer chains [234]. In addition, amphiphilic
polymers are known to increase the viscosity of aqueous solutions; they are, therefore,
referred to as associative thickeners [235, 236]. This behavior can be explained by the
transient network theory [237]. Water-soluble polymers with “sticky” hydrophobic
end-groups associate in water to form physically stabilized networks in which the
cross-links are weak enough to constantly break and re-combine. Winnik and Yekta
reviewed the available literature and discussed how the formation of micelles and
transient networks can explain the behavior of associative polymers in aqueous
solution [238]. Based on this combined theory, the association of 8armPEG40k-
C6 and 8armPEG40k-C12 macromonomers solution can be described as follows.
At very low concentrations, isolated macromonomers exist that only engage in
transient random interactions (Fig. 3.2A). Therefore, solutions of 8armPEG40k-
C6-NH-Boc or 8armPEG40k-C12-NH-Boc should exhibit nearly the same viscosity
as solutions of polymers without hydrophobic end-modification. However, with
increasing concentration, interactions between individual macromonomers become
more likely and the hydrophobic end-groups start to associate (Fig. 3.2B). With
further increasing concentration, more and more micelles are formed. These
micelles are ultimately bridged by polymer chains resulting in the formation
of transient networks that consequently increase the viscosity of the solution
(Fig. 3.2C). Solutions of 8armPEG40k-C6-NH-Boc or 8armPEG40k-C12-NH-Boc
should, therefore, exhibit much higher viscosities than equally concentrated solutions
of polymers without hydrophobic end-modification.
To test this hypothesis, aqueous solutions of 8armPEG40k-OH, 8armPEG40k-
C6-NH-Boc and 8armPEG40k-C12-NH-Boc were prepared; their viscosities were
measured at room temperature (Fig. 3.3). At polymer concentrations of 2% (w/V),
viscosities of about 2 mPa s were determined. There were no significant differences
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Figure 3.2: Association of hydrophobically modified eight-armed PEG in aqueous so-
lution at increasing concentrations. Isolated macromonomers engage in random in-
teractions at low macromonomer concentrations (A). With increasing concentration,
interactions become more likely and the hydrophobic end-groups start to associate
(B). Formation of bridged micelles and transient networks at high macromonomer
concentrations (C).
between the polymer types, suggesting no additional physical interactions between
macromonomers with hydrophobic end-groups. After increasing the polymer
concentrations to 20% (w/V), i.e., above the CMC of 8armPEG40k-C6-NH-Boc
and 8armPEG40k-C12-NH-Boc, the viscosities of all polymer solutions had increased
accordingly. However, compared with 8armPEG40k-OH, solutions of 8armPEG40k-
C6-NH-Boc and 8armPEG40k-C12-NH-Boc showed significantly higher viscosities.
For example, the viscosity of a 20% (w/V) solution of 8armPEG40k-C6-NH-Boc
was 1.6-times higher than the viscosity of an equally concentrated solution of
8armPEG40k-OH. This finding clearly demonstrates the existence of additional
physical interactions between 8armPEG40k-C6 macromonomers. The effect was
even more pronounced when 8armPEG40k-C12-NH-Boc was used; the viscosity was
5.5-times higher than for 8armPEG40k-OH. The differences between 8armPEG40k-
C6-NH-Boc and 8armPEG40k-C12-NH-Boc were expected based on the determined
CMC values (10.4% vs. 3.3%). Macromonomers end-capped with long alkyl chains
(e.g., 12-aminododecanoic acid) show a higher tendency for hydrophobic interaction
than those end-capped with short chains (e.g., 6-aminohexanoic acid). In summary,
it can be concluded that star-shaped PEG molecules end-capped with hydrophobic
alkyl chains are capable of physical interactions; the association of macromonomers
with hydrophobic end-groups is likely to influence hydrogel formation.
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Figure 3.3: Viscosity of aqueous solutions of 8armPEG40k-OH, 8armPEG40k-C6-NH-
Boc and 8armPEG40k-C12-NH-Boc at 25
◦C. * indicates statistically significant dif-
ferences to all other groups of the same polymer concentration.
3.3.3 Acceleration of gel formation by hydrophobic association
For the following experiments, hydrogels were prepared from macromonomers
functionalized with furyl and maleimide end-groups; different alkyl spacer lengths
were used. In the first experiment, the effect of macromonomer association on the
gel time of DA hydrogels was studied. The DA reaction allows the preparation of
covalently cross-linked, degradable hydrogels. In contrast to other cross-linking
reactions, such as radical polymerization or the copper(I)-catalyzed azide–alkyne
cycloaddition, the use of potentially toxic initiators or catalysts can be avoided. This
is important for applications such as controlled protein release or cell encapsulation.
However, a major disadvantage of the DA reaction is the comparably low cross-
linking rate at ambient temperature. Consequently, it would be beneficial if gel
formation were accelerated by hydrophobic interactions between macromonomers.
As shown in Fig. 3.4A, the gel times of plain 8armPEG40k-hydrogels were
166 min (5% polymer), 83 min (10% polymer) and 57 min (15% polymer). Upon
modification with 12-aminododecanoic acid, the gel times decreased on average by
55%, with gel points at 78 min (5% polymer), 36 min (10% polymer) and 26 min
(15% polymer) being determined. Apparently, the association of macromonomers
by hydrophobic interactions promotes the cross-linking process independent from
the polymer concentration. In comparison, modification with 6-aminohexanoic acid
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also influenced the gel formation rate, but the effect was much weaker. This is in
line with the previous results, which showed that both macromonomer association
and viscosity enhancement depend on the spacer length. To elucidate the contribu-
tion of macromonomer association on gel formation, a further experiment was done
(Fig. 3.4B). When both 8armPEG40k-C12-furan and 8armPEG40k-C12-maleimide
were used, gelation proceeded twice as fast as in hydrogels made from unmodified
macromonomers, i.e., 8armPEG40k-furan and 8armPEG40k-maleimide. How-
Figure 3.4: Gel time of 8armPEG40k, 8armPEG40k-C6 and 8armPEG40k-C12 hydro-
gels at 37 ◦C (A). Influence of hydrophobic interactions on gel formation (B). Gel
formation only proceeded twice as fast when both components (i.e., 8armPEG40k-
furan or 8armPEG40k-maleimide) were modified with hydrophobic C12 spacers (C12-
Fur/C12-Mal). The polymer concentration was 10% (w/V). * indicates statistically
significant differences to all other groups of the same polymer concentration; # indi-
cates statistically significant differences between the specified groups.
ever, when 8armPEG40k-C12-furan was combined with unmodified 8armPEG40k-
maleimide, or vice versa, no significant acceleration of gelation was observed.
Although association of 8armPEG40k-C12-furan (or 8armPEG40k-C12-maleimide)
occurs at the tested concentration, this does apparently not affect cross-linking
via DA reaction. This result, therefore, suggests that hydrophobic modification
of both macromonomers (i.e., 8armPEG40k-furan and 8armPEG40k-maleimide)
is required to accelerate gel formation. It is conceivable that the association of
8armPEG40k-C12-furan and 8armPEG40-C12-maleimide into mixed micelles brings
the reactive furyl and maleimide groups into close proximity. This makes the
cross-linking process more efficient and accelerates gel formation.
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3.3.4 Network mesh size and mechanical properties
To study the influence of hydrophobic modification on the cross-linking density of
hydrogels, the average network mesh size (ξ) of 8armPEG40k, 8armPEG40k-C6
and 8armPEG40k-C12 hydrogels was determined as previously described [155]. In
brief, the gel volume after cross-linking, Vgc, and after swelling in water, Vgs, was
determined by weighing cylindrical gel samples in air and hexane. Afterwards, the
gel samples were freeze-dried and the volume of the dry polymer, Vp, was determined.
After calculating the polymer fraction of the hydrogel after cross-linking (v2c=
Vp
Vgc
)
and in the swollen state (v2s=
Vp
Vgs
), the number of moles of elastically active chains
within the network, νe, was calculated using a modified version of the Flory–Rehner
eqn (3.1) [239–241].
νe = − Vp
V1v2c
· [ln(1− v2s) + v2s + χ12v
2
2s][(
v2s
v2c
) 1
3 − 2
f
(
v2s
v2c
)] (3.1)
The calculation requires several parameters, namely the molar volume of water
(V1 = 18 mL mol
-1), the branching factor of the macromonomers (f = 8), and
the polymer-water interaction parameter (χ12). The parameter χ12 describes the
average extent of interaction between a macromonomer and water; it depends on
the hydrophilic lipophilic balance (HLB) of the macromonomer. For amphiphilic
macromonomers that are composed of both ethylene oxide (EO) and hydrocarbon
chains (HC), χ12 can be calculated according to [242]:
χ12 = ωEOχW,EO + (1− ωEO)χW,HC − VW
VHC
(1− ωEO)ωEOχHC,EO (3.2)
In this equation, ωEO represents the weight fraction of the ethylene oxide chain;
VW and VHC are the molar volumes of water and the hydrocarbon part of the
macromonomer. The water-ethylene oxide interaction parameter (χW,EO) was set
to 0.4; the water-hydrocarbon interaction parameter (χW,HC) was set to 2.0 and
the term χHC,EO (
VW
VHC
) was taken as 0.4. Based on these values, the interaction
parameters for 8armPEG40k-C6 (χ12 = 0.42) and 8armPEG40k-C12 in water (χ12
= 0.45) were calculated; for unmodified 8armPEG40k hydrogels, the PEG–water
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interaction parameter (χ12 = 0.40) was used. Together with the average bond
length along the PEG backbone (l = 0.146 nm), the molecular mass of the PEG
repeating unit (Mr = 44 g mol
-1), the total mass of PEG in the hydrogel (mp), and
the Flory characteristic ratio (Cn = 4), νe allows the calculation of ξ according to
eqn (3.3) [243]:
ξ = v
− 1
3
2s l
(
2mp
νeMr
) 1
2
C
1
2
n (3.3)
The data listed in Table 3.1 shows that ξ is decreasing with increasing polymer
concentration. The effect was more pronounced in 8armPEG40k and 8armPEG40k-
C6 hydrogels than in 8armPEG40k-C12 hydrogels. The modification of 8armPEG40k
with 6-aminohexanoic acid spacers only had a minor influence on ξ. In contrast
to that, modification with more hydrophobic 12-aminododecanoic acid spacers
significantly decreased ξ. Apparently, the association of 8armPEG40k-C12-furan
and 8armPEG40k-C12-maleimide results in more densely cross-linked hydrogels
with less network defects.
Table 3.1: Average network mesh size (ξ) and Young’s modulus of compression (E) of
8armPEG40k, 8armPEG40k-C6 and 8armPEG40k-C12 hydrogels at concentrations of
5, 10 and 15% (w/V).
Polymer type Concentration(%) ξ(nm) E(kPa)
8armPEG40k 5 25.9 ± 0.2 8.1 ± 4.1
10 19.6 ± 0.1 33.2 ± 4.0
15 17.5 ± 0.1 87.2 ± 19.6
8armPEG40k-C6 5 24.3 ± 1.0 25.0 ± 4.0
10 20.3 ± 0.6 50.3 ± 5.4
15 17.4 ± 1.7 117.5 ± 13.1
8armPEG40k-C12 5 18.2 ± 0.6 38.9 ± 4.6
10 15.4 ± 0.1 79.6 ± 12.1
15 14.3 ± 0.2 172.8 ± 28.4
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Since cross-linking density and material stiffness are closely related, the associa-
tion of 8armPEG40k-C12-furan and 8armPEG40k-C12-maleimide should also be
reflected in the mechanical properties of the hydrogels. To confirm this relation,
the Young’s modulus of compression (E) was determined. It is defined as the ratio
of compressive stress to compressive strain and frequently used to describe the
mechanical properties of materials [161, 244]. As expected, the modification of
macromonomers with hydrophobic residues had a strong effect on the mechanical
properties of hydrogels. For example, the Young’s modulus of 8armPEG40k-C12
hydrogels (10% and 15% polymer concentration) was twice as high as that of unmod-
ified 8armPEG40k hydrogels. The effect was even more pronounced at low polymer
concentrations; the Young’s modulus of 5% (w/V) 8armPEG40k-C12 hydrogels was
approximately five times higher than that of unmodified 8armPEG40k hydrogels
(Table 3.1). As already observed in the other experiments, modification with
6-aminohexanoic acid residues resulted in much weaker effects. In summary, using
hydrophobically modified macromonomers for hydrogel preparation resulted in
higher cross-linking densities, as indicated by the values of ξ and E. The association
of hydrophobically modified macromonomers to micelles and transient networks is
thought to make the cross-linking process more efficient. As a consequence, more
densely cross-linked networks are formed and the number of imperfections, such as
elastically inactive chains, is reduced.
3.3.5 Swelling, degradation and antibody release
As discussed in the previous section, using hydrophobically modified macromonomers
increases the cross-linking density of hydrogels. Since the cross-linking density
has a strong influence on hydrogel degradation, the swelling behavior of gel cylin-
ders in phosphate buffer pH 7.4 was monitored over time at 37 ◦C (Fig. 3.5).
As expected, the swelling and degradation behavior of hydrogels was dependent
on the polymer concentration. Furthermore, it was found that hydrophobically
modified macromonomers yielded hydrogels with increased stability to degradation.
For example, at a concentration of 10% (w/V), 8armPEG40k hydrogels showed
a 9-fold mass increase during incubation, whereas the mass of 8armPEG40k-C6
and 8armPEG40k-C12 hydrogels increased only 6-fold and 4-fold, respectively.
The gel samples were completely degraded after 20 (8armPEG40k hydrogels),
40 (8armPEG40k-C6 hydrogels) and 60 days (8armPEG40k-C12 hydrogels). In
summary, upon introduction of hydrophobic residues, the swelling of hydrogels
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Figure 3.5: Swelling and degradation of 8armPEG40k (A), 8armPEG40k-C6 (B),
8armPEG40k-C12 hydrogels (C) in phosphate buffer, pH 7.4 at 37
◦C.
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proceeds more slowly and the mass increase is less pronounced. In addition,
hydrogels made of hydrophobically modified macromonomers showed considerably
higher resistance to degradation than unmodified hydrogels.
This may be due to several reasons. On the one hand, the extent of interaction
between water and polymer chains has an impact on hydrogel swelling. The inter-
action between water and purely hydrophilic polymers is preferred over interactions
with polymers that comprise both hydrophilic and hydrophobic parts. The presence
of hydrophobic domains within the hydrogel network may, therefore, limit the
overall degree of swelling [245–247]. In addition, hydrogels made of hydrophobically
modified macromonomers have a higher crosslinking density than 8armPEG40k
hydrogels. This directly translates into reduced swelling and improved stability
to degradation. Finally, the degradation rate of DA hydrogels is governed by the
hydrolytic stability of the involved maleimide groups [156]. It has been shown
that degradation occurs by retro-Diels–Alder (rDA) reaction and subsequent ring-
opening hydrolysis of the newly generated maleimide groups. The rate of the
rDA reaction is low at 37 ◦C; however, ring-opening hydrolysis of maleimide to
unreactive maleamic acid shifts the DA/rDA equilibrium and significantly accel-
erates the degradation rate. To check the influence of hydrophobic modification,
the hydrolytic stability of 8armPEG40k-maleimide, 8armPEG40k-C6-maleimide
and 8armPEG40k-C12-maleimide was determined in phosphate buffer, pH 7.4 at
37 ◦C (Fig. 3.6). Assuming a pseudo-first-order reaction, rate constants (kobs) and
half-lives (t1/2) were calculated by fitting the integrated form of eqn (3.4) to the
experimental data.
−d[maleimide]
dt
= kobs[maleimide] (3.4)
The results listed in Table 3.2 show that hydrophobic modification increases
the stability of maleimide groups. The half-lives of 8armPEG40k-C6-maleimide
and 8armPEG40k-C12-maleimide were 2.2 and 3.4 times longer than the half-
life of unmodified 8armPEG40k-maleimide. These results are in good agreement
with literature data, which also showed improved hydrolytic stability of N-alkyl
substituted maleimides [248–251]. Electron-donating N-substituents, such as alkyl
groups, stabilize the C–N–C bonds of maleimide; moreover, the enolization of the
carbonyl group is accelerated by N-alkyl substituents. Both effects retard the
nucleophilic attack by hydroxide ions [248].
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Figure 3.6: Absorbance of 8armPEG40k-maleimide, 8armPEG40k-C6-maleimide and
8armPEG40k-C12-maleimide in phosphate buffer, pH 7.4 at 37
◦C. The absorbance
decreased due to ring-opening hydrolysis of maleimide; hydrophobic modification re-
sulted in improved hydrolytic resistance. Experimental data are indicated by symbols;
solid lines represent the best fits of eqn (3.4).
Table 3.2: Calculated rate constants (kobs) and half-lives (t1/2) for the ring-opening
reaction of 8armPEG40k-maleimide, 8armPEG40k-C6-maleimide and 8armPEG40k-
C12-maleimide in phosphate buffer, pH 7.4 at 37
◦C.
Polymer type kobs (min
-1) t1/2 (min) R
2
8armPEG40k-maleimide 4.06 × 10−3 170 0.9986
8armPEG40k-C6-maleimide 1.89 × 10−3 367 0.9853
8armPEG40k-C12-maleimide 1.19 × 10−3 585 0.9998
In the final experiment, hydrogels were loaded with bevacizumab (Avastin
r©
),
which served as a model antibody. The release of bevacizumab from 8armPEG40k,
8armPEG40k-C6 and 8armPEG40k-C12 hydrogels is shown in Fig. 3.7; the polymer
concentration was 10% (w/V) in all groups. As it was expected from the previous
studies, the release rate was strongly influenced by the length of the hydrophobic
spacer. Release from unmodified 8armPEG40k hydrogels was comparatively fast;
the incorporated bevacizumab was completely released after 10 days. In contrast
to 8armPEG40k, release from 8armPEG40k-C6 and 8armPEG40k-C12 hydrogels
was significantly delayed. Both release profiles had a hyperbolic shape; however,
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Figure 3.7: Release of bevacizumab from 8armPEG40k, 8armPEG40k-C6 and
8armPEG40k-C12 hydrogels in phosphate buffer, pH 7.4 at 37
◦C. The polymer con-
centration was 10% (w/V) in all groups.
their time scales were different. The first phase was characterized by fast, diffusion-
controlled release. This was followed by a plateau during which little or no protein
release was observed. Apparently, the incorporated protein is physically trapped
within the polymer network. In addition, a small fraction of the protein is immobi-
lized during cross-linking by Michael-type addition to 8armPEG40k-C6-maleimide
and 8armPEG40k-C12-maleimide. The third phase of release starts with the onset
of hydrogel degradation. Once a critical mesh size had been exceeded after 20
(8armPEG40k-C6) and 45 days (8armPEG40k-C12), the entrapped bevacizumab
was suddenly released; the release was completed after 30 (8armPEG40k-C6) and
55 days (8armPEG40k-C12). Although it is obvious that bevacizumab release is
mainly controlled by degradation, some discrepancies appear when the swelling and
release data are compared. For example, 8armPEG40k-C12 hydrogels started to
degrade after approximately 55 days, while the onset of antibody release was after
approximately 45 days. A possible explanation for the observed time difference
between the beginning of degradation and the onset of antibody release may be the
fact that the incorporation of proteins into hydrogels can lead to network imperfec-
tions, which consequently affect the degradation rate. This explanation seems likely,
as a correlation between the extent of network defects and the incorporation of cells
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[252] or nanoparticles [253] into hydrogels has already been described. In summary,
the obtained in vitro data suggests that 8armPEG40k-C6 and 8armPEG40k-C12
hydrogels may be suitable for controlled protein release in general, and for delayed
antibody release in particular.
3.4 Conclusion
Cross-linking via DA chemistry is a promising method to prepare hydrogels for
controlled release of therapeutic proteins. However, before their application in
pre-clinical studies, the hydrogels still need to be optimized regarding their gel
points, stability to degradation and time frames of drug release. In this study, it
has been demonstrated that the combination of hydrophobic interactions and DA
chemistry can contribute to improved hydrogel properties, such as faster gelation
and increased stability to degradation. Modification of hydrophilic PEG with alkyl
chains induces hydrophobic interactions between the macromonomers, which result
in the formation of micellar structures and transient networks. The resulting inner
structure of the polymer solution has been shown to facilitate crosslinking via DA
chemistry. Using hydrophobically modified macromonomers, therefore, results in
hydrogels with improved properties, in particular if long alkyl chains (e.g., C12)
are employed. For example, hydrogels prepared from 8armPEG40k-C12-furan and
8armPEG40k-C12-maleimide were characterized by significantly faster gelation,
smaller mesh sizes, higher cross-linking densities, increased resistance to mechanical
stress and improved stability to degradation. As a consequence, the in vitro release
of incorporated proteins is considerably delayed; for example, bevacizumab was
released from 8armPEG40k-C12 hydrogels after almost 60 days. Interestingly,
the observed effects have been demonstrated to correlate with the length of the
hydrophobic moieties. Short alkyl chains (e.g., C6) result in much weaker effects
regarding gelation time, stability to degradation and time frame of drug release.
Thus, hydrogel characteristics can be tailored by employing shorter or longer alkyl
chains for hydrophobic modification. In summary, the combination of hydrophobic
association and chemical cross-linking is a promising approach to improve the
properties of hydrogels and bring them closer to clinical application.
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Abstract
Amine-modified four- and eight-armed poloxamines were prepared and subsequently
functionalized with maleimide or furyl groups. Aqueous solutions of these polymers
exhibited an immediate gelation at a temperature above 37 ◦C. Concomitantly, Diels–
Alder reactions gradually cross-linked and cured the gels. Different ratios between
four- and eight-armed macromonomers were used to tune hydrogel stability and
mechanical properties. In this way, hydrogel stability could be precisely controlled in
the range of 14 to 329 days. Controlled release of the model antibody bevacizumab
was achieved over a period of 7, 21, and 115 days. Release profiles were triphasic
with a low burst; approximately 87% of the released antibody was intact and
displayed functional binding. The hydrogels presented in this study are degradable,
nontoxic, rapidly gelling, stable, and provide controlled antibody release. They can
be tailored to match the demands of various applications and present an attractive
platform for antibody delivery.
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4.1 Introduction
The Diels–Alder (DA) reaction is a highly attractive reaction for the design of in
situ cross-linking hydrogels. DA reactions of maleimide and furan are particularly
promising, as they are efficient, require no catalysts, form no toxic side products,
and can be carried out in water at ambient temperatures [254]. Recently, the
DA reaction between maleimide and furan has been introduced as a cross-linking
mechanism for the preparation of degradable poly(ethylene glycol) (PEG) based
hydrogels [155]. Overall, these hydrogels have outstanding potential for antibody
delivery and controlled release. However, they are associated with relatively long
gel times of 14 min or more due to the slow reaction kinetics of the DA reaction.
As this is regarded a major drawback for future applications as injectable depot
system, attempts have been made to accelerate gel formation, for example, by
utilizing hydrophobic association [254] or by introducing additional branches [221].
Although both approaches led to significant decreases in gel times, instantaneous
gel formation could still not be achieved.
As an alternative approach to design DA hydrogels that gel more quickly, the
DA reaction could be combined with a second gelation mechanism that provides
immediate gel formation upon injection. This could be achieved by using materi-
als that respond to external stimuli, such as temperature, pH, or ionic strength
[67, 255–257]. For example, in situ forming hydrogels can be prepared using
thermoresponsive block copolymers, for example, poly(N-isopropylacrylamide),
poloxamer (Pluronic
r©
), and poloxamine (Tetronic
r©
) [258]. These polymers exhibit
a sudden reduction in solubility above a certain temperature, leading to rapid gel
formation. This respective temperature is referred to as lower critical solution
temperature (LCST). Therefore, the goal of this study was to develop thermore-
sponsive materials that can additionally undergo DA cross-linking. In this way,
immediate gelation could be achieved, while at the same time, a major drawback
of exclusively physically cross-linked gels can be eliminated: low resistance against
dissolution and, thus, limited stability after administration [218–220].
For example, in a recent approach by Boere et al. thermal gelation was combined
with native chemical ligation to obtain degradable hydrogels with controlled me-
chanical properties [259]. However, until now, most attempts to combine thermal
gelation and covalent cross-linking have involved Michael-type additions between
acrylate and thiol groups. For example, Cellesi et al. designed materials for cell
encapsulation [260–262], Cho et al. developed tissue sealants [263], and Censi et al.
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prepared a controlled release system for bradykinin [264]. Although Michael-type
additions between thiol and acrylate groups are suitable for dual gelation and
in situ cross-linking, there are some disadvantages associated with the reaction
that render it unsuitable for antibody delivery. For example, thiol groups on poly-
mer chains can form dimers or alter the protein structure through thiol-disulfide
exchange [182]. Furthermore, thiol-Michael additions are often conducted in a
basic environment to accelerate the reaction [265]. However, high pH could be
detrimental for antibody stability for example as many antibodies are formulated in
acidic buffers, such as, adalimumab (pH 5.2), ranibizumab (pH 5.5), trastuzumab
(pH 6.0), and bevacizumab (pH 6.2) [186].
In this study, degradable hydrogels for controlled antibody delivery were prepared
based on a dual approach involving both thermal gelation and the DA reaction.
After rapid gel formation at body temperature, DA reactions gradually cured
and stabilized the hydrogel. In this way, in situ forming yet highly stable hydro-
gels could be obtained. To prepare four-armed macromonomers, poloxamine, a
tetrafunctional thermoresponsive polymer, was end-functionalized with maleimide
(4armPoloxamine-maleimide) or furyl groups (4armPoloxamine-furan). To prepare
eight-armed macromonomers, branched poloxamines were first synthesized and
then end-functionalized (8armPoloxamine-maleimide, 8armPoloxamine-furan). DA-
Poloxamine hydrogels were prepared by dissolving the macromonomers in water
using a polymer concentration of 30 wt %. Different hydrogel types were prepared
using various ratios of 8armPoloxamine to 4armPoloxamine. In the first part of
the study, rheological experiments were carried out to characterize gel formation
and mechanical properties. In the next part, hydrogel stability was analyzed and
cytotoxicity was assessed. Finally, hydrogels were loaded with the model antibody
bevacizumab (Avastin
r©
) to analyze the in vitro release. Bevacizumab was selected
as intravitreal injections of this antibody are currently used to treat neovascular
age-related macular degeneration and the treatment might benefit from controlled
long-term release. Finally, antibody binding ability after release was confirmed to
exclude a negative influence of gel formation on antibody stability.
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4.2.1 Materials
Boc-6-aminohexanoic acid and Fmoc-Lys(Boc)-OH were purchased from Bachem
(Weil am Rhein, Germany). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was obtained from PanReac AppliChem (Darmstadt, Germany).
Poloxamine (Tetronic
r©
1107) was provided by BASF SE (Ludwigshafen am
Rhein, Germany). Deuterated chloroform (CDCl3), N,N’-dicyclohexylcarbodiimide
(DCC), Eagle’s minimum essential medium (EMEM), fetal calf serum (FCS),
3-(2-furyl)propanoic acid, N-hydroxysuccinimide (NHS), and N-methoxycarbonyl-
maleimide were received from Sigma-Aldrich (Taufkirchen, Germany). Mouse
fibroblast L-929 cells were a kind gift from the group of Prof. Armin Buschauer
(University of Regensburg). Bevacizumab (Avastin
r©
, 25 mg mL-1, Roche Ltd,
Basel, Switzerland) was kindly provided by the hospital pharmacy of the University
of Regensburg (Germany). All other chemicals were obtained from Merck KGaA
(Darmstadt, Germany). Purified water was freshly prepared using a Milli-Q water
purification system (Millipore, Schwalbach, Germany).
4.2.2 1H-NMR spectroscopy
1H-NMR spectra were recorded in CDCl3 at 295 K using a Bruker Avance 300
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany).
4.2.3 Synthesis of four-armed macromonomers
The terminal poloxamine hydroxyl groups were first converted to amino groups [225],
and then end-functionalized with maleimide and furyl moieties (Scheme 4.1) as pre-
viously described for poly(ethylene glycol) (PEG)-based macromonomers [155, 225].
In brief, poloxamine (Tetronic
r©
1107) was converted to 4armPoloxamine-NH2 by
means of a Mitsunobu reaction, followed by hydrazinolysis. 4armPoloxamine-NH2
was then reacted with N-methoxycarbonylmaleimide to yield 4armPoloxamine-
maleimide. The reaction of 4armPoloxamine-NH2 with 3-(2-furyl)propanoic acid,
DCC, and NHS led to 4armPoloxamine-furan. The degree of end-group function-
alization among the batches was 76 ± 8% for 4armPoloxamine-maleimide and
81 ± 1% for 4armPoloxamine-furan, as determined by 1H-NMR.
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4.2.4 Synthesis of eight-armed macromonomers
Eight-armed poloxamines were synthesized through branching as previously de-
scribed for PEG-based macromonomers [221]. Briefly, 4armPoloxamine-NH2 was
first reacted with Fmoc-Lys(Boc)-OH, DCC, and NHS. The Fmoc-groups were
removed and Boc-6-aminohexanoic acid was reacted with the free amino-group
via DCC/NHS chemistry. All Boc-groups were then removed and the free amino-
groups were functionalized with furyl (8armPoloxamine-furan) or maleimide moi-
eties (8armPoloxamine-maleimide) as described above. The degree of end-group
functionalization among the batches was 64 ± 6% for 8armPoloxamine-maleimide
and 82 ± 4% for 8armPoloxamine-furan as determined by 1H-NMR.
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Scheme 4.1: Four- and eight-armed poloxamines were end-functionalized with
maleimide or furyl groups. Macromonomers were synthesized from Tetronic
r©
1107;
the x (poly(ethylene glycol), PEG) to y (poly(propylene glycol), PPG) ratio was 70:30.
Branching was achieved by introducing lysine and 6-aminohexanoic acid residues.
4.2.5 Gel formation and rheological properties
For hydrogel preparation, the respective polymers were dissolved in water using a
total polymer concentration of 30 wt %. Various ratios between 8armPoloxamine
and 4armPoloxamine were used to prepare hydrogels with different properties.
For example, in order to prepare 1000 mg of a hydrogel composed of 20 wt %
8armPoloxamine and 10 wt % 4armPoloxamine, that is, a 20%/10% hydrogel, a total
amount of 300 mg polymer was dissolved in 700 mg water. To be more precise, for
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this type of hydrogel 100 mg 8armPoloxamine-maleimide, 100 mg 8armPoloxamine-
furan, 50 mg 4armPoloxamine-maleimide, and 50 mg 4armPoloxamine-furan were
used. Immediate gel formation could be induced by increasing the temperature to
37 ◦C.
Rheological characterization was performed on a TA Instruments AR 2000
rheometer (TA Instruments, Eschborn, Germany). Oscillatory shear experiments
were carried out using a 40 mm parallel plate geometry with a 500 µm gap size
at a constant frequency of 0.5 Hz. Polymer solutions were prepared as described
above; a sample volume of 750 µL was used. Absolute values of the complex shear
modulus (|G∗|) and phase angles (δ) were recorded as a function of time. In order
to characterize the thermoresponsive behavior of the polymer solutions, heating (20
to 37 ◦C) and cooling (37 to 20 ◦C) steps were included in the procedure. Water
evaporation was minimized by using a solvent trap and by pipetting silicone oil
around the gap between the plates. However, in order to minimize the influence
of drying on the obtained |G∗| values, rheological experiments were limited to
100 min.
4.2.6 Swelling and degradation
Swelling and degradation of DA-Poloxamine hydrogels was studied in 50 mM
phosphate buffer, pH 7.4 at 37 ◦C as previously described [221]. Different ratios
between 8armPoloxamine and 4armPoloxamine were used as described above; a
polymer concentration of 30 wt % was used for all hydrogels.
4.2.7 Hydrolytic stability of maleimides
The hydrolytic stability of 4armPoloxamine-maleimide and 8armPoloxamine-malei-
mide was investigated in phosphate buffer, pH 7.4 at 37 ◦C as previously described
[254].
4.2.8 Cytotoxicity
In order to assess the cytotoxicity of DA-Poloxamine hydrogels a metabolic assay
using the reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was performed according to ISO 10993-5:2009 (Biological evaluation of
medical devices, part 5: Tests for in vitro cytotoxicity). In brief, 300 µL of 0%/30%,
15%/15%, and 30%/0% hydrogels were prepared, cast into a 24-microtiter plate and
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allowed to cross-link overnight in cell culture conditions (37 ◦C, 5% CO2). On the
next day, extracts were prepared by adding 2.0 mL of EMEM supplemented with
10% FCS to the hydrogels, which were then incubated for 24 h. Mouse fibroblast
L-929 cells were seeded in 96-microtiter plates at a density of 10,000 cells per
well and allowed to adhere overnight. 100 µL of extract was added to each well.
SDS (0.1%) served as a negative control and pure medium as a positive control
(n = 12). Cells were incubated with the test media for 24 h after which the medium
was removed and 200 µL of serum-containing medium with 1.5 mM MTT was
added to each well. After 5 h of incubation the MTT solution was removed and
200 µL PBS containing 10% SDS was added to each well. After 16 h of incubation,
absorbance at 570 and 690 nm was determined for each well using a FluoStar
Omega fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). The
difference in absorbance at 570 and 690 nm was used to calculate the viability of
cells. The viability of the treated cells was normalized to the value for the positive
control, that is, medium alone.
4.2.9 Antibody release and analytics
Release experiments were carried out as previously described [254]. However, in this
study the bevacizumab loading was 6.25 mg mL-1 and the polymer concentration
used was 30 wt %. Due to the high stability of some hydrogels, release experiments
were only carried out using 0%/30%, 5%/25%, and 10%/20% hydrogels. In order to
investigate a potential negative influence of hydrogel preparation and cross-linking
reactions on the stability of bevacizumab, the antibody was analyzed after release.
Functional binding to vascular endothelial growth factor (VEGF) was investigated
using a Shikari
r©
Q-beva enzyme-linked immunosorbent assay (ELISA) kit (Matriks
Biotek, Ankara, Turkey). The amount of binding antibody was compared to a
solution containing the same concentration of fresh bevacizumab.
4.2.10 Statistical analysis
All results are presented as mean ± standard deviation, based on the data obtained
from at least n = 3 samples. Statistical significance was determined by means
of one-way ANOVA, followed by Tukey’s post-hoc test using GraphPad Prism
6.0 (GraphPad Software Inc., La Jolla, CA, U.S.A.). Differences were considered
statistically significant at p < 0.05.
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4.3 Results and discussion
4.3.1 Hypothesis and proof of concept
The goal of this study was to develop hydrogels that combine thermal gelation and
DA chemistry in a dual gelation process. This combination has several advantages
for the delivery of therapeutic antibodies. First, precursor solutions can easily
be prepared by dissolving the polymer components in water or buffer together
with the antibody to be encapsulated. Second, due to the slow reaction kinetics
of the DA reaction, the fluidity of the polymer solution will remain unaffected
at room temperature for a time span long enough to allow convenient handling
and application. Third, the thermoresponsive behavior will lead to immediate
gel formation at a site of injection. In that way, high amounts of antibody can
be “encapsulated” in situ. Finally, in contrast to hydrogels that rely exclusively
on thermal gelation, these hydrogels are expected to be significantly more stable
concerning degradation as a result of covalent cross-linking.
In a proof of concept experiment, the rheological properties of modified 4arm-
Poloxamines (“DA-Poloxamine”) were investigated and compared to unmodified
commercially available Tetronic
r©
1107 (“Poloxamine”). For this purpose, 30 wt %
polymer was dissolved in water and analyzed using a three-step temperature
program (Fig. 4.1). Absolute values of the complex shear modulus (|G∗|) and
phase angles were recorded over time to monitor gel formation and stiffness. At
20 ◦C, both Poloxamine and DA-Poloxamine were in the liquid state which was
confirmed by |G∗| values of 0.7 ± 0.2 Pa for Poloxamine and 0.8 ± 0.4 Pa for DA-
Poloxamine. The phase angles (δ) were 90.1 ± 0.2◦ (Poloxamine) and 88.5 ± 2.4◦
(DA-Poloxamine), and the loss modulus (G′′) was larger than the storage modulus
(G′) indicating mainly viscous behavior. Upon increasing the temperature to 37 ◦C
(+∆T), the |G∗| values for both sample types immediately increased confirming
their thermoresponsive properties. Directly after heating, the |G∗| values were 48.6
± 6.9 kPa for Poloxamine and 36.2 ± 9.8 kPa for DA-Poloxamine; differences were
not statistically significant (p < 0.05). At the same time, δ strongly decreased
for both samples indicating the formation of a viscoelastic gel (G′ > G′′). During
the following incubation time at 37 ◦C, the stiffness of Poloxamine gels remained
unchanged. In contrast, |G∗| values for DA-Poloxamine gels increased to 67.0 ±
13.7 kPa. The increase in stiffness was attributed to covalent cross-linking reactions
that occurred while already in the gel state. It could also be observed that the
increase in |G∗| was mainly governed by the strongly rising G′. The contribution
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of G′′ was much weaker. In a third step, the temperature was lowered to 20 ◦C
(-∆T). As expected, unmodified Poloxamine gels returned to the liquid state (|G∗|
= 0.7 ± 0.3 Pa, δ = 90.3 ± 0.2◦, G′ < G′′), whereas DA-Poloxamines remained in
the gel state (|G∗| = 15.3 ± 3.2 kPa, δ = 3.5 ± 0.3◦, G′ > G′′). Taken together,
the experiment confirmed the hypothesis that DA-Poloxamines exhibit thermal
gelation and DA cross-linking in a dual gelation process.
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Figure 4.1: Rheological behavior of 30 wt % Poloxamine (A) and DA-Poloxamine (B)
solutions in the course of a three-step temperature program. Absolute values of the
complex shear modulus (|G∗|), represented as white squares, and phase angles (δ),
represented as black circles, were recorded as a function of temperature and time at a
0.5 Hz oscillatory frequency. The initial temperature was set to 20 ◦C. After 10 min,
the temperature was increased to 37 ◦C (+∆T) and kept constant for 180 min. In
the third step, the temperature was again reduced to 20 ◦C (-∆T). Both polymer
solutions displayed thermal gelation, however, only for DA-Poloxamines stiffness in-
creased during incubation and could be retained after cooling. For the sake of clarity,
error bars are not shown in the diagram.
4.3.2 Gel formation and mechanical properties
In order to utilize DA-Poloxamines for antibody delivery, hydrogels with tun-
able properties would be desired. To this end, both four- and eight-armed
macromonomers were employed for hydrogel preparation. In this way, hydrogels
with different amounts of functional groups and, therefore, cross-linking densi-
ties could be obtained. In the following section, hydrogels composed of both
4armPoloxamines and 8armPoloxamines were analyzed for their thermal gelation
properties and gel stiffness. In the nomenclature used to describe the composi-
tions, the first number denotes the amount of 8armPoloxamine in the mixture, the
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second number refers to the amount of 4armPoloxamine. For example, in order
to prepare 1000 mg of a 20%/10% hydrogel, 100 mg 8armPoloxamine-maleimide,
100 mg 8armPoloxamine-furan, 50 mg 4armPoloxamine-maleimide, and 50 mg
4armPoloxamine-furan were dissolved in 700 mg water. The total polymer concen-
tration was 30 wt % for all hydrogel types. This was identified as the minimum
concentration to induce immediate thermal gelation.
In the next experiment, the rheological behavior of hydrogels with different 8arm
to 4arm ratios was analyzed (Fig. 4.2). |G∗| was recorded at 20 ◦C for 10 min.
Then, the temperature was increased to 37 ◦C and kept constant for 90 min.
Initially, all compositions were liquid and did not show significant stiffness; |G∗|
values ranged between 0.5 and 0.8 Pa. After 10 min at 20 ◦C the stiffness had
slightly increased due to the beginning DA cross-linking, for example to 1.0 ±
0.6 Pa for 0%/30% gels and to 1.7 ± 0.3 Pa for 20%/10% gels. Here, the slow
reaction kinetic of the DA reaction is an advantage as faster covalent cross-linking
could cause faster gel formation and might prevent administration, for example,
by clogging the needle. For example, hydrogels that rely on the relatively fast
Michael-type addition reaction already exhibit gel formation after about 100 s at
room temperature and neutral pH [266].
Upon increasing the temperature to 37 ◦C, stable viscoelastic gels were formed
immediately. |G∗| values determined directly after increase in temperature are
listed in Table 4.1. For all compositions, a strong increase in stiffness was observed.
Interestingly, there was no significant difference between |G∗| values directly after
the increase in temperature (p < 0.05). Consequently, the strength of the thermally
induced gel formation is governed by the backbone and is hardly affected by the
number of functional end-groups on the macromonomer. The thermoresponsive
properties were comparable for all compositions. In contrast, the increase in
stiffness after 90 min at 37 ◦C strongly depended on the 8arm/4arm-ratio used. For
0%/30% hydrogels, a |G∗| increase of only 1.4-fold could be observed. However, the
|G∗| increase was considerably more pronounced for hydrogels containing a higher
concentration of branched macromonomers, for example, 3.6-fold for 20%/10%
hydrogels. This observation can be explained by the fact that hydrogel curing is
caused by covalent DA cross-linking while already in the gel state. When more
functional groups are present, both the likelihood of covalent reactions and the
maximum number of elastically active chains increases.
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Figure 4.2: Initial thermal gelation and subsequent increase of stiffness for different
8armPoloxamine and 4armPoloxamine mixtures using an overall polymer concentra-
tion of 30 wt %. Absolute values of the complex shear modulus (|G∗|) were recorded
over time at a 0.5 Hz oscillatory frequency. The initial temperature was set to 20 ◦C.
After 10 min, the temperature was increased to 37 ◦C (+∆T) and then kept constant
for 90 min. All polymer solutions were characterized by an immediate increase of
stiffness at 37 ◦C. The further increase of stiffness was attributed to covalent cross-
linking via Diels–Alder reaction and was stronger when more functional end-groups
were present in the solution.
Table 4.1: Absolute values of the complex shear modulus (|G∗|) determined for hydro-
gels with different 8armPoloxamine to 4armPoloxamine ratios, measured directly after
increase of temperature (0 min) and after incubation (90 min).
Hydrogel composition |G∗|(0 min), kPa |G∗|(90 min), kPa
20%/10% 35.6 ± 10.3 126.7 ± 19.0
15%/15% 40.6 ± 1.3 114.0 ± 2.6
10%/20% 45.2 ± 3.7 94.0 ± 7.2
5%/25% 46.1 ± 3.9 83.0 ± 8.5
0%/30% 36.2 ± 9.8 52.1 ± 11.9
4.3.3 Hydrogel swelling and degradation
In the previous experiments, it was demonstrated that DA-Poloxamines can be
prepared using different amounts of four- and eight-armed macromonomers. For
all compositions, immediate gel formation at body temperature was observed.
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Hydrogel stiffness could be increased using a higher amount of 8armPoloxamine.
Due to their rapid gelation and controllability, DA-Poloxamine hydrogels present
an attractive candidate as a “smart” material for drug delivery. However, in
order to utilize these hydrogels for controlled antibody delivery, sufficient stability
must be demonstrated. To this end, the swelling and degradation behavior of
DA-Poloxamine gel cylinders was analyzed in phosphate buffer, pH 7.4 at 37 ◦C
(Fig. 4.3A). Similar to hydrogel stiffness, the stability and swelling properties of
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Figure 4.3: Swelling and degradation of DA-Poloxamine hydrogels with different com-
positions in phosphate buffer, pH 7.4 at 37 ◦C (A). A higher number of functional
end-groups correlated with an increase in stability and a lower degree of swelling.
The onset of hydrogel erosion, that is, beginning decrease of relative hydrogel mass,
could be correlated with the concentration of 8armPoloxamine using a second-order
polynomial (B).
DA-Poloxamine hydrogel can be controlled by choosing the right composition. For
example, hydrogels prepared based on four-armed macromonomers alone (0%/30%)
completely dissolved after approximately 14 days. The maximum relative mass
increase was 5.7 ± 1.0. In comparison, hydrogels containing the highest amount
of branched macromonomers (20%/10%) completely dissolved after 329 days and
reached a relative mass of only 2.9 ± 0.3.
In order to select the right composition for a certain application it would be highly
desirable to be able to predict hydrogel stability. Therefore, the relationship between
onset of hydrogel erosion and 8armPoloxamine content was investigated (Fig. 4.3B).
The onset of erosion was defined as the time-point where the relative hydrogel mass
started to decrease. Interestingly, the relation between 8armPoloxamine content
and onset erosion can be described using a second-order polynomial (R2 = 0.9988).
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This correlation can be used to predict the stability of a specific composition
or to tailor hydrogel stability for a given application. In order to understand
why the relationship between 8armPoloxamine concentration and stability is not
a linear but a quadratic one, it must be taken into account that there are two
factors influencing DA-Poloxamine hydrogel stability. On the one hand, hydrogels
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Scheme 4.2: Diels–Alder (DA) reactions of maleimide and furyl functionalized polox-
amines (R) lead to covalent hydrogel cross-linking. Hydrogel degradation is medi-
ated by retro-Diels–Alder (rDA) reactions followed by the ring-opening hydrolysis of
maleimide.
containing a higher amount of branched macromonomers possess a higher number
of functional end-groups and can, therefore, build up more elastically active chains.
Hydrogels with a higher cross-linking density exhibit a higher resistance to swelling
and more cross-links have to be broken until hydrogels degrade. On the other hand,
it has already been described by Kirchhof et al. that maleimide hydrolysis plays a
pivotal role for DA-hydrogel stability (Scheme 4.2) [156]. As degradation occurs
by retro-Diels–Alder (rDA) reaction and subsequent ring-opening hydrolysis of
maleimide moieties, a higher hydrolytic resistance is accompanied by an increase in
hydrogel stability. In the course of synthesizing branched poloxamines, lysine and
6-aminohexanoic acid residues were introduced between the polymer backbone and
the maleimide moieties. According to literature, N-alkylation generally increases
the hydrolytic stability of maleimides [248–251]. This can be explained by the
fact that electron donating N-substituents stabilize the C-N-C bond of maleimide
and that enolization of the carbonyl group can be accelerated by N-alkylation
[248]. Consequently, nucleophilic attacks by hydroxide ions that lead to maleimide
hydrolysis are hampered. This is in line with the experimental results obtained for
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4armPoloxamine-maleimide and 8armPoloxamine-maleimide (Fig. 4.4). Maleimide
hydrolysis was monitored for both macromonomers in phosphate buffer, pH 7.4 at
37 ◦C. Assuming a pseudo-first order reaction, half-lives (t1/2) and rate constants
(kobs) were calculated by fitting the integrated form of eqn (4.1) to the experimental
data.
−d[maleimide]
dt
= kobs[maleimide] (4.1)
The results are listed in Table 4.2. On average, the half-life of 8armPoloxamine-
maleimide was 2.8-fold higher than for 4armPoloxamine-maleimide. Interestingly,
the half-life of 8armPoloxamine-maleimide (t1/2 = 874 min) was also considerably
higher than for PEG-based macromonomers, which were branched using the same
chemistry (t1/2 = 412 min) [221], or macromonomers bearing an even longer C12
N-alkyl spacer (t1/2 = 585 min) [254]. Similarly, 4armPoloxamine-maleimide (t1/2
= 315 min) displayed a much longer half-life than PEG-based maleimides, for
example, 8armPEG20k-maleimide (t1/2 = 177 min) [221]. These observations
can be explained by the more hydrophobic PEG–PPG polymer backbone used
in this study. Taken together, the combined effects of retarded hydrolysis and
increased cross-linking density contribute to the massive stability increase observed
for hydrogels containing 8armPoloxamine.
Table 4.2: Calculated rate constants (kobs) and half-lives (t1/2) for the ring-opening
reaction of 4armPoloxamine-maleimide and 8armPoloxamine-maleimide in phosphate
buffer, pH 7.4 at 37 ◦C.
Macromonomer kobs(min
-1) t1/2(min) R
2
4armPoloxamine-maleimide 2.20 × 10−3 315 0.9972
8armPoloxamine-maleimide 0.79 × 10−3 874 0.9972
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Figure 4.4: Absorbance of 4armPoloxamine-maleimide and 8armPoloxamine-maleimide
in phosphate buffer, pH 7.4 at 37 ◦C. The absorbance decreased due to ring-opening
hydrolysis of maleimide. Experimental data are indicated by box symbols; solid lines
represent the best fits of eqn (4.1).
4.3.4 Cytotoxicity
Before application of DA-Poloxamine hydrogels in preclinical studies, toxicological
safety should be demonstrated. PEG–PPG block copolymers like poloxamer
(Pluronic
r©
) and poloxamine (Tetronic
r©
) are generally regarded as safe and are
approved by regulatory authorities such as the U.S. Food and Drug Administration
[267–269].
However, as the poloxamines were chemically modified in this study their toxico-
logical potential should be reassessed. In particular, leaching of side-products and
reactants that could not be removed during purification might have toxic potential.
In order to assess the cytotoxicity of DA-Poloxamine hydrogels, an MTT assay was
performed. The test was carried out using mouse fibroblast L-929 cells according to
ISO 10993-5:2009. Extracts were prepared by incubating FCS containing medium
with 0%/30%, 15%/15%, or 30%/0% hydrogels for 24 h at 37 ◦C (Fig. 4.5). Cell
viability after exposure to the extracts was referenced to pure medium (positive
control); medium containing 0.1% (w/V) SDS served as a negative control. The
relative cell viabilities were 93.9 ± 5.4% (0%/30%), 96.6 ± 5.7% (15%/15%), and
100.7 ± 5.8% (30%/0%). Therefore, incubation with extracts from DA-Poloxamine
hydrogels did not exhibit a strong negative effect on cell viability. However, hydro-
gels composed of 4armPoloxamine alone displayed a significantly higher cytotoxicity
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Figure 4.5: L-929 cell viability after exposure to extracts from 0%/30%, 15%/15%, and
30%/0% DA-Poloxamine hydrogels was determined using an MTT assay. Cell culture
medium containing 0.1% (w/V) SDS served as a negative control. A cell viability
of < 70% (dotted line) was considered cytotoxic. * indicates statistically significant
differences to all other groups.
than hydrogels containing 8armPoloxamine (p < 0.05). This can be explained based
on two effects: When macromonomers were not properly bound to the network
or covalent cross-links were broken, polymer could be eluted. As eight-armed
macromonomers bear more functional end-groups, they are bound more strongly
to the network. Therefore, the likelihood for an elution of 4armPoloxamine during
extraction is higher. This is reflected by a higher cellular toxicity. One potential
source for the cytotoxicity of the extracted polymer is its surface-active properties
that might interfere with the integrity of cell membranes. A second source for
cytotoxic effects could be the extraction of acidic Poloxamine-maleamic acid which
could alter the pH of the cell culture medium. In summary, DA-Poloxamines
displayed a very low cellular toxicity. However, in future in vivo investigations are
necessary to confirm these results and to ensure biocompatibility.
4.3.5 Controlled antibody release
In the final experiment, antibody release from DA-Poloxamine hydrogels was studied.
To this end, three hydrogel compositions were loaded with the model antibody
bevacizumab (Avastin
r©
), and the in vitro release was analyzed in phosphate buffer,
pH 7.4 at 37 ◦C (Fig. 4.6). As expected from swelling and degradation experiments,
the release rate was strongly influenced by hydrogel composition. The least stable
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Figure 4.6: Release of bevacizumab from 0%/30%, 5%/25%, and 10%/20% DA-
Poloxamine hydrogels in phosphate buffer, pH 7.4 at 37 ◦C.
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hydrogel (0%/30%) released the antibody after 7 days. When higher ratios of
branched macromonomer was used for gel preparation, antibody release could
be significantly delayed. Bevacizumab was released over the course of 21 days
for 5%/25% hydrogels and 115 days for 10%/20% hydrogels. In all three cases,
more than 90% of the antibody that had been loaded could be recovered after
release. Interestingly, the release profiles for the three hydrogel types all had a
comparable shape but on different time-scales. Initially, a notably low burst release
of about 2 - 6% was observed. After a short lag phase, a rapid antibody release
could be observed. The fast release can be explained by an increase of meshwork
size resulting from hydrogel swelling. Consequently, antibodies were able to freely
diffuse out of the network. The cumulative antibody release in the first phase was
67.9 ± 8.0% (0%/30%), 53.2 ± 4.9% (5%/25%), and 30.3 ± 3.9% (10%/20%). The
amount of antibody released in this phase was higher for hydrogels with a lower
number of covalent cross-links. In the next phase, antibody release was considerably
slower. During this plateau phase, the majority of antibody was trapped within
the polymer network. During this phase, single cross-links were broken over time
due to rDA reaction and maleimide hydrolysis. Consequently, antibody release was
strongly delayed. In case of the most stable gel, this plateau phase spanned over
93 days. In the third phase, a rapid antibody release was observed. The constant
breaking of cross-links led to a gradual increase of average meshwork size until a
critical meshwork size had been exceeded. At this point, the previously entrapped
antibody was rapidly released.
A triphasic release profile could be beneficial for various applications. One
example could be in the treatment of ocular neovascularizations, in which anti-
VEGF antibodies are directly administered into the vitreous body. As the ocular
half-life of antibodies is 7-10 days [270] sustained release systems could be used
to provide sufficient antibody concentrations over weeks. However, as VEGF is
a key player in maintaining cone photoreceptors and the choroidal vasculature, a
constant blockage of VEGF signaling might lead to additional side effects. The
intermittent release profile provided by DA-Poloxamine hydrogels might be an
attractive alternative as VEGF-dependent structures can recover from the action
of VEGF-neutralizing antibodies during the plateau phase [271, 272]. Another
potential application for DA-Poloxamine hydrogels could be in the administration
of vaccines. The intermittent release profile could be used to deliver antigens
in a pulsed manner following a single administration [273–275]. Moreover, DA-
Poloxamine hydrogels could most likely also be used for the controlled release of
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other biopharmaceuticals, for example, immunoglobulin G with a size comparable
to bevacizumab.
Finally, as hydrogel preparation and cross-linking are known to potentially impair
protein stability the binding ability of released bevacizumab was analyzed. To
this end, bevacizumab was incorporated into 0%/30% and 5%/25% hydrogels.
The hydrogels were then allowed to fully degrade for 7 and 30 days, respectively.
Samples were taken and bevacizumab binding to VEGF was analyzed using ELISA.
Fresh bevacizumab in the same concentration as the sample solution was used as a
reference. As the focus was put on the influence of preparation and cross-linking, the
antibody binding was not analyzed for 10%/20% hydrogels. The long degradation
time of more than 100 days would have influenced the results through unspecific
effects, such as oxidation, deamidation, aggregation, and adsorption to the vial
surface [276–278]. For both hydrogel types, most of the released bevacizumab
retained its binding properties (Table 4.3). The proportion of binding antibody
was 87.0 ± 5.6% for 0%/30% hydrogels and 87.1 ± 1.7% for 5%/25% hydrogels.
Consequently, preparation, thermal gelation, and cross-linking had only a minimal
influence on antibody binding. Interestingly, when bevacizumab was incubated in
phosphate buffer pH 7.4 for 30 days at 37 ◦C, the amount of binding bevacizumab
was only 82.5 ± 2.7%. When compared to bevacizumab released from 5%/25%
hydrogels over 30 days, the amount of intact antibody was significantly lower
(p < 0.05). Consequently, it can be concluded that DA-Poloxamine hydrogels
exhibit a protective effect against antibody degradation in vitro.
Table 4.3: Analytical investigation of bevacizumab released from DA-Poloxamine hy-
drogels. Bevacizumab binding to VEGF was quantified using ELISA; results were
compared to a solution containing the same concentration of fresh bevacizumab.
Hydrogel composition Time-scale (days) Binding antibody (%)
0%/30% 7 87.0 ± 5.6
5%/25% 30 87.1 ± 1.7
To summarize, it could be demonstrated that DA-Poloxamine hydrogels are an
outstanding material for the controlled release of therapeutic antibodies. Time-
scales of release can be influenced by hydrogel composition. The general release
profile was independent from hydrogel composition and is characterized by three
phases and a low burst release. In all cases, > 90% of the loaded bevacizumab was
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released and about 87% of the released antibody showed a binding comparable to
fresh bevacizumab.
4.4 Conclusion
In this study, poloxamines were branched and end-functionalized with maleimide or
furyl groups to yield four- and eight-armed macromonomers. At room temperature,
aqueous solutions of these polymers were viscous fluids. Upon increasing the
temperature to 37 ◦C, viscoelastic gels were immediately formed while subsequent
DA reactions covalently cross-linked the gel. In this way, the many advantages of
the DA reaction for hydrogel design could be utilized while avoiding the drawback
of slow gelation. In addition, the hydrogels presented in this work are degradable
and nontoxic. Their mechanical properties can be precisely tailored to match
the demands of various applications using appropriate compositions. Moreover,
hydrogel stability could be adjusted between 14 days and 329 days; the onset of
hydrogel erosion could be predicted using a second-order polynomial. Controlled
in vitro release of the model antibody bevacizumab was achieved over periods of
7, 30, and 115 days. In all cases, more than 90% of the loaded bevacizumab was
released and 87% exhibited binding capabilities comparable to fresh bevacizumab.
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Abstract
Reducing burst effects, providing controlled release, and safeguarding biologics
against degradation are a few of several highly attractive applications for microgels
in the field of controlled release. However, the incorporation of proteins into micro-
gels without impairing stability is highly challenging. In this proof of concept study,
the combination of microfluidics and thiol-ene photoclick chemistry was evaluated
for the fabrication of antibody-loaded microgels with narrow size distribution.
Norbornene-modified eight-armed poly(ethylene glycol) with an average molecular
mass of 10,000 Da, 20,000 Da, or 40,000 Da were prepared as macromonomers for
microgel formation. For functionalization, either hydrolytically cleavable ester or
stable amide bonds were used. A microfluidic system was employed to generate pre-
cursor solution droplets containing macromonomers, the cross-linker dithiothreitol,
and the initiator Eosin-Y. Irradiation with visible light was used to trigger thiol-ene
reactions which covalently cross-linked the droplets. For all bond-types, molecular
masses, and concentrations gelation was very rapid (< 20 s) and a plateau for the
complex shear modulus was reached after only 5 min. The generated microgels had
a rod-like shape and did not show considerable cellular toxicity. Stress conditions
during the fabrication process were simulated and it could be shown that fabrication
did not impair the activity of the model proteins lysozyme and bevacizumab. It was
confirmed that the average hydrogel network mesh size was similar or smaller than
the hydrodynamic diameter of bevacizumab which is a crucial factor for restricting
diffusion and delaying release. Finally, microgels were loaded with bevacizumab
and a sustained release over a period of 28 and 46 days could be achieved in vitro.
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5.1 Introduction
Microgels have several properties that make them highly attractive for drug delivery
applications, e.g., their size, swelling and mechanical properties are tunable, they
can be loaded with cargo, are considered biocompatible, and their surface can
be modified [279–281]. One way to utilize this potential is to load microgels
with biologics and employ them as a delivery system for controlled local release.
Moreover, many frequently used cross-linking reactions for bulk hydrogels can
negatively impact the stability of the incorporated proteins, e.g., the Diels–Alder
reaction, Michael-type additions or radical polymerizations [182, 282]. In this
context, microgels could serve as a protective carrier system that can safeguard
proteins during bulk hydrogel preparation. Furthermore, antibody-loaded microgels
with a small network mesh size could be used to reduce burst effects from bulk
hydrogels by restricting uncontrolled antibody diffusion [283] or providing pulsed
antibody release as demonstrated for vaccines [273]. However, the incorporation of
proteins into microgels without negatively affecting conformational and colloidal
stability is highly challenging. Therefore, in this proof of concept study a protein-
compatible method for protein loading of microgels was developed to provide a
platform technology for drug delivery applications.
In order to achieve this goal, several prerequisites had to be met. On the one
hand, a narrow size distribution was desired, as particle size and surface area
are factors that most likely influence release properties [284]. On the other, the
method used for droplet generation must not generate excessive stress. For these
reasons, microfluidics was selected for droplet generation. Next, the generated
droplets had to be cross-linked to yield stable microgels. For this purpose, a
fast, efficient, and protein compatible cross-linking reaction was required. This
reaction mechanism should also require a trigger for initiation in order to avoid
premature gelation and to preserve fluidity of the precursor solution. In order
to meet all these requirements, the thiol-ene photoclick reaction was selected
as a cross-linking reaction. In recent years, this reaction has received growing
attention, e.g., for protein immobilization [285, 286], tissue engineering [287–291],
preparation of microcapsules [292], microspheres [293, 294], microgels [295], and
hydrogels [296–298]. As with other click reactions, thiol-ene chemistry proceeds at
mild conditions, is highly specific, efficient, and does not form toxic side-products
[299]. Most notably, the reaction is considered to be compatible with proteins. For
example, McCall et al. [300] have shown that thiol-ene photoclick reactions can be
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carried out in presence of proteins without negatively affecting their bioactivity.
In addition, there are several studies in which the reaction has been successfully
employed for the incorporation of proteins and cells into hydrogels, e.g., bovine
serum albumin and carbonic anhydrase [301], valvular interstitial cells [302], human
mesenchymal stem cells [287, 288], and pancreatic β-cells [303]. Another advantage
for biomedical applications is that they can be initiated using the biocompatible
radical starter Eosin-Y [304, 305] in combination with visible light [295]. Briefly,
the reaction mechanism can be explained as a cyclic process [299]: In the first step,
irradiation excites a photoinitiator that causes the formation of a thiyl radical. In
the next step, the thiyl radical propagates across the ene’s carbon-carbon double
bond generating a carbon radical. Finally, chain-transfer from the carbon radical
to a new thiol group regenerates the thiyl radical and the process repeats.
The goal of this study was to evaluate the combination of microfluidics and thiol-
ene chemistry for the fabrication of antibody-loaded microgels. For this purpose,
eight-armed PEGs were end-functionalized with norbornene moieties using either
ester or amide bonds to yield degradable and stable macromonomers. Under
irradiation and in presence of a suitable initiator, norbornene groups can undergo
reactions with thiol groups. In the first part of the study, rheological experiments
were used to study light-induced gel formation and mechanical properties. Thereby,
gelation times and stiffness could be determined. In the next part, droplets were
generated using a microfluidic device and then irradiated to yield covalently cross-
linked microgels. Microgel size distribution was analyzed and cellular toxicity was
evaluated. Moreover, stress conditions during the fabrication process were simulated
and their influence on the activity of three model proteins was investigated. In the
final part, the average hydrogel network mesh sizes were determined and suitable
microgel types were selected for antibody loading. Finally, the model antibody
bevacizumab (Avastin
r©
) was incorporated into microgels and the in vitro release
was studied.
5.2 Materials and methods
5.2.1 Materials
Dichloromethane (DCM) and 4-dimethylaminopyridine (DMAP) were purchased
from Acros Organics (Geel, Belgium). Diethyl ether was obtained from CSC
Ja¨cklechemie (Nuremberg, Germany). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
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zolium bromide (MTT) was obtained from PanReac AppliChem (Darmstadt, Ger-
many). Eight-armed poly(ethylene glycol) with molecular masses of 10,000 g mol-1,
20,000 g mol-1, and 40,000 g mol-1 were purchased from JenKem Technology (Allen,
TX, USA). Deuterated chloroform (CDCl3), N,N’-dicyclohexylcarbodiimide (DCC),
dithiothreitol (DTT), N,N-diisopropylethylamine (DIPEA), Eagle’s minimum es-
sential medium (EMEM), Eosin-Y, fetal calf serum (FCS), L-lactate dehydrogenase
(from rabbit muscle), lysozyme (from chicken egg white), methoxy poly(ethylene
glycol) with a molecular mass of 5000 g mol-1, micrococcus lysodeikticus, exo-5-
norbornenecarboxylic acid, pyruvate and silicone oil were received from Sigma-
Aldrich (Taufkirchen, Germany). Poly(tetrafluoroethylene) (PTFE) tubing (1/16′′
× 0.50 mm inner diameter) was bought from Vici AG International (Schenkon,
Switzerland). Female luer fitting systems (1/16′′) and a poly(etheretherketone)
(PEEK) MicroTee (1/16′′) were received from Cole-Parmer GmbH (Wertheim,
Germany). 2 mL and 10 mL B. Braun Injekt
r©
luer-lock syringes were purchased
from Carl Roth GmbH & Co KG (Karlsruhe, Germany). All other chemicals were
obtained from Merck KGaA (Darmstadt, Germany). Bevacizumab (Avastin
r©
, 25
mg mL-1, Roche Ltd, Basel, Switzerland) was kindly provided by the hospital
pharmacy of the University of Regensburg (Germany). Mouse fibroblast L-929
cells were a kind gift from the group of Prof. Armin Buschauer (University of
Regensburg). Purified water was freshly prepared using a Milli-Q water purification
system (Millipore, Schwalbach, Germany).
5.2.2 Synthesis of macromonomers
In order to prepare suitable macromonomers, eight-armed PEG molecules with a
molecular mass of 10,000 Da (8armPEG10k), 20,000 Da (8armPEG20k), and 40,000
Da (8armPEG40k) and methoxy PEG with a molecular mass of 5000 Da (mPEG5k)
were end-functionalized with norbornene moieties (Scheme 5.1). Hydrolytically
cleavable and non-cleavable end-groups were introduced using either amide or ester
bonds.
For the synthesis of macromonomers with hydrolytically cleavable functional-
ities, 8armPEGs were end-functionalized with exo-5-norbornenecarboxylic acid
by esterification using a slightly modified version of the synthesis described in
literature [287, 296]. In brief, exo-5-norbornenecarboxylic acid (5-fold excess of
PEG hydroxyl groups) and DCC (2.5-fold excess of OH-groups) were dissolved in
anhydrous DCM and stirred for 30 min at 0 ◦C. After removing the precipitate,
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Scheme 5.1: Eight-armed PEG was end-functionalized with norbornene (NB) moi-
eties. Ester (8armPEG-e-NB) or amide (8armPEG-a-NB) bonds were used to yield
macromonomers with hydrolytically cleavable or non-cleavable functionalities. PEG
with molecular masses of 10,000 Da, 20,000 Da, and 40,000 Da were used.
the solution was combined with a PEG solution containing pyridine (5-fold excess
of OH-groups) and DMAP (0.5-fold of OH-groups). After overnight stirring in an
ice-bath the solution was washed with a 5% sodium bicarbonate solution two times
and with brine once. The product was then precipitated in cold diethyl ether. The
degree of end-group functionalization was 71 - 85% as determined by 1H-NMR.
For the synthesis of hydrolytically stable macromonomers, PEG hydroxyl groups
were first converted to amino groups (8armPEG-NH2) by means of a Mitsunobu
reaction followed by hydrazinolysis [225] and then reacted with exo-5-norbornenecar-
boxylic acid using DCC chemistry. In brief, exo-5-norbornenecarboxylic acid (4-fold
excess of PEG amino groups) and DCC (2-fold excess of NH2-groups) were dissolved
in anhydrous DCM and stirred for 30 min at 0 ◦C. After filtration, the solution
was combined with a solution of PEG in DCM, neutralized with DIPEA (2-fold
excess of NH2-groups), stirred for at least 1.5 hours at room temperature and was
then precipitated in cold ethyl ether. The degree of end-group functionalization
was 73 - 83% as determined by 1H-NMR.
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5.2.3 Hydrogel preparation, swelling and network mesh size
Precursor solutions for the formation of hydrogel cylinders were prepared by
dissolving appropriate amounts of the respective macromonomer in purified water.
DTT (0.5-fold of NB-groups) and Eosin-Y (0.1 mM) were added. 375 µL of
the precursor solution were cast into cylindrical molds and gels were formed by
irradiation with Luxeon
r©
Rebel LXML PM01 0100 green light emitting diodes
(LEDs, λ = 520 - 550 nm) for at least 15 min. Hydrogel swelling and degradation
was analyzed as previously described [221]. The average network mesh size (ξ) of
8armPEG10k-e-NB, 8armPEG20k-e-NB, and 8armPEG40k-e-NB hydrogels with
concentrations of 5%, 10%, and 15% (w/V) was determined as previously described
[221, 254].
5.2.4 Rheology
Precursor solutions were prepared as described above. 750 µL of the precursor
solution were used for the measurements; the polymer concentrations were 5%,
10% and 15 % (w/V). Oscillatory shear experiments were conducted on a TA
Instruments AR 2000 rheometer (TA Instruments, Eschborn, Germany) at a
temperature of 25 ◦C and a constant frequency of 0.5 Hz. The instrument was
equipped with a 40 mm parallel steel plate and a flat transparent glass plate
underneath (Fig. 5.1). H6-RGB-9 LEDs with a wavelength maximum at 515 -
520 nm (Roithner Lasertechnik GmbH, Vienna, Austria) were installed below
the transparent plate to allow irradiation of the sample during the measurement.
First, LEDs were switched off to analyze the rheological properties of the precursor
solutions and to demonstrate that no gel formation occurred without light. After
one minute, LEDs were switched on to investigate light-induced gel formation. The
absolute value of the complex shear modulus (|G∗|) was recorded over time.
91
Chapter 5 Fabrication of microgels using microfluidics and thiol-ene chemistry
Figure 5.1: A rheometer was modified with a transparent lower plate to allow irradiation
during oscillatory shear measurements. In this way, gel formation in response to green
light could be followed in real-time.
5.2.5 Microgel fabrication
A suitable amount of the respective macromonomer and DTT (0.5-fold of NB-
groups) were dissolved in phosphate buffered saline (PBS); 0.1 mM Eosin-Y was
added. This precursor solution was transferred to a 2.0 mL syringe and another
10.0 mL syringe was filled with silicone oil with a dynamic viscosity (η) of 5 mPa s.
Both syringes were connected to PTFE tubes using a Luer lock system and then
mounted on a KDS 220 infusion pump (Cole Parmer, Vernon Hills, IL, USA). The
pump was adjusted to yield a constant flow of 20 µL/min. Droplets were generated
using a T junction and cross-linking was induced by 5 min of irradiation at a
wavelength of 520 - 550nm. Microgels were collected in a glass vial filled with
1.0 mL of PBS and the silicone oil was removed. In order to study microgel size,
the length and width of 100 microgel particles were determined using a Leica DM
IRB optical microscope (Leica Microsystems GmbH, Wetzlar, Germany) connected
to a DS-5M digital camera (Nikon GmbH, Du¨sseldorf, Germany) in combination
with EclipseNet software (Nikon GmbH, Du¨sseldorf, Germany). In order to study
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the influence of flow ratio on microgel size, a 2 mL syringe was used to yield the
silicone oil flow instead of a 10 mL syringe.
5.2.6 In vitro release
For the release studies, 8armPEG10k-e-NB, 8armPEG20k-e-NB, and 8armPEG40k-
e-NB microgels were loaded with 5 mg/mL bevacizumab. A polymer concentration
of 5% (w/V) was used. Microgels were transferred to glass vials containing 4.0 mL
PBS and incubated in a shaking water bath at 37 ◦C. 300 µL release media were
drawn at defined time-points and replaced with fresh media; samples were stored at
2 - 8 ◦C until further analysis. The amount of released bevacizumab was determined
by fluorescence spectroscopy (λex. = 280 nm and λem. = 335 nm) on a PerkinElmer
LS 55 Fluorescence spectrometer (Perkin Elmer, Wiesbaden, Germany). For the
release curves, the amount of bevacizumab was standardized to the concentration
at the final plateau.
5.2.7 Simulation of stress conditions
Stress conditions that occurred during microgel fabrication were simulated and
their influence on protein stability was investigated. Sample solutions containing
10% mPEG5k-e-NB, DTT (0.5-fold of NB-groups), 0.1 mM Eosin-Y and either
1 mg mL-1 lysozyme, 1 mg mL-1 L-lactate dehydrogenase (LDH), or 5 mg mL-1
bevacizumab were prepared. Linear mPEG5k-e-NB was used to simulate thiol-ene
reactions while avoiding actual hydrogel formation. To study the influence of the
cross-linking reaction on protein stability the sample solutions were irradiated (λ =
520 - 550 nm) for 5 min. In addition, the microgel fabrication process was carried
out as described above without irradiation to study the effect of microfluidics alone.
Moreover, the combined effects of microfluidics and cross-linking on protein stability
were studied. After stress simulation, protein activity was analyzed and compared to
a non-treated sample solution which served as a positive control. Lysozyme activity
was analyzed using a micrococcus lysodeikticus assay as suggested by Shugar [306].
LDH activity was determined by measuring the decrease of pyruvate absorbance
over time as described by Bergmeyer and Bernt [307]. Functional binding of
bevacizumab (Avastin
r©
) was investigated using a Shikari
r©
Q-beva enzyme-linked
immunosorbent assay (ELISA) kit (Matriks Biotek, Ankara, Turkey).
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5.2.8 Cytotoxicity
To study the cytotoxicity of thiol-ene microgels an MTT assay was carried out
according to ISO 10993-5:2009 (Biological evaluation of medical devices, part 5:
Tests for in vitro cytotoxicity). Over the course of the experiment, the toxicity of
the microgels was evaluated both directly, by adding particles to wells containing
cells, and indirectly, by preparing extracts.
Briefly, 8armPEG10k-e-NB, 8armPEG20k-e-NB and 8armPEG40k-e-NB micro-
gels with a polymer concentration of 10% (w/V) were fabricated; a total volume of
600 µL was prepared for each gel type. Extract media were prepared by incubating
one half of the microgels with 1.0 mL of EMEM supplemented with 10% FCS for
24 hours at 37 ◦C. The other half of the microgel samples was stored at 2 - 8 ◦C
overnight to be directly added to cell culture. Mouse fibroblast L-929 cells were
seeded in 96-microtiter plates at a density of 10,000 cells per well and allowed to
adhere overnight. 100 µL of extract was added per well. Alternatively, 100 µL
microgel suspension were added directly to the wells. 0.1% SDS served as a negative
control and pure medium as a positive control (n = 10). Cells were incubated with
the test media for 24 hours. For the extract samples, the medium was removed and
200 µL of serum-containing medium with 1.5 mM MTT was added to each well.
For the microgel samples, media was not removed and 100 µL of serum-containing
medium with 3.0 mM MTT was added. After 4 hours of incubation, the MTT
solution was removed and 200 µL PBS containing 10% SDS was added to each well.
After 16 hours, absorbance at 570 nm and 690 nm was determined for each well
using a FluoStar Omega fluorescence microplate reader (BMG Labtech, Ortenberg,
Germany). The difference in absorbance at 570 nm and 690 nm was used to
calculate the viability of cells. The viability of the treated cells was normalized to
the value for the positive control, i.e., medium alone.
5.2.9 Statistical analysis
All results are presented as mean ± standard deviation based on data obtained
from at least n = 3 samples. Statistical significance was determined by means
of one-way ANOVA, followed by Tukey’s post-hoc test using GraphPad Prism
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Differences were considered
statistically significant at p < 0.05.
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5.3 Results and discussion
5.3.1 Gelation and material properties
The goal of this study was to fabricate protein-loaded microgels with a narrow size
distribution for drug delivery applications. The first prerequisite for this process
was to select a method for droplet generation that leads to uniform droplets and
is compatible with fragile antibodies. To this end, droplets containing antibodies
and reactive macromonomers were generated using microfluidics. Then, chemical
reactions were triggered to cross-link the droplets and incorporate the antibody
inside the generated microgels. For cross-linking, the radical-based reaction between
norbornene and thiol groups was selected. This photoclick reaction is rapid,
highly specific, proceeds at mild conditions, and does not form toxic side-products.
Additionally, in contrast to many other reactions that involve free radicals [308, 309],
polymerizations based on thiol-ene reactions are efficient step-growth processes
that are accompanied by relatively short radical lifetimes [310].
In order to yield suitable macromonomers, eight-armed PEG was end-functional-
ized with norbornene groups; DTT was used as a cross-linker and Eosin-Y as
an initiator (Scheme 5.2A). Norbornene (NB) moieties were selected as they
undergo rapid and nearly ideal thiol-ene reactions with a minimum degree of
homopolymerization and chain-growth [299, 311]. Consequently, hydrogels with
few network defects can be obtained while minimizing stress on the proteins
to be incorporated. Modification with NB groups was carried out employing
either amide (8armPEG-a-NB) or ester (8armPEG-e-NB) bonds. The use of
Scheme 5.2: Light induced cross-linking of PEG-e-NB with dithiothreitol (DTT) via
thiol-ene reaction (A). Ester hydrolysis which is fundamental for hydrogel degradation
(B).
amide bonds should lead to non-degradable hydrogels while ester bonds should
lead to hydrolytically degradable ones (Scheme 5.2B). As a proof of concept,
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degradability of the prepared hydrogels was investigated in a swelling study at
37 ◦C in phosphate buffer pH 7.4 (Fig. 5.2). Gel cylinders were prepared using
a polymer concentration of 10% (w/V) and mass increase due to swelling was
monitored over time. As expected, 8armPEG40k-a-NB did not show considerable
swelling and did not degrade over a period of at least 150 days. In contrast, the
swelling of 8armPEG40k-e-NB hydrogels led to a 5-fold mass increase within 50
days and the hydrogels were fully degraded after about 60 days. The shape of the
swelling curves was comparable to the ones reported in the literature [296].
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Figure 5.2: Swelling and degradation of 10% (w/V) 8armPEG40k-e-NB and
8armPEG40k-a-NB hydrogels in phosphate buffer, pH 7.4 at 37 ◦C.
Prior to application in combination with microfluidics, gel times and mechanical
properties had to be analyzed. In this way, the general suitability of the synthesized
macromonomers and the cross-linking reaction was assessed. For this purpose,
oscillatory shear experiments were performed to determine the gel point and the
absolute value of the complex shear modulus (|G∗|) as a function of irradiation
and time. In order to study light-induced gel formation, an experimental setup
was used to record these parameters in real-time. Precursor solutions containing
macromonomers, DTT and Eosin-Y were prepared and irradiation with green light
was initiated one minute into the measurement (Fig. 5.3).
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Figure 5.3: Gelation of hydrogels with amide or ester bonds, a molecular mass of
10,000 Da, 20,000 Da, or 40,000 Da, and a concentration of 5%, 10% or 15% (w/V)
were studied at 37 ◦C. Without light (0 - 1 min) no gel formation occurred. Irradiation
with green light (1 - 10 min) triggered rapid gelation. After about 5 min, a plateau
in |G∗| was reached and cross-linking was considered completed.
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Macromonomers with different molecular masses (10,000 Da, 20,000 Da, 40,000
Da) and bonds (ester, amide) at various polymer concentrations (5, 10, 15% (w/V))
were used. Overall, all precursor solutions displayed a very similar gelation behavior.
During the first minute without irradiation, no gel formation was observed. At this
point, |G∗| values were < 0.1 Pa and viscous properties were dominant (storage
modulus (G′) < loss modulus (G′′)). This finding was important for a later
application in microfluidics as maintaining fluidity is a prerequisite for droplet
formation. Upon irradiation, |G∗| values increased rapidly and elastic properties
became dominant (G′ > G′′). Rapid gelation (< 20 s) could be observed for all
sample types at all polymer concentrations investigated. It was concluded that
thiol-ene reactions proceed fast enough to cross-link droplets during microfluidics.
Besides rapid gelation, it would be favorable if cross-linking were completed
rapidly in order to avoid unnecessarily long irradiation times and to reduce the
process duration. Indeed, a plateau phase for |G∗| could be observed in all cases
(Fig. 5.3A-F). After 5 min of irradiation, the further increase of |G∗| was only
marginal and the gelation process was considered complete. The |G∗| values
determined after 5 min of irradiation are listed in Table 5.1. As expected, hydrogel
stiffness increased with polymer concentration and decreased with macromonomer
molecular mass. Additionally, it could be verified that the bond type has no
considerable influence on hydrogel stiffness in most cases. |G∗| values were not
significantly different (p < 0.05) except for 8armPEG10k-a-NB and 8armPEG10k-
e-NB hydrogels at a concentration of 15%.
In summary, all synthesized macromonomers were considered suitable for microgel
fabrication. All gel types displayed rapid gel formation with an early plateau and
did not gel without exposure to light. The desired stiffness could be tailored by
varying molecular mass and concentration. However, as degradability is often
considered a prerequisite for biomedical applications, all further experiments were
carried out using hydrolytically degradable hydrogels.
98
5.3 Results and discussion
Table 5.1: Absolute plateau values of the complex shear modulus (|G∗| ) for the different
hydrogel types after 5 min of irradiation as determined using rheology.
Polymer type Concentration (%) |G∗| (kPa)
8armPEG10k-a-NB 5 3.2 ± 0.8
10 27.2 ± 1.0
15 45.1 ± 5.8
8armPEG10k-e-NB 5 3.9 ± 0.4
10 27.2 ± 4.9
15 63.8 ± 9.3
8armPEG20k-a-NB 5 4.4 ± 0.3
10 15.6 ± 0.6
15 27.4 ± 1.6
8armPEG20k-e-NB 5 5.3 ± 0.5
10 17.1 ± 1.9
15 30.6 ± 0.8
8armPEG40k-a-NB 5 4.3 ± 0.6
10 12.6 ± 1.2
15 22.8 ± 2.7
8armPEG40k-e-NB 5 5.2 ± 0.8
10 13.1 ± 2.0
15 26.9 ± 0.7
5.3.2 Microfluidics, stress conditions and toxicity
As a next step, thiol-ene reactions were utilized for droplet cross-linking. To
generate droplets, a microfluidic system which allowed for subsequent irradiation
was used (Fig. 5.4).
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Figure 5.4: Precursor solution droplets were generated using a microfluidic system.
Irradiation with visible light induced thiol-ene reactions which yielded covalently cross-
linked microgels.
A syringe pump provided a continuous flow of silicone oil and aqueous polymer
solution in two 500 µm diameter tubes. The polymer solution contained the
selected macromonomer, DTT, and Eosin-Y. As silicone oil and aqueous solutions
are immiscible, droplets could be formed by connecting the tubes and converging
the fluids. For this purpose, the T-junction, which was first utilized by Thorsen
et al. [312] was selected from the various ways described in literature [313]. After
droplet formation, 5 min of irradiation with green light, i.e., the time required for
complete gelation as determined by rheology, were used to cross-link the droplets
while moving through the tube. Interestingly, the prepared microgels had a rod-like
shape. This is explained by the large droplet volume which was squeezed into the
tube before the droplet breaks off. Besides surface tension, viscosity and capillary
forces [314], the droplet volume in the present system mainly depends on the ratio
between the flow rate of silicone oil and polymer phase [315, 316]. Therefore,
changes in this ratio can be used as a tool to control microgel length. For example,
when two 2 mL syringes were used, the average microgel length was 2150 ± 108 µm
and the average microgel width was 385 ± 13 µm. When the flow ratio was changed
by employing a 10 mL syringe for silicone oil in combination with a 2 mL syringe
for the polymer solution, the microgel length decreased to 1395 ± 48 µm. In both
cases the size distribution was very narrow with relative standard deviations of
3.5 - 5.0% for microgel length and 3.5 - 4.9% for microgel width. As microgel
width mainly depends on the tube diameter, this parameter was not significantly
influenced by changes in flow ratio (377 ± 18 µm). In conclusion, the developed
process can be used to generate microgels with a narrow size distribution while
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microgel length and width can be adjusted by changing the flow rates and the
tube diameter. Droplet size and shape result from a complex interplay of various
parameters. Therefore, it should be noted that an in-depth investigation of all
influence factors would be beyond the scope of the present study.
Besides narrow size distribution, another important argument for the selection
of microfluidics was protein compatibility. During the microfluidic process a
protein-compatible cross-linking reaction was used in combination with visible light.
Nevertheless, it had to be demonstrated that the herein used process could be
employed for microgel fabrication while preserving protein activity. Therefore, in
the next experiment stress conditions that arise during the process were simulated.
To this end, the process was carried out as described above, however, in this
experiment monofunctional mPEG5k-e-NB was employed to simulate cross-linking
while avoiding actual microgel formation. Moreover, one of the model proteins
lysozyme, L-lactate dehydrogenase (LDH), and bevacizumab was added to the
polymer solution. Furthermore, the influence of cross-linking alone, i.e., irradiation
for 5 minutes, and microfluidics alone, i.e., droplet generation without irradiation,
were evaluated. Protein activity was determined directly after the experiment and
related to a non-treated control solution (Table 5.2).
Table 5.2: Residual activity of lysozyme and LDH, and residual binding ability of beva-
cizumab to VEGF after exposure to stress factors arising during microgel fabrication.
Microfluidics Irradiation Combined Process
Bevacizumab 103.4 ± 1.5% 95.9 ± 1.8% 96.3 ± 1.6%
Lysozyme 91.1 ± 0.3% 95.1 ± 0.5% 93.1 ± 0.4%
L-lactate dehydrogenase 78.8 ± 0.5% 64.0 ± 0.7% 24.7 ± 1.7%
It was found that the amount of binding bevacizumab decreased only marginally
to 95.9 ± 1.8% after irradiation and to 96.3 ± 1.6% after the combined process. For
microfluidics alone, no decrease was observed; the value > 100% was attributed to
measurement variations. Similarly, for lysozyme only a slight decrease of activity to
91.1 ± 0.3% (microfluidics), 95.1 ± 0.5% (irradiation), and 93.1 ± 0.4% (combined
process) was determined. In contrast, for LDH a significant decrease of activity
was detected. The amount of active LDH decreased to 78.8 ± 0.5% after treatment
with microfluidic stress and to 64.0 ± 0.7% after irradiation. After the combined
process, a LDH activity of only 24.7 ± 1.7% remained. In summary, the developed
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microfluidic process can be considered suitable for the incorporation of proteins.
Bevacizumab binding and lysozyme activity were hardly influenced by either of
the stress factors. However, it should be noted that the stability of very sensitive
proteins like LDH can be impaired by both microfluidics and cross-linking. In case
of microfluidics, shear forces and, even more importantly, interfacial phenomena are
reported to exhibit the greatest effect on protein stability [317]. Moreover, although
silicone oil is frequently used as a coating material for the primary packaging of
protein pharmaceutics, it has been reported to induce protein aggregation [318]. In
case of cross-linking, radical formation is still the greatest factor influencing protein
stability despite the short radical lifetimes. In combination, all stress factors may
amplify their effects and lead to significant activity loss. Therefore, protein stability
should always be evaluated carefully when microfluidics and thiol-ene reactions are
combined for protein loading.
In order to utilize the prepared microgels in the pharmaceutical and medical
field, their toxicological safety has to be demonstrated. For example, reactants and
unbound macromonomers which could be leached out of the gels might have toxic
potential. Therefore, in order to assess the cytotoxicity of the microgels, an MTT
assay was performed. In all cases, the average cell viability did not decrease below
70% which is regarded the critical threshold according to ISO (Fig. 5.5).
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Figure 5.5: L-929 cell viability after direct contact with microgels or exposure to ex-
tracts was determined using an MTT assay. A cell viability of < 70% (dotted line)
was considered cytotoxic.
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However, it was observed that viabilities were lower when particles were added
directly to the cells. It is very likely that this was the result of cell abrasion during
handling caused by the direct contact of the particles with the cell layer. In summary,
neither the microgels themselves nor potentially leached out reactants displayed
considerable cellular toxicity. However, with regard to therapeutic applications the
in vivo biocompatibility needs to be assessed.
5.3.3 Network mesh size and release studies
In the previous sections, it was demonstrated that microfluidics in combination
with subsequent thiol-ene reactions can be employed to generate microgels with
a narrow size distribution. Moreover, it was shown that the developed process
is compatible with bevacizumab and that the generated microgels are non-toxic.
In the final part of the study it was investigated whether bevacizumab can be
incorporated and retained inside the microgels. In order to select an appropriate gel
type for the release study, the average meshwork size (ξ) was determined first. ξ is
an important parameter for release studies as it has to be smaller than the average
diameter of the incorporated protein to restrict Fickian diffusion. ξ was determined
as previously described [221, 254]. Briefly, the polymer fraction of the hydrogel
after cross-linking and in the swollen state were determined and the polymer-water
interaction parameters (χ12) were calculated as suggested by Kronberg [242]. χ12
was taken as 0.49 for 8armPEG10k-e-NB, 0.44 for 8armPEG20k-e-NB, and 0.42
for 8armPEG40k-e-NB. These values were then used to calculate the number of
elastically active chains (νe) using a modified version of the Flory-Rehner equation
[239–241]. With νe, it was then possible to determine ξ as suggested by Canal and
Peppas [243]:
ξ = v
− 1
3
2s l
(
2mp
νeMr
) 1
2
C
1
2
n (5.1)
In eqn (5.1), Mr represents the molecular mass of the PEG repeating unit
(44 g mol-1), l is the average bond length along the PEG backbone (0.146 nm),
mp is the total mass of PEG in the hydrogel, and Cn is the Flory characteristic
ratio (4). ξ values were determined for 8armPEG10k-e-NB, 8armPEG20k-e-NB,
and 8armPEG40k-e-NB hydrogels with a polymer concentration of 5%, 10%,
and 15% (w/V). The data listed in Table 5.3 shows that ξ values decrease with
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decreasing molecular mass and increasing polymer concentration. This data is
in good agreement with theoretical considerations which predict a decrease of ξ
with increasing number of functional groups and, consequently, cross-links. As
discussed above, ξ should ideally be smaller than the hydrodynamic diameter of
the antibody (dH) to enable long-term release by restricting diffusion. According
to literature, the hydrodynamic radius of bevacizumab is approximately 6.5 nm
(dH = 13 nm) [319]. As all determined ξ values are below or only slightly higher,
all hydrogel types could theoretically be used to retard the release of bevacizumab.
However, when assessing ξ, it should be kept in mind that the calculated values
only represent the mean and conclusions on the width of the distribution cannot
be drawn.
Table 5.3: Average network mesh size (ξ) of 8armPEG10k-NB, 8armPEG20k-NB and
8armPEG40k-NB at polymer concentrations of 5, 10 and 15% (w/V).
Polymer type Concentration (%) ξ (nm)
8armPEG10k-e-NB 5 10.0 ± 0.7
10 5.1 ± 0.1
15 4.5 ± 0.2
8armPEG20k-e-NB 5 9.5 ± 0.4
10 8.4 ± 0.3
15 6.8 ± 0.3
8armPEG40k-e-NB 5 13.9 ± 0.6
10 12.0 ± 0.2
15 10.5 ± 0.1
In the final experiment, microgels were loaded with bevacizumab and the in
vitro release was studied (Fig. 5.6). To this end, microgels were prepared using
8armPEG10k-e-NB, 8armPEG20k-e-NB, and 8armPEG40k-e-NB using a polymer
concentration of 5% (w/V). In all cases, after the initial burst a sustained and almost
linear release profile was determined. As expected, the most rapid release was
observed for 8armPEG40k-e-NB microgels. Here, bevacizumab was released over a
period of only 28 days. In contrast, both 8armPEG10k-e-NB and 8armPEG20k-e-
NB microgels provided sustained release over about 46 days. Interestingly, despite
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the difference in macromonomer molecular mass, the release behavior of these
microgel types was very similar. This is in line with their ξ values of 10.0 ± 0.7 nm
and 9.5 ± 0.4 nm which are also not significantly different (p < 0.05). In general,
the release behavior from thiol-ene microgels can be explained as follows. First,
bevacizumab loosely bound to the gel surface or located in areas with a less dense
network is released during an inital burst phase. As expected, at 30.5 ± 6.9% the
highest burst release was observed for 8armPEG40k-e-NB microgels as it has the
highest average mesh size. However, the majority of bevacizumab is prevented
from diffusing out of the microgel network as ξ < dH . During the following time,
ester bonds are subjected to hydrolytic degradation following a pH dependent
pseudo-first-order reaction kinetic [296]. As a result of the constant breaking of
cross-links, average network mesh size gradually increases and bevacizumab is
released when ξ > dH .
In summary, bevacizumab could be successfully incorporated into different mi-
crogels and an almost linear release profile was achieved over 28 and 46 days in
vitro. In order to tailor release kinetics, polymer concentration and molecular mass
can be varied to influence microgel mesh sizes and, ultimately, the time-scales for
antibody release.
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Figure 5.6: Release of bevacizumab from 8armPEG10k-e-NB, 8armPEG20k-e-NB and
8armPEG40k-e-NB microgels in PBS at 37 ◦C. A polymer concentration of 5% (w/V)
was used.
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5.4 Conclusion
Microfluidics and thiol-ene photoclick chemistry present a powerful combination for
the fabrication of antibody-loaded microgels. Hydrogel particles could be prepared
with a narrow size distribution and microgel length could be adjusted by employing
different flow ratios between silicone oil and polymer solution. Microgel stabil-
ity, stiffness, and network mesh size could be tailored by varying macromonomer
concentration and molecular mass. Microgels were non-cytotoxic in vitro and the
microgel fabrication process was demonstrated to generally be protein compatible.
Finally, microgels were successfully employed to sustain the release of bevacizumab
over a period of 28 and 46 days in vitro. The herein presented microgels could be
used to provide sustained intravitreal release of bevacizumab during the treatment
of neovascular age-related macular degeneration. Moreover, incorporation of anti-
bodies into microgels could be used as a tool to protect proteins against detrimental
cross-linking reactions. However, to prove that the technology is suitable for these
applications further studies are necessary.
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Abstract
In situ encapsulation is a frequently used method to prepare hydrogels loaded with
high quantities of therapeutic proteins. However, many cross-linking reactions,
such as Michael-type addition or Diels–Alder (DA) reaction are not tolerant toward
nucleophiles; therefore, side-reactions with proteins can occur during cross-linking.
This may lead to undesired protein conjugation, activity loss and incomplete protein
release. In this study, a number of polyanions, namely alginate, dextran sulfate,
hyaluronic acid, heparin, and poly(acrylic acid), were screened for their capability to
protect proteins during covalent cross-linking. To this end, lysozyme was incubated
with furyl- and maleimide-substituted methoxy poly(ethylene glycol); different pH
values were tested. The degree of PEGylation and the residual activity of lysozyme
were investigated. Without polyanions, 61.1% of the total lysozyme amount was
PEGylated at pH 7.4; the residual activity was 20.3% of the initial activity. With
the most effective polyanion (dextran sulfate), PEGylation could be completely
suppressed; the residual activity was 98.4%. The protective effect of polyanions
was attributed to electrostatic interactions with proteins; the“shielding” could be
reversed by adding high salt concentrations. Furthermore, the protective effect
was dependent on the concentration and molecular mass of the polyanion, but
almost independent of the protein concentration. As a proof of concept, hydrogels
were loaded with lysozyme and bevacizumab during cross-linking via DA reaction.
Without polyanions, a large fraction of the protein was covalently bound to the
polymer network resulting in degradation-controlled release; the residual activity of
lysozyme was 50.0%. With polyanions, the protein molecules were mobile and their
release was diffusion-controlled. The residual activity of lysozyme was 88.9%; the
released bevacizumab was structurally intact. Polyanions can, therefore, be used
as protective additive to prevent chemical protein modification during hydrogel
cross-linking.
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6.1 Introduction
Hydrogels are frequently used as carrier systems for the delivery of therapeutic
proteins [146, 183]. In general, protein loading can be achieved by incubating pre-
formed hydrogels in concentrated protein solutions (post-fabrication partitioning),
or by cross-linking the hydrogel-forming polymers together with the protein (in situ
encapsulation) [184]. While post-fabrication partitioning is beneficial for protein
stability, the method provides less control over the amount of protein loading.
Therefore, in situ encapsulation is often considered the method of choice for loading
large protein quantities into hydrogels. However, only few cross-linking reactions
proceed under sufficiently mild conditions to allow in situ encapsulation of proteins.
Among these reactions, Michael-type additions and radical polymerizations have
been frequently used to prepare in situ forming hydrogels [215, 217, 241, 320]. And
recently, the Diels–Alder (DA) reaction has been employed to develop poly(ethylene
glycol) (PEG)-based hydrogels for controlled antibody release [221, 254]. However,
these cross-linking reactions are not tolerant toward nucleophiles, i.e., side reactions
with proteins can occur [182]. For example, maleimide is a strong electrophile; it
can react with nucleophilic amino acid residues such as cysteine, lysine, histidine,
tryptophan or arginine [321]. This side reaction inhibits cross-linking; furthermore,
protein molecules are covalently bound to the polymer network. This may result in
incomplete protein release, loss of activity, and increased immunogenicity [184, 322].
For these reasons, it would be desirable to suppress side reactions between
polymers and proteins during cross-linking. This would make the DA reaction, and
other cross-linking reactions, more suitable for in situ encapsulation of proteins.
For example, it has been reported that precipitation by zinc chloride or PEG can
protect proteins from Michael-type additions during cross-linking [323]. However,
both methods might cause protein degradation or aggregation. As a potential
alternative, we investigated the use of polyanions to prevent protein conjugation and
activity loss during cross-linking. Polyanions have been frequently used to formulate
and stabilize therapeutic proteins [324–326]. For example, it has been shown that
ionic interactions between alginate and monoclonal antibodies are present; these
interactions could be exploited for sustained protein release [327]. Furthermore,
sulfated β-cyclodextrin and heparan sulfate could protect acidic fibroblast growth
factor (FGF) from urea-induced unfolding [328]. Martin et al. [329] have shown that
non-covalent association with hydrophobically modified poly(acrylate) copolymers
could prevent the thermal aggregation of immunoglobulin G. Positive effects of
109
Chapter 6 Polyanions effectively prevent protein conjugation and activity loss
polyanions on the stability have also been described for FGF-20 [330], keratinocyte
growth factor-2 [331], human growth hormone [332], and parathyroid hormone
[333].
In this study, a number of pharmaceutically relevant polyanions, namely algi-
nate (ALG), dextran sulfate (DXS), heparin (HEP), hyaluronic acid (HA) and
poly(acrylic acid) (PAA) (Scheme 6.1), were screened for their capability to pro-
tect proteins during hydrogel cross-linking. The DA reaction between furan and
maleimide was chosen as cross-linking reaction; lysozyme was used as a model pro-
tein. To estimate the occurring protein modification, lysozyme was incubated with
Scheme 6.1: Chemical structures of alginate (ALG), dextran sulfate (DXS), heparin
(HEP), hyaluronic acid (HA), and poly(acrylic acid) (PAA).
monofunctional, furyl- and maleimide-substituted methoxy poly(ethylene glycol);
different pH-values and polyanion concentrations were tested. After incubation,
the degree of PEGylation and the residual activity of lysozyme were analyzed.
Furthermore, possible factors influencing the “shielding” effect of polyanions, such
as ionic strength and molecular mass of the polyanion, were investigated. Finally,
lysozyme and bevacizumab were encapsulated into hydrogels with and without
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polyanions added. The in vitro release of the incorporated proteins was measured;
furthermore, the activity and integrity of the released proteins were analyzed.
6.2 Materials and methods
6.2.1 Materials
Eight-armed poly(ethylene glycol) with molecular masses of 10,000 g mol-1 (8arm-
PEG10k) and 40,000 g mol-1 (8armPEG40k), and methoxy poly(ethylene glycol)
vinyl sulfone with a molecular mass of 5000 g mol-1 (mPEG5k-vinyl sulfone) were
purchased from JenKem Technology (Allen, TX, USA). Coomassie brilliant blue
G-250, deuterated chloroform (CDCl3), dextran sulfate, heparin, lysozyme (from
chicken egg white), methoxy poly(ethylene glycol) with a molecular weight of
5000 g mol-1 (mPEG5k), methoxy poly(ethylene glycol) thiol with a molecular
mass of 6000 g mol-1 (mPEG6k-thiol), micrococcus lysodeikticus, poly(acrylic
acid) (100,000 g mol-1 molecular mass, 35% solution), poly(acrylic acid) sodium
salt (2100 g mol-1 molecular mass), sodium phosphate monobasic monohydrate
and D-(+)-trehalose dihydrate were received from Sigma-Aldrich (Taufkirchen,
Germany). Tris(hydroxymethyl)aminomethane was purchased from GE Healthcare
Europe GmbH (Freiburg, Germany). Acrylamide/bis-acrylamide (37.5:1) solu-
tion, bromphenol blue sodium salt and sodium dodecylsulfate (SDS) were received
from Serva Electrophoresis GmbH (Heidelberg, Germany). Hyaluronic acid (7500
and 289,000 g mol-1 molecular mass) was obtained from Lifecore Biomedical LLC
(Chaska, MN, USA). Dulbecco’s phosphate buffered saline (PBS) was purchased
from Invitrogen GmbH (Karlsruhe, Germany). Alginate (Protanal
r©
LF10/ 60FT)
was purchased from FMC BioPolymer (Ratingen, Germany). Tetramethylethylen-
diamin (TEMED) was obtained from Carl Roth GmbH & Co KG (Karlsruhe,
Germany). Boc-6-aminohexanoic acid was purchased from Bachem (Weil am Rhein,
Germany). Bevacizumab (Avastin
r©
, 25 mg/mL, Roche Ltd, Basel, Switzerland)
was kindly provided by the hospital pharmacy of the University of Regensburg
(Germany). 96-Well flourescence plates were purchased from Greiner Bio-One
(Frickenhausen, Germany). All other materials were obtained from Merck KGaA
(Darmstadt, Germany). Purified water was freshly prepared using a Milli-Q system
(Millipore, Schwalbach, Germany).
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6.2.2 Functionalization of polymers
The functionalization of 8armPEG10k with furyl (8armPEG10k-furan) and maleimide
(8armPEG10k-maleimide) end-groups has been described by Kirchhof et al. [155].
The functionalization of mPEG5k with furyl (mPEG5k-furan) and maleimide
(mPEG5k-maleimide) end-groups was achieved as described for 8armPEG10k-furan
and 8armPEG10k-maleimide, respectively [155]. The hydrophobic modification of
8armPEG40k with 6-aminohexanoic acid, and the subsequent functionalization with
furyl (8armPEG40k-C6-furan) and maleimide (8armPEG40k-C6-maleimide) end-
groups has been described in chapter 3 [254]. The synthesis of mPEG5k-acrylamide
was carried out as described by Browning et al. [334].
6.2.3 Incubation of lysozyme
The conditions during hydrogel cross-linking were mimicked by incubating lysozyme
with monofunctional PEG derivatives at 37 ◦C in a shaking water bath for 24 h. The
incubation was done in 25 mM acetic acid buffer pH 5.0, 50 mM phosphate buffer
pH 7.4, and 50 mM borate buffer pH 9.0. In order to simulate cross-linking via DA
reaction, 9.15 mg (1.83 µmol) of mPEG5k-maleimide and 9.15 mg (1.83 µmol) of
mPEG5k-furan were dissolved in 400 µL of buffer, and incubated with 0.40-0.52
mg of lysozyme. Similarly, cross-linking via Michael-type addition was simulated
using 9.15 mg (1.83 µmol) of mPEG5k-vinyl sulfone and 10.98 mg (1.83 µmol) of
mPEG6k-thiol. A radical polymerization was simulated using 9.15 mg (1.83 µmol)
of mPEG5k-acrylamide combined with a radical initiator composed of 1.83 µL of
TEMED (10% dilution) and 3.66 µL of a 10% (m/V) ammonium persulfate solution.
The incubation was performed without additives, or in the presence of different
polyanions, i.e., ALG, DXS, HEP, HA, and PAA. In all cases it was checked that
the pH did not change during incubation. The concentrations of ALG, DXS, HEP,
and HA were 2 mg/mL; the concentration of PAA was reduced to 1 mg/mL to
maintain the pH of the reaction medium.
6.2.4 Degree of lysozyme PEGylation
After incubation, samples were taken and the degree of lysozyme PEGylation was
determined by SDS PAGE as previously described [182].
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6.2.5 Lysozyme activity assay
To determine the activity of lysozyme, the incubation protocol was slightly modified.
A lower lysozyme concentration of 0.25 mg/mL was used; moreover, lysozyme was
incubated with 20 mg (4 µmol) of mPEG5k-maleimide. In this way, the influence
of polyanions on lysozyme activity could be studied more accurately. The activity
of lysozyme was determined as described by Shugar [306]. In brief, lysozyme was
diluted with 70 mM phosphate buffer pH 6.2 to a final concentration of 0.01 mg/mL.
A 0.015% micrococcus lysodeikticus suspension was prepared using the same buffer.
In a cuvette, 100 µL of the lysozyme dilution was added to 2.5 mL of the micrococcus
suspension, and the decrease of the absorbance at 450 nm was recorded for 6 min
at 25 ◦C using a Kontron UVIKON
r©
941 spectrophotometer (Kotron Instruments
S.p.A., Milan, Italy). The activity of lysozyme was calculated from the slope of
the linear part of the curve.
6.2.6 Turbidity measurement
Lysozyme was diluted to a final concentration of 1.3 mg/mL; for this purpose, a
50 mM phosphate buffer pH 7.4 containing 0 mM, 37.5 mM, 75 mM, 100 mM,
150 mM or 300 mM of NaCl was used. Different amounts of PAA were added;
the final concentrations were 0 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.5 mg/mL and
1.0 mg/mL. The samples were vortexed; 200 µL were transferred into a microtiter
plate. The turbidity was measured at a wavelength of 450 nm using a FLUOstar
Omega mircoplate reader (BMG Labtech, Durham, NC, USA).
6.2.7 Release experiments
The influence of polyanions on the in vitro release of lysozyme from 10% 8arm-
PEG10k hydrogels was studied. For hydrogel preparation, 36.9 mg of 8armPEG10k-
maleimide and 38.1 mg of 8armPEG10k-furan were separately dissolved in 300 µL
of 50 mM phosphate buffer pH 7.4. Both solutions were gently mixed; 150 µL of
a solution containing lysozyme and the polyanion, i.e., PAA, HEP or DXS, were
added. Then, 250 µL of the mixture were transferred into cylindrical glass molds
with a diameter of 7 mm. The samples were allowed to cross-link overnight at
37 ◦C. The amount of protein loading was 2 mg per gel cylinder; the final polyanion
concentrations were 0 and 0.5 mg/mL. The gel cylinders were incubated in 5.0 mL
of PBS at 37 ◦C in a shaking water bath. At predetermined time points, samples of
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300 µL were taken and replaced with fresh PBS. The amount of released lysozyme
was quantified (λex = 280 nm, λem = 335 nm) using a LS 55 Fluorescence spec-
trophotometer (Perkin Elmer, Wiesbaden, Germany). The influence of polyanions
on the in vitro release of bevacizumab from 10% 8armPEG40k-C6 hydrogels was
carried out as described in chapter 3 [254]. The control sample (hydrogel without
PAA) was cross-linked in 50 mM phosphate buffer pH 7.4; the sample containing
1 mg/mL PAA was cross-linked in 25 mM acetic acid buffer pH 5.0.
6.2.8 Size-exclusion chromatography
SEC analysis of bevacizumab was performed on a Shimadzu HPLC system (Shi-
madzu Corporation, Kyoto, Japan) consisting of a SIL-10AD auto injector, LC-10AT
liquid chromatograph, DGU-14A degasser, CTO-10AS column oven, and SPD-10A
fixed wavelength programmable UV-Vis detector. A Tosoh G3000SWXL column
(Tosoh Bioscience, Griesheim, Germany) was used. Sterile filtered 50 mM phosphate
buffer pH 7.4 was used as mobile phase; the flow rate was adjusted to 0.5 mL/min.
Samples of 20 µL were injected and eluted for 40 min; the chromatograms were
recorded at a wavelength of 280 nm.
6.2.9 Circular dichroism spectrometry
CD spectra of lysozyme were recorded on a Jasco J-815 spectropolarimeter (Jasco
International, Tokyo, Japan) using a 0.2 mm quartz cuvette (Starna GmbH,
Pfungstadt, Germany). For samples without polyanions, a lysozyme concentration
of 1 mg/mL was used; samples containing polyanions were diluted to a lysozyme
concentration of 0.2 mg/mL due to opalescence. Spectra smoothing was performed
using a Savitzky-Golay polynomial.
6.2.10 Statistical analysis
All results are presented as mean ± standard deviation, based on the data obtained
from n = 3 samples. Statistical significance was determined by means of one-way
ANOVA, followed by Tukey’s post-hoc test using GraphPad Prism 6.0 (Graph-
Pad Software Inc., La Jolla, CA, USA). Differences were considered statistically
significant at p < 0.05.
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6.3 Results and discussion
The hypothesis for this study was that polyanions could prevent chemical protein
modification during hydrogel cross-linking. A schematic representation of this
hypothesis is given in Fig. 6.1. Without the addition of polyanions, macromonomers
can react with amino acids on the protein surface during hydrogel cross-linking.
Consequently, protein molecules may be covalently bound to the polymer network.
In contrast, in the presence of polyanions, the protein surface is thought to be
covered with a “shell” that prevents reactions between macromonomers and proteins.
Consequently, the amount of covalently bound protein is reduced. To verify this
hypothesis, the influence of polyanions on the availability and activity of proteins
after cross-linking via DA reaction was investigated. Lysozyme was used as a
model protein; five different polyanions, namely alginate (ALG), dextran sulfate
(DXS), heparin (HEP), hyaluronic acid (HA), and poly(acrylic acid) (PAA) were
investigated. All of these polyanions are considered appropriate for pharmaceutical
or biomedical applications.
6.3.1 Influence of polyanions on lysozyme PEGylation and
activity
In the first experiment, the degree of protein modification during cross-linking was
estimated. For this purpose, monofunctional mPEG5k-maleimide and mPEG5k-
furan were used instead of branched derivatives; in this way, the conditions during
cross-linking can be simulated while avoiding gel formation. Lysozyme was in-
cubated with mPEG5k-maleimide and mPEG5k-furan either without additives
(CTRL) or in the presence of polyanions. The degree of PEGylation was subse-
quently quantified using SDS PAGE. Lysozyme has one N-terminus and six lysine
residues (Lys1, Lys13, Lys33, Lys96, Lys97, and Lys116) which are susceptible
to Michael-type additions to mPEG5k-maleimide [180, 335, 336]. However, due
to the better accessibility, PEGylation will mainly occur at Lys33 and Lys97.
Consequently, SDS PAGE showed three major bands of unmodified lysozyme, and
lysozyme modified with one or two PEG chains. PEGylation at Lys1, Lys13, Lys96
or Lys116 resulted in further bands of lysozyme modified with three or more PEG
chains.
The degree of PEGylation was generally much lower at pH 5.0 than at pH 7.4
or pH 9.0 (Fig. 6.2). This effect was observed in all groups. For example, in the
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Figure 6.1: Schematic representation of the“shielding” effect of polyanions. During hy-
drogel cross-linking, maleimide groups can react with furyl groups (Diels–Alder reac-
tion) or amino groups on the protein surface (Michael–type addition) (A). Polyanions
interact with proteins and protect them during cross-linking (B). Without polyan-
ions, amino acids on the protein surface can react with polymers resulting in covalent
immobilization.
control group, the amounts of free lysozyme were 77.9 ± 1.4% (pH 5.0), 38.9 ± 2.0%
(pH 7.4), and 38.9 ± 0.5% (pH 9.0). At acidic pH, basic amino acids are present in
the ionized form. Since ammonium groups exhibit significantly lower nucleophilicity
than amino groups [337], the degree of PEGylation resulting from Michael–type
additions of basic amino acids to mPEG5k-maleimide is pH-dependent. Therefore,
as it has already been suggested, the use of acidic reaction conditions represents
an option to reduce nucleophilic side reactions during cross-linking [182]. However,
as acidic pH is unphysiological and may influence protein stability, this approach
might not be feasible for all proteins [338, 339].
Interestingly, as shown in Fig. 6.2, polyanions were capable of significantly
reducing lysozyme PEGylation at acidic, neutral and basic pH. At pH 5.0, the
degree of PEGylation was lowest, most likely due to synergistic effects of pH and
polyanions. The amounts of free lysozyme were 100.0% (DXS), 99.1 ± 0.2% (PAA),
97.3 ± 2.1% (HEP), and 96.8 ± 3.8% (ALG). Lysozyme has an isoelectric point
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Figure 6.2: The influence of DXS, PAA, HEP, ALG and HA on the degree of PEGy-
lation was studied and compared to a control group without polyanions (CTRL). At
acidic pH, the degree of PEGylation was considerably lower than at neutral or basic
pH. The addition of polyanions protected lysozyme from PEGylation with DXS, PAA
and HEP being most effective.
(IEP) at about pH 11 [340]; the protein, therefore, carries a net positive charge
below pH 11. As discussed above, the nucleophilicity of basic amino acids is lowest
at acidic pH; furthermore, an acidic pH facilitates interactions with polyanions as
protein molecules carry more positive charges. However, it should be noted that
interactions with polyanions do not necessarily require a net positive charge on the
protein surface. Polyanions may also bind to proteins with a net negative charge,
given that there are positively charged patches present on the protein surface [341].
For example, lysozyme has eight positive charges at neutral pH [342]. At pH 7.4,
the amounts of free lysozyme were 100.0% (DXS), 91.0 ± 7.5% (PAA), 92.8 ± 0.7%
(HEP), and 77.7 ± 2.5% (ALG); at pH 9.0, 100.0% (DXS), 86.9 ± 9.8% (PAA),
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88.4 ± 1.8% (HEP), and 77.1 ± 4.3% (ALG) of the protein remained unmodified.
In contrast to DXS, PAA, HEP and ALG, “shielding” with HA resulted in 89.8
± 6.7% (pH 5.0), 36.8 ± 4.2% (pH 7.4), and 39.7 ± 4.4% (pH 9.0) unmodified
lysozyme. The weaker effect of HA can be explained by the lower number of acid
functionalities.
Figure 6.3: Activity of lysozyme after incubation with mPEG5k-maleimide and
mPEG5k-furan at pH 7.4. The activity was determined prior to incubation (LYS),
after incubation without polyanions (CTRL), and after incubation with DXS, PAA,
HEP, ALG and HA. Without polyanions, the activity of lysozyme considerably de-
creased. Polyanions could prevent activity loss with DXS, PAA and HEP being most
effective.
Since uncontrolled PEGylation can impair the biological activity of proteins, the
activity of lysozyme was studied after incubation with mPEG5k-maleimide and
mPEG5k-furan (Fig. 6.3). Native lysozyme (LYS) had an activity of 28,580 ±
22 U mg-1. After incubation with mPEG5k-maleimide and mPEG5k-furan (CTRL),
the activity had decreased to 5807 ± 56 U mg-1. The activity loss is explained
by Michael–type additions of nucleophilic amino acids to mPEG5k-maleimide. As
the most reactive lysine residue of lysozyme (i.e., Lys97) is located in a region
responsible for substrate specificity [343], it is likely that PEGylation at this position
causes activity loss. Changes in the secondary structure, which would also result
in activity loss, were excluded by circular dichroism (CD) spectroscopy (Fig. 6.4).
Since the addition of polyanions could reduce the degree of PEGylation, it can be
expected that polyanions preserve the activity of lysozyme. Indeed, the addition
of polyanions could reduce activity loss due to PEGylation; the residual activities
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Figure 6.4: CD spectra of lysozyme after incubation with mPEG5k-maleimide and
mPEG5k-furan at pH 7.4 without polyanions (CTRL), and in the presence of PAA or
DXS. Lysozyme incubated in pure buffer served as a control (LYS). Neither incubation
with mPEG5k-maleimide and mPEG5k-furan, nor interactions with polyanions caused
changes in the secondary structure of lysozyme.
were 28,120 ± 103 U mg-1 (DXS), 25,850 ± 56 U mg-1 (PAA), 21,600 ± 54 U mg-1
(HEP), 14,460 ± 113 U mg-1 (ALG), and 8652 ± 107 U mg-1 (HA). Again, DXS,
PAA and HEP were the most effective additives to preserve the enzymatic activity
of lysozyme; HA was found to be the least effective polyanion. This is consistent
with the data on PEGylation presented above. In summary, it can be stated that
the addition of polyanions represents an effective way to reduce PEGylation and
activity loss during hydrogel cross-linking.
6.3.2 Factors influencing the “shielding” effect of polyanions
The ability of polyanions to protect proteins from PEGylation is a remarkable
finding. According to the hypothesis introduced above, this “shielding” effect is
based on electrostatic interactions between proteins and polyanions. To verify this
assumption, the influence of ionic strength on protein-polyanion interactions was
investigated. The association of proteins and polyanions leads to the formation of
colloidal particles and, thus, to an increase of turbidity. On the other hand, high
ionic strength is known to reduce the attractive forces between oppositely charged
molecules in solution. Therefore, the turbidity of lysozyme-PAA mixtures was
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Figure 6.5: Influence of different salt concentrations on the turbidity of solutions con-
taining lysozyme and PAA. High ionic strength decreased the extent of electrostatic
interactions resulting in clear solutions above 100 mM NaCl.
measured at different salt concentrations (Fig. 6.5). At a low NaCl concentration
of 37.5 mM, the analyzed samples were opalescent. This was due to interactions be-
tween lysozyme and PAA, which led to the formation of colloidal protein-polyanion
complexes. However, at a NaCl concentration of 100 mM, the samples started to
become clear. Finally, above a NaCl concentration of 150 mM, the samples were
totally clear. These results indicate that the interactions between lysozyme and
polyanions are electrostatic interactions.
If the “shielding” effect was also based on electrostatic interactions, it should
be possible to reverse the protecting effect of polyanions by increasing the ionic
strength. In the next experiment, lysozyme was, therefore, incubated with mPEG5k-
maleimide and mPEG5k-furan at a NaCl concentration of 300 mM. As expected,
none of the polyanions were able to “shield” lysozyme from PEGylation (Fig. 6.6A).
For all tested polyanions, the degree of PEGylation was comparable to the control
group. Similarly, at a NaCl concentration of 300 mM, the addition of polyanions
could not prevent activity loss due to PEGylation (Fig. 6.6B). Therefore, it can be
concluded that the “shielding” effect of polyanions is due to electrostatic interactions
with proteins. At high salt concentrations, polyanions cannot bind to the protein
surface; consequently, proteins are affected by PEGylation and activity loss. This
should be kept in mind when concentrated buffer solutions are used. For example,
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high concentrations of sodium acetate or sodium citrate reduced the “shielding”
effect of polyanions (Fig. 6.7A). In contrast to that, typical cryoprotectants for
freeze-drying, such as sucrose or trehalose [344, 345], did not negatively affect
the protective effect of polyanions (Fig. 6.7B). To get a better understanding
of the “shielding” mechanism, additional influencing factors were investigated.
At first, the influence of the polyanion concentration was investigated. For this
purpose, lysozyme was incubated with mPEG5k-maleimide and mPEG5k-furan
at different PAA concentrations. It could be observed that the “shielding” effect
was dependent on the polyanion concentration (Fig. 6.8A). When a low PAA
concentration of 0.025 mg/mL was used, the residual lysozyme activity was 37.3
± 2.1% of the initial activity. However, in comparison to the activity of the
control group (20.3 ± 1.0% of the initial activity), PAA still has a protective
effect at this low concentration. With increasing PAA concentrations, the residual
activity of lysozyme constantly increased until a plateau was reached at about
1.00 mg/mL. Furthermore, increasing amounts of lysozyme were incubated with
mPEG5k-maleimide and mPEG5k-furan at a PAA concentration of 1.00 mg/mL.
The results shown in Fig. 6.8B indicate that the “shielding” effect is almost
independent from the protein concentration. Upon addition of PAA, the residual
activity of lysozyme increased by 205.6% (0.05 mg/mL lysozyme) and 207.8%
(0.5 mg/mL lysozyme), respectively. In addition to the polyanion concentration,
the influence of the molecular mass of the polyanion was studied. For this purpose,
the shielding effects of low- and high-molecular-mass polyanions were compared
(Fig. 6.8C and D); two different polyanions (PAA and HA) were studied. In both
cases, high-molecular-mass polyanions had a better “shielding” capacity than their
low-molecular-mass counterparts; the effect was more pronounced with PAA than
with HA. According to the literature, high molecular mass is one of the factors
that facilitates the formation of protein-polyanion complexes [341]. However, the
interactions between proteins and polyanions, and thus the “shielding” effect, may
also be influenced by other factors such as charge density [346], rigidity of the
polyanion backbone [347], and the existence of hydrophobic interactions [348, 349].
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Figure 6.6: Influence of high salt concentrations (300 mM NaCl) on the “shield-
ing” effect of polyanions at pH 7.4. The degree of PEGylation (A) and the activ-
ity of lysozyme (B) were determined after incubation with mPEG5k-maleimide and
mPEG5k-furan. Fresh lysozyme (LYS), and lysozyme without polyanions (CTRL)
served as controls. High salt concentrations reduced the binding of polyanions to
lysozyme. Consequently, the degree of PEGylation and the enzymatic activity were
similar to the control without polyanions.
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Figure 6.7: SDS PAGE of lysozyme-PEG conjugates resulting from side reactions dur-
ing incubation with mPEG5k-maleimide and mPEG5k-furan at pH 7.4. The influence
of sodium acetate and sodium citrate (300 mM) on the protective effect of PAA and
DXS was studied (A). As already shown for NaCl, increasing the ionic strength re-
duced the protective effect of polyanions; the reduction was more pronounced with
sodium citrate than with sodium acetate. Additionally, the influence of the cryopro-
tectants sucrose and trehalose (50 mg/mL) on the protective effect of PAA and DXS
was studied (B). The “shielding” efficiency was not impaired by the addition of sucrose
or trehalose.
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Figure 6.8: Factors influencing the “shielding” effect of polyanions. The residual
lysozyme activity is dependent on the polyanion concentration (A), but almost in-
dependent from the protein concentration (B). The degree of PEGylation depends on
the molecular mass of PAA (C) and HA (D). As can be seen from the lower degree of
PEGylation, high molecular mass polyanions were more effective than low molecular
mass polyanions.
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Furthermore, it should be noted that the charge density of polyanions is related
to the pKa of the acid functionalities. Therefore, the pKa of the polyanion is an
important parameter controlling the strength of the “shielding” effect, in particular
when proteins are formulated at acidic pH. For example, at low pH, the sulfate
groups of DXS (pKa < 2) [350] are ionized to a higher degree than the carboxylate
groups of HA (pKa ≈ 3-4) [351]. Therefore, in order to achieve a protective effect
at low pH, the use of polyanions with low pKa might be preferred. Moreover, it
should be considered that interactions with polyanions might impair the structural
integrity of some proteins. This should be carefully evaluated from case to case
to prevent loss of bioactivity. In summary, in order to utilize protein-polyanion
complexation to reduce chemical protein modification during cross-linking, multiple
variables must be taken into account and the conditions must be optimized for
each specific protein-polyanion pair.
6.3.3 Investigation of alternative cross-linking mechanisms
Thus far, the ability of different polyanions to protect lysozyme during cross-
linking via DA reaction was investigated. However, the “shielding” effect of
polyanions might also be applicable to other cross-linking reactions. In the following
experiments, the Michael–type addition of mPEG5k-vinyl sulfone and mPEG6k-
thiol, and the radical polymerization of mPEG5k-acrylamide were investigated.
The degree of PEGylation resulting from incubation with mPEG5k-vinyl sulfone
and mPEG6k-thiol is presented in Fig. 6.9A. Lysozyme incubated at pH 7.4 (LYS)
was compared to samples with (+) PAA and without (-) PAA. Without PAA,
29.3 ± 2.0% of the introduced lysozyme remained unmodified. PEGylation results
from Michael-type additions of nucleophilic amino acids to mPEG5k-vinyl sulfone.
This type of reaction has already been used for the PEGylation of therapeutic
proteins [352, 353]. In addition, disulfide exchange reactions between cysteine
residues and mPEG6k-thiol may occur. Nevertheless, the addition of PAA could
significantly reduce the degree of PEGylation; with PAA, 71.1 ± 5.4% of the protein
was not affected by PEGylation. In contrast to that, the radical polymerization
of mPEG5k-acrylamide led to a lower degree of PEGylation, which could not be
reduced by adding PAA (Fig. 6.9A). The amounts of free lysozyme were 70.2 ±
1.7% (- PAA) and 75.7 ± 2.1% (+ PAA).
As observed for PEGylation, the addition of PAA could reduce the activity loss
caused by incubation with mPEG5k-vinyl sulfone and mPEG6k-thiol (Fig. 6.9B).
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Figure 6.9: “Shielding” of lysozyme against Michael–type addition and radical poly-
merization at pH 7.4. The degree of PEGylation (A) and the activity of lysozyme
(B) were determined without (-) PAA and with (+) PAA. PAA reduced the degree
of PEGylation and loss of activity during cross-linking via Michael–type addition.
During radically mediated cross-linking, the effect of PAA was considerably weaker.
* indicates statistically significant differences between the specified groups.
The residual activities of lysozyme were 44.9 ± 0.8% (- PAA) and 90.5 ± 0.6%
(+ PAA), respectively. In contrast to that, the activity loss caused by radical
polymerization of mPEG5k-acrylamide was higher than expected from the PE-
Gylation data (Fig. 6.9B). While only 25-30% of the protein was PEGylated, the
loss of activity was 38-45%. The addition of PAA could not reduce the activity
loss; the residual activities of lysozyme were 55.0 ± 0.4% (- PAA) and 61.5 ± 0.2%
(+ PAA), respectively. Apparently, the activity is not only affected by PEGylation,
but also by radical-mediated inactivation [354], oxidative effects [355, 356], and
peroxide formation [357]. These additional effects cannot be suppressed by the
addition of polyanions. It can be concluded that polyanions may also be effective
in preventing chemical protein modification caused by other cross-linking methods
than the DA reaction. In particular, “shielding” with polyanions proved to be
effective in preventing Michael–type additions to vinyl sulfone. In contrast to that,
polyanions are less effective in preventing radical-induced damage.
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6.3.4 Impact of polyanions on protein release from hydrogels
In the previous experiments, lysozyme was incubated with monofunctional mPEG5k-
furan and mPEG5k-maleimide to avoid gel formation. For the following experiment,
eight-armed PEG (10 kDa molecular mass, 8armPEG10k) was functionalized with
furyl and maleimide end-groups. The two complementary macromonomers were
dissolved in buffer (10% polymer concentration), mixed with lysozyme, and cross-
linked via DA reaction to yield elastic hydrogels. The average mesh size of this type
of hydrogel is 5.5 nm [155]. Lysozyme, which has a hydrodynamic radius of about
1.9 nm [358, 359], should be able to freely diffuse through the gel network. Fig. 6.10A
shows the cumulative release of lysozyme from 8armPEG10k hydrogels. Without
Figure 6.10: (A) Release of lysozyme from 8armPEG10k hydrogels. Cross-linking via
DA reaction was performed without polyanions (CTRL), or in the presence of DXS,
PAA and HEP. Without polyanions, lysozyme was immobilized within the hydrogel
until the onset of degradation at day 20. In contrast to that, lysozyme was rapidly
released by diffusion in the presence of polyanions. (B) Residual activity of lysozyme
after release from 8armPEG10k hydrogels. The measured values were compared to
the activity of fresh lysozyme (LYS). Lysozyme that was protected by PAA during
cross-linking showed a considerably higher activity. * indicates statistically significant
differences between the specified groups.
the addition of polyanions (CTRL), the initial release rate was unexpectedly low.
Only 40% of the incorporated protein was released after 20 days. The major part
of the protein was released between day 20 and 25 when the hydrogel started to
degrade. This is in contrast to theoretical considerations (see above), which predict
rapid protein release from 8armPEG10k hydrogels through Fickian diffusion [360].
Presumably, the majority of the protein was covalently bound to the polymer
127
Chapter 6 Polyanions effectively prevent protein conjugation and activity loss
network during cross-linking. Consequently, the release of lysozyme was controlled
by degradation rather than diffusion. The experiment was repeated with DXS,
PAA and HEP to “shield” the protein during cross-linking. As a result, the amount
of covalently bound lysozyme was considerably reduced and the majority of the
protein was released within the first 3 days. These results suggest that “shielding”
with polyanions can be used to reduce chemical protein modification during cross-
linking of hydrogels. The activity of the released protein should, therefore, be
preserved in the presence of polyanions. To verify this assumption, the activity
of the released lysozyme was determined after 30 days. The residual activity of
the released lysozyme (CTRL and PAA) was compared to the activity of fresh
lysozyme (LYS). Without the addition of PAA, the activity had decreased to 50.0
± 2.8%, suggesting that the released lysozyme was PEGylated (Fig. 6.10B). In
contrast to that, the residual activity was 88.9 ± 1.5% when PAA was added to
“shield” the protein during cross-linking. These results are in good agreement with
the conclusions drawn above. The slightly reduced activity of the released lysozyme
can be explained by unspecific degradation.
In the last experiment, the release of a therapeutically relevant protein was studied.
For gel preparation, eight-armed PEG (40 kDa molecular mass) was reacted with
6-aminohexanoic acid (8armPEG40k-C6) and subsequently functionalized with
furyl and maleimide end-groups. Bevacizumab (Avastin
r©
), a monoclonal antibody
against vascular endothelial growth factor (VEGF), was incorporated into 10%
8armPEG40k-C6 hydrogels. This antibody is currently used in the treatment of
cancer and age-related macular degeneration [197, 210] and has an IEP of about
8.4 [361]. According to the literature, the hydrodynamic radius of bevacizumab is
about 6.5 nm [319]; the average mesh size of 10% 8armPEG40k-C6 hydrogels is
20.3 ± 0.6 nm [254]. When the release profiles of bevacizumab and lysozyme are
compared, similar trends can be seen (Figs. 6.10A and 6.11A). At characteristic
time points, i.e., after 3, 6, 10, and 14 days, the release of bevacizumab was
significantly higher in the presence of PAA than in the control group without PAA
(Fig. 6.11A, p < 0.05). The release of bevacizumab reached a plateau in both
groups; the released amount was 67% (PAA) and 47% (CTRL), respectively. In
addition, PAA reduced the amount of bevacizumab that was released between
day 20 and 25 when the hydrogel started to degrade. These findings suggest that
“shielding” with PAA can significantly decrease the fraction of covalently bound
bevacizumab. Fragmentation of the antibody, possibly caused by complexation with
PAA, could have been another explanation for the faster release of bevacizumab.
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Figure 6.11: (A) Release of bevacizumab from 8armPEG40k-C6 hydrogels. Cross-
linking via DA reaction was performed without polyanion (CTRL), or in the presence
of PAA. Without PAA, a higher amount of bevacizumab was covalently bound to the
gel network. With PAA, the major amount of bevacizumab was rapidly released by
diffusion. (B) The integrity of the released bevacizumab was confirmed by SEC. Fresh
bevacizumab (BEVA) served as a control. The analysis confirmed that the released
antibody was structurally intact.
Therefore, in order to exclude that the observed effect was due to fragmentation,
samples were taken on day 6 of the release experiment and analyzed by SEC (Fig.
6.11B). For comparison, fresh bevacizumab was analyzed as well (BEVA). All three
chromatograms showed one major peak at a retention time of 17 min, which was
assigned to intact bevacizumab. The chromatograms of the PAA and the control
group showed two additional peaks at retention times of 14 and 24 min. These
signals were assigned to the dissolved gel components, i.e., 8armPEG40k-C6-furan
and 8armPEG40k-C6-maleimide (Fig. 6.12). Therefore, it can be concluded from
the SEC data that the released bevacizumab was structurally intact; there was no
evidence for fragmentation, PEGylation, or aggregation.
In summary, the experiments demonstrate that PAA can effectively “shield”
lysozyme and bevacizumab against chemical modification during cross-linking. In
this way, the fraction of covalently bound protein is reduced; this results in fast,
diffusion-controlled release.
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Figure 6.12: Size exclusion chromatograms of 8armPEG40k-C6-maleimide and
8armPEG40k-C6-furan.
6.4 Conclusion
Hydrogels can be prepared from a wide range of natural and synthetic polymers;
however, only few cross-linking reactions can be carried out without adversely
affecting the stability and availability of incorporated proteins. As it has been
shown in the present study, the addition of polyanions represents an interesting
option to reduce chemical protein modification and activity loss during cross-linking.
The association of proteins with polyanions is driven by electrostatic interactions;
the polyanion binds to the protein surface and reduces chemical reactions between
proteins and polymers, e.g., during hydrogel formation via DA reaction or Michael–
type addition. The association of proteins and polyanions is reversible; it neither
causes protein aggregation or fragmentation, nor does it affect protein activity. The
electrostatic interactions are effective at acidic, neutral and basic pH, which allows
protein “shielding” at many different cross-linking conditions. However, it should be
noted that the conditions must be optimized for each specific protein-polyanion pair.
Furthermore, all polyanions included in this study can be considered biocompatible
and have already been used for drug delivery and biomaterial development [362–366].
Moreover, only minimum amounts of polyanions are required to achieve protective
effects. In conclusion, the possibility to “shield” proteins with polyanions facilitates
the preparation of protein-loaded hydrogels. Cross-linking reactions, which usually
affect the stability and availability of proteins, can be made “protein-compatible”
by simply adding polyanions. In most cases, this method will not affect the material
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properties, such as cross-linking density, swelling capacity, and degradability. In
this way, the herein presented concept might facilitate the development of new
delivery systems for therapeutic proteins.
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7.1 Summary
In 2001, the term “click chemistry” was first introduced by Sharpless and coworkers
as an umbrella term for “spring-loaded” reactions that are modular, wide in scope,
stereospecific, give high yields, proceed at simple conditions, and do not form toxic
by-products [6]. Since that time, click reactions have had tremendous influence in
many research areas including pharmaceutics and material science.
Without a doubt, the Diels-Alder (DA) reaction is one of the click reactions with
the greatest potential for the development of biomaterials and drug delivery systems.
For example, besides the above-mentioned general advantages of click chemistry,
the DA reaction does not require a metal catalyst. Therefore, the DA reaction has
already been utilized in various biomedical areas, such as the synthesis of polymers
and dendrimers, surface functionalization, bioconjugation, nanotechnology, and
hydrogel design. For many of these applications the diene-dienophile pair furan
and maleimide was utilized as they are readily available and the functionalization
is comparably simple. For example, multi-armed poly(ethylene glycol) (PEG)
functionalized with maleimide and furan have been utilized to prepare DA-hydrogels.
However, the DA reaction is also associated with a number of disadvantages. For
example, the reaction is reversible which may be unfavorable for the preparation of
stable conjugates. However, the two most serious drawbacks of the reaction are its
low reaction rate and potential side-reactions, e.g., the reaction of maleimide with
nucleophilic amino acid side-chains (Chapter 1).
The goal of this thesis was to utilize the DA reaction for the development of
hydrogels that can be applied in local antibody therapy. In order to exploit its full
potential, the two main disadvantages of the DA reaction had to be circumvented
while its advantages had to be utilized. To be more specific, DA hydrogels that
gel more rapidly and that do not undergo side-reactions with proteins had to be
developed. To this end, various approaches including chemical modification, the
use of protective additives or combination with other click reactions were employed
(Chapter 2).
For DA hydrogels, gelation is achieved through covalent cross-linking. Therefore,
it was hypothesized that gel formation can be accelerated by facilitating the inter-
action between the reactive groups. Amphiphilic macromonomers were prepared
by introducing hydrophobic 6-aminohexanoic acid (C6) and 12-aminododecanoic
acid (C12) spacers between the polymer backbone and the functional end-groups.
The general associative nature of the macromonomers was verified by an increase
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in viscosity and the formation of associates or micelles. As a consequence of the
hydrophobic association, the reactive groups were brought into close proximity
and gelation occurred significantly faster, e.g., twice as fast using a C12 spacer.
Interestingly, gel times did not decrease when a modified and a non-modified com-
ponent were combined, e.g., unmodified PEG-maleimide with modified PEG-furan.
This finding further emphasizes the importance of hydrophobic association for
accelerated gel formation. Moreover, hydrogels with hydrophobic modification were
characterized by a lower average network mesh size and a higher elastic modulus
which suggested a more efficient cross-linking process. Furthermore, through hy-
drophobic modification an increase of hydrogel stability could be achieved. This
could be explained by the combined effects of higher cross-linking density and the
increased hydrolytic resistance of maleimide moieties resulting from N-alkylation.
All of these effects were influenced by spacer length: C12-modification exhibited
stronger effects on gelation, stability, and stiffness than C6-modification. In addi-
tion, it was found that hydrophobic modification can be used as a tool to achieve
delayed antibody release. While the in vitro release of bevacizumab from the un-
modified DA-hydrogel was completed after only 10 days, hydrophobic modification
delayed the release for about 30 days using C6 and almost 60 days using C12 spacers
(Chapter 3).
Although gel times could be significantly decreased using hydrophobic modi-
fication instantaneous gelation still could not be achieved. In order to develop
DA-hydrogels that provide immediate gelation a dual approach was employed.
Instead of eight-armed PEGs, thermoresponsive four-armed poloxamines were
utilized for macromonomer synthesis and functionalized with maleimide and furyl
moieties. Aqueous solutions of these macromonomers exhibited an immediate
gelation at body temperature. Concomitantly, the functional end-groups led to
covalent cross-linking of the gels. In this way, the rapid sol-gel transition of physical
gelation and the stability of chemically cross-linked gels were combined in a hybrid
system. In addition, further branches were introduced to create a more versatile
hydrogel platform that allowed for tailoring of the core characteristics, i.e., mechan-
ical properties and stability. Hydrogel stability could be precisely controlled in the
range of 14 to 329 days depending on the composition used. Finally, controlled
release of the model antibody bevacizumab could be achieved over a period of 7, 21,
and 115 days in vitro. The release curves were characterized by a notably low burst
and a triphasic shape. Most importantly, almost all of the loaded antibody could
be recovered after release and approximately 87% displayed functional binding. In
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conclusion, DA-Poloxamines are rapidly gelling, mechanically stable, degradable,
nontoxic, and provide controlled antibody release. As they can be tailored to match
the demands of various applications they present a powerful material for controlled
local antibody delivery (Chapter 4).
Besides slow gelation, the second major drawback of DA-hydrogels are undesired
side-reactions with proteins. As potential approach to solve this issue, antibodies
could be incorporated into hydrogel microparticles to safeguard them from detri-
mental cross-linking reactions. Moreover, such antibody-loaded microgels could
find use as a delivery platform for controlled local release. However, the fabri-
cation of antibody-loaded microgels with a narrow size distribution and without
impairing protein stability is a challenging task. To achieve this goal, a fabrication
method combining microfluidics and thiol-ene photoclick chemistry was employed.
Microfluidics is a well-characterized approach for the generation of uniform droplets
that does not expose materials to harmful stress conditions. On the other hand,
the thiol-ene reaction is known to be compatible with proteins [300] and can
be triggered using visible light. To fabricate the microparticles, first aqueous
droplets containing antibody, macromonomers and reactants were generated using
a microfluidic device. Then, green light was used to covalently cross-link the
droplets and encapsulate the antibody. In order to tailor microgel properties a
macromonomer library comprising both hydrolytically labile and stable eight-armed
PEGs with various molecular masses was synthesized. Then, rheology was used to
determine the necessary irradiation time and to study mechanical properties. These
microgels had a rod-like shape and a narrow size distribution with an approximate
width of 380 µm and lengths of 1400 µm or 2150 µm, depending on the process
parameters. Bevacizumab was successfully incorporated into the microgels and a
sustained release could be achieved over a period of 28 and 46 days. Moreover, it
was confirmed that the process developed does not significantly impair the binding
ability of bevacizumab. Therefore, the strategy is suitable for loading antibodies
into microgels and presents a promising starting point for further development. In
future experiments, the general hypothesis that the incorporation into microgels
safeguards proteins needs to be verified. Moreover, for delivery purposes microgels
with smaller dimensions should be generated to allow for injection or inhalation.
This could be achieved by fine tuning of the flow ratio and by using tubes with
smaller diameters (Chapter 5).
Although encapsulation into microgels might be an effective approach to overcome
protein-polymer conjugation during cross-linking, it is a comparably complicated
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approach. It would be ideal if Michael-type reactions of maleimide could be
avoided by simply adding a protective additive. For this purpose, a number of
pharmaceutically relevant polyanions were evaluated, i.e., alginate, dextran sulfate,
heparin, hyaluronic acid, and poly(acrylic acid). Electrostatic interactions led to
reversible binding of the polyanions to the protein surface. Thereby, the reaction
of maleimide with nucleophilic moieties on the protein surface could be prevented.
These results were confirmed using the model protein lysozyme and by simulating
the reaction conditions with monofunctional mPEG5k-maleimide and mPEG5k-
furan. For example, at pH 7.4 and without polyanions about 61% of lysozyme was
PEGylated and the activity had decreased to about 20% of the initial activity. In
comparison, when dextran sulfate had been added an activity of 98% remained and
no PEGylation was detected. Overall, dextran sulfate, heparin, and poly(acrylic
acid) were identified as the most effective additives to shield proteins during cross-
linking. In addition, it could be confirmed that the “shielding” is solely based
on electrostatic interactions as the effect could be reversed by adding high salt
concentrations. Furthermore, it could be demonstrated that the protective effect can
be utilized at acidic, neutral, and basic pH which makes it a particularly versatile
tool for protein formulation and delivery. Nevertheless, in order to optimally protect
proteins from undesired reactions, cross-linking should be carried out at acidic pH
and with polyanions present. These conditions are optimal because on the one
hand, at acidic pH the reactivity of nucleophilic groups (e.g., amines) is decreased
and on the other, proteins carry a higher positive charge than at neutral pH which
facilitates electrostatic interactions with polyanions (Chapter 6).
7.2 Conclusion
In this thesis, the DA click reaction was utilized to develop hydrogels for con-
trolled local antibody delivery. Hydrophobic association was identified as a tool
to facilitate covalent cross-linking and to obtain hydrogels that gel more rapidly,
have improved mechanical properties, and a higher stability. Moreover, thermore-
sponsive DA-hydrogels were designed that immediately gel at body temperature
and concomitantly cross-link via DA reaction. Both approaches were successful in
eliminating the disadvantage of slow gelation while still utilizing the advantages of
the DA reaction. As both rapid and instantaneous gelation could be useful depend-
ing on the demands of the application both materials might find use in therapy.
Furthermore, the combination of microfluidics and thiol-ene photoclick chemistry
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could be employed for protein incorporation into uniform microgels. It will be
interesting to further assess the potential of this delivery platform for safeguarding
proteins and controlled release. Finally, the “shielding” effect of polyanions against
side-reactions with the protein was discovered. Adding polyanions to the precursor
solutions prior to cross-linking presents a particularly elegant and simple way to
overcome this serious problem. In conclusion, the materials and mechanisms de-
scribed in this thesis present a great advancement for antibody delivery using click
hydrogels. Regarding material properties, all major drawbacks of the DA reaction
could be eliminated while its advantages were preserved. Therefore, as a next
step the biocompatibility of the materials and their in vivo performance should be
assessed. In addition, in order to broaden the spectrum of applications it should be
evaluated whether these hydrogels can be applied to the delivery of other antibodies
and biologics, such as fusion proteins and antibody fragments. Furthermore, a more
in-depth analysis of the physicochemical properties of the antibody after release is
a crucial aspect with regard to therapeutic success. In addition to presenting novel
antibody delivery systems, the mechanisms that are presented in this thesis are of
particular scientific significance as they can be translated to other research areas.
For example, both hydrophobic association and dual gelation could be utilized in
combination with other reactions to facilitate the development of novel biomaterials
and delivery systems. Similarly, as “shielding” with polyanions could be utilized to
safely deliver multiple other protein pharmaceuticals it might open up new avenues
for protein delivery. In conclusion, the materials and mechanisms presented in this
thesis have the potential to make a broad impact in the biomedical field.
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Supplementary Spectroscopic
Information
A) 1H-NMR spectra for the polymers described in chapter 3
8armPEG40k-furan
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 2.47 (t, 16H, -C(O)CH 2CH2Ar), 2.97 (t, 16H,
-C(O)CH2CH 2Ar), 3.62 (s, -OCH 2CH 2-), 6.01 (s, 8H, Ar), 6.24 (s, 8H, Ar), 7.28 (s, 8H, Ar).
8armPEG40k-maleimide
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 3.62 (s, -OCH 2CH 2-), 6.64 (s, 16H,
-C(O)CH=CHC(O)-).
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8armPEG40k-C6-NH-Boc
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.32 (m, 16H, -C(O)CH2CH 2CH2CH2CH2NH-), 1.42
(s, 72H, -NHC(O)OC(CH 3)3), 1.47 (m, 16H,-C(O)CH2CH2CH 2CH2CH2NH), 1.63 (m, 16H,
-C(O)CH2CH2CH2CH 2CH2NH-), 2.17 (m, 16H, -C(O)CH 2CH2CH2CH2CH2NH-), 3.08 (m,
16H, -C(O)CH2CH2CH2CH2CH 2NH-), 3.62 (s, -OCH 2CH 2-).
8armPEG40k-C6-furan
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.29 (m, 16H, -C(O)CH2CH 2CH2CH2CH2NH-), 1.46
(m, 16H, -C(O)CH2CH2CH 2CH2CH2NH-), 1.62 (m, 16H, -C(O)CH2CH2CH2CH 2CH2NH-),
2.17 (m, 16H, -C(O)CH 2CH2CH2CH2CH2NH-), 2.47 (t, 16H, -C(O)CH 2CH2Ar), 2.96 (t, 16H,
-C(O)CH2CH 2Ar), 3.20 (m, 16H, -C(O)CH2CH2CH2CH2CH 2NH-), 3.62 (s, -OCH 2CH 2-),
6.00 (s, 8H, Ar), 6.25 (s, 8H, Ar), 7.27 (s, 8H, Ar).
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8armPEG40k-C6-maleimide
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.29 (m, 16H, -C(O)CH2CH 2CH2CH2CH2N-), 1.61
(m, 32H, -C(O)CH2CH2CH 2CH 2CH2N-), 2.15 (m, 16H, -C(O)CH 2CH2CH2CH2CH2N-), 3.62
(s, -OCH 2CH 2-), 6.67 (s, 16H, -C(O)CH=CHC(O)-).
8armPEG40k-C12-NH-Boc
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.24 (m, 112H, -C(O)CH2(CH 2)7CH2CH2CH2NH-),
1.42 (s, 72H, -NHC(O)OC(CH 3)3), 1.43 (m, 16H,-C(O)CH2(CH2)7CH 2CH2CH2NH), 1.60 (m,
16H, -C(O)CH2(CH2)7CH2CH 2CH2NH-), 2.20 (m, 16H, -C(O)CH 2(CH2)7CH2CH2CH2NH-),
3.08 (m, 16H, -C(O)CH2(CH2)7CH2CH2CH 2NH-), 3.62 (s, -OCH 2CH 2-).
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8armPEG40k-C12-furan
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.23 (m, 112H, -C(O)CH2(CH 2)7CH2CH2CH2NH-),
1.42 (m, 16H, -C(O)CH2(CH2)7CH 2CH2CH2NH-), 1.60 (m, 16H,
-C(O)CH2(CH2)7CH2CH 2CH2NH-), 2.15 (m, 16H, -C(O)CH 2(CH2)7CH2CH2CH2NH-), 2.47
(t, 16H, -C(O)CH 2CH2Ar), 2.96 (t, 16H, -C(O)CH2CH 2Ar), 3.20 (m, 16H,
-C(O)CH2(CH2)7CH2CH2CH 2NH-), 3.62 (s, -OCH 2CH 2-), 6.00 (s, 8H, Ar), 6.26 (s, 8H, Ar),
7.26 (s, 8H, Ar).
8armPEG40k-C12-maleimide
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.23 (m, 112H, -C(O)CH2(CH 2)7CH2CH2CH2N-),
1.56 (m, 32H, -C(O)CH2(CH2)7CH 2CH 2CH2N-), 2.14 (m, 16H,
-C(O)CH 2(CH2)7CH2CH2CH2N-), 3.62 (s, -OCH 2CH 2-), 6.66 (s, 16H, -C(O)CH=CHC(O)-).
188
Supplementary Spectroscopic Information
B) 1H-NMR spectra for the polymers described in chapter 4
4armPoloxamine-furan
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.12 (-OCH2CH(CH 3)-), 2.50 (t, 8H, -
C(O)CH 2CH2Ar), 2.97 (t, 8H, -C(O)CH2CH 2Ar), 3.40 (m, -OCH2CH (CH3)-), 3.54 (m, -
OCH 2CH(CH3)-), 3.63 (s, -OCH 2CH 2-), 6.02 (s, 4H, Ar), 6.24 (s, 4H, Ar), 7.28 (s, 4H, Ar).
4armPoloxamine-maleimide
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.12 (m, -OCH2CH(CH 3)-), 3.40 (m,
-OCH2CH (CH3)-), 3.54 (m, -OCH 2CH(CH3)-), 3.63 (s, -OCH 2CH 2-), 6.69 (s, 8H,
-C(O)CH=CHC(O)-).
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8armPoloxamine-furan
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.12 (-OCH2CH(CH 3)-), 1.30-1.82 (48 H,
-CH 2CH 2CH 2CH2NH-), 2.20 (t, 8H, -C(O)CH 2CH2CH2CH2CH2NH-),
2.48 (t,16H,-C(O)CH 2CH2Ar), 2.95 (t,16H,-C(O)CH2CH 2Ar), 3.21 (t, 16H,
-CH2CH2CH2CH 2NH-), 3.40 (m, -OCH2CH (CH3)-), 3.54 (m, -OCH 2CH(CH3)-), 3.63 (s,
-OCH 2CH 2-), 4.35 (m, 4H, -C(O)C(NHR)HCH2CH2CH2CH2NH-), 6.00 (s, 8H, Ar), 6.26 (s,
8H, Ar), 7.28 (s, 8H, Ar).
8armPoloxamine-maleimide
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 1.12 (-OCH2CH(CH 3)-), 1.28-1.82 (48 H,
-CH 2CH 2CH 2CH2N-), 2.18 (t, 8H, -C(O)CH 2CH2CH2CH2CH2N-), 3.39 (m,
-OCH2CH (CH3)-), 3.54 (m, -OCH 2CH(CH3)-), 3.63 (s, -OCH 2CH 2-), 4.35 (m, 4H,
-C(O)C(NHR)HCH2CH2CH2CH2N-), 6.68 (s, 16H, -C(O)CH=CHC(O)-).
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Acronyms
2D . . . . . . . . . . . two-dimensional
3D . . . . . . . . . . . three-dimensional
Ala . . . . . . . . . . alanine
ALG . . . . . . . . . alginate
AMD . . . . . . . . . age-related macular degeneration
ANOVA . . . . . . . analysis of variance
Arg . . . . . . . . . . arginine
Asp . . . . . . . . . . aspartic acid
ATRP . . . . . . . . . atom transfer free radical polymerization
Boc . . . . . . . . . . tert-butyloxycarbonyl
C6 . . . . . . . . . . . 6-aminohexanoic acid spacer
C12 . . . . . . . . . . 12-aminododecanoic acid spacer
CD . . . . . . . . . . circular dichroism
CMC . . . . . . . . . critical micelle concentration
CPP . . . . . . . . . . cell penetrating peptide
CTRL . . . . . . . . . control
CuAAC . . . . . . . . copper(I)-catalyzed azide–alkyne Huisgen cycloaddition
DA . . . . . . . . . . Diels–Alder
DCC . . . . . . . . . N,N’ -dicyclohexylcarbodiimide
DIPEA . . . . . . . . N,N -diisopropylethylamine
DMAP . . . . . . . . 4-dimethylaminopyridine
DNA . . . . . . . . . deoxyribonucleic acid
DTT . . . . . . . . . dithiothreitol
DXS . . . . . . . . . . dextran sulfate
ECM . . . . . . . . . extracellular matrix
ELISA . . . . . . . . enzyme-linked immunosorbent assay
EMEM . . . . . . . . Eagle’s minimum essential medium
EO . . . . . . . . . . ethylene oxide chain
FGF . . . . . . . . . . fibroblast growth factor
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Acronyms
Fmoc . . . . . . . . . fluorenylmethyloxycarbonyl
Gly . . . . . . . . . . glycine
GRGDS . . . . . . . Gly–Arg–Gly–Asp–Ser
HA . . . . . . . . . . hyaluronic acid
HC . . . . . . . . . . hydrocarbon chain
HEP . . . . . . . . . heparin
HER2 . . . . . . . . . human epidermal growth factor receptor 2
HLB . . . . . . . . . . hydrophilic lipophilic balance
HMEC . . . . . . . . human mammary epithelial cell
hMSC . . . . . . . . . human mesenchymal stem cell
IEDDA . . . . . . . . inverse electron-demand Diels–Alder
IEP . . . . . . . . . . isoelectric point
IKVAV . . . . . . . . isoleucine–lysine–valine–alanine–valine
Ile . . . . . . . . . . . isoleucine
ISO . . . . . . . . . . International Organization for Standardization
LCST . . . . . . . . . lower critical solution temperature
LDH . . . . . . . . . L-lactate dehydrogenase
LED . . . . . . . . . . light-emitting diode
LYS . . . . . . . . . . native lysozyme
Lys . . . . . . . . . . lysine
MaLA . . . . . . . . . Lipoic acid
MES . . . . . . . . . 2-(N -morpholino)ethanesulfonic acid
mPEG5k . . . . . . . methoxy poly(ethylene glycol), 5 kDa
MTT . . . . . . . . . 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NB . . . . . . . . . . norbornene
NHS . . . . . . . . . . N -hydroxysuccinimide
NIR . . . . . . . . . . near-infrared
NLS . . . . . . . . . . nuclear localization sequence
NMR . . . . . . . . . nuclear magnetic resonance
NSPC . . . . . . . . . neural stem/progenitor cell
PAA . . . . . . . . . . poly(acrylic acid)
PAGE . . . . . . . . . polyacrylamide gel electrophoresis
PBS . . . . . . . . . . phosphate buffered saline
PDR . . . . . . . . . proliferative diabetic retinopathy
PEEK . . . . . . . . poly(etheretherketone)
PEG . . . . . . . . . poly(ethylene glycol)
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Acronyms
8armPEG10k . . . . eight-armed poly(ethylene glycol), 10 kDa
8armPEG20k . . . . eight-armed poly(ethylene glycol), 20 kDa
8armPEG40k . . . . eight-armed poly(ethylene glycol), 40 kDa
PET . . . . . . . . . . positron emission tomography
PLA . . . . . . . . . . poly(lactic acid)
PMMA . . . . . . . . poly(methyl methacrylate)
4armPoloxamine . . four-armed poloxamine
8armPoloxamine . . eight-armed poloxamine
PPG . . . . . . . . . poly(propylene glycol)
PS . . . . . . . . . . . polystyrene
PTFE . . . . . . . . . poly(tetrafluoroethylene)
RAFT . . . . . . . . reversible addition fragmentation chain transfer
rDA . . . . . . . . . . retro-Diels–Alder
RGD . . . . . . . . . arginine–glycine–aspartic acid
RGDS . . . . . . . . arginine–glycine–aspartic acid–serine
RNA . . . . . . . . . ribonucleic acid
ROMP . . . . . . . . ring-opening metathesis polymerization
SDS . . . . . . . . . . sodium dodecyl sulfate
SEC . . . . . . . . . . size-exclusion chromatography
Ser . . . . . . . . . . . serine
SPAAC . . . . . . . . strain-promoted azide–alkyne cycloaddition
SPR . . . . . . . . . . surface plasmon resonance
TEMED . . . . . . . tetramethylethylenediamine
TMZ . . . . . . . . . temozolomide
Tyr . . . . . . . . . . tyrosine
UV . . . . . . . . . . ultraviolet
Val . . . . . . . . . . valine
VEGF . . . . . . . . vascular endothelial growth factor
YIGSR . . . . . . . . tyrosine–isoleucine–glycine–serine–arginine
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Symbols
Cn . . . . . . . . . . . Flory characteristic ratio
χ12 . . . . . . . . . . . Flory–Huggins polymer-solvent interaction parameter
E . . . . . . . . . . . Young’s modulus of compression
f . . . . . . . . . . . . branching factor of the macromonomers
|G∗| . . . . . . . . . . absolute value of the complex shear modulus
G′ . . . . . . . . . . . storage modulus
G′′ . . . . . . . . . . . loss modulus
kobs . . . . . . . . . . pseudo-first-order rate constant
l . . . . . . . . . . . . average bond length
mp . . . . . . . . . . . total mass of the polymer in the hydrogel
Mr . . . . . . . . . . . relative molecular mass
t1/2 . . . . . . . . . . half-life time
V1 . . . . . . . . . . . molar volume of the swelling agent
v2c . . . . . . . . . . . polymer fraction of the gel after cross-linking
v2s . . . . . . . . . . . polymer fraction of the gel in the swollen state
Vgc . . . . . . . . . . . volume of the gel cylinder after cross-linking
Vgs . . . . . . . . . . . volume of the gel cylinder after swelling
Vp . . . . . . . . . . . volume of the dry polymer
δ . . . . . . . . . . . . chemical shift
δ . . . . . . . . . . . . phase angle
η . . . . . . . . . . . . dynamic viscosity
λem . . . . . . . . . . emission wavelength
λex . . . . . . . . . . . excitation wavelength
νe . . . . . . . . . . . number of moles of elastically active chains
ξ . . . . . . . . . . . . average network mesh size
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